WO2011149874A2 - N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 - Google Patents
N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 Download PDFInfo
- Publication number
- WO2011149874A2 WO2011149874A2 PCT/US2011/037651 US2011037651W WO2011149874A2 WO 2011149874 A2 WO2011149874 A2 WO 2011149874A2 US 2011037651 W US2011037651 W US 2011037651W WO 2011149874 A2 WO2011149874 A2 WO 2011149874A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carboxamide
- imidazole
- amino
- piperidinyl
- aminomethyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 13
- 108010082078 3-Phosphoinositide-Dependent Protein Kinases Proteins 0.000 title description 11
- 102000003737 3-Phosphoinositide-Dependent Protein Kinases Human genes 0.000 title description 11
- OSUMTOORAWCHGK-UHFFFAOYSA-N n-phenyl-1h-imidazole-2-carboxamide Chemical compound N=1C=CNC=1C(=O)NC1=CC=CC=C1 OSUMTOORAWCHGK-UHFFFAOYSA-N 0.000 title description 2
- NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical class NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 claims abstract description 72
- 150000003839 salts Chemical class 0.000 claims abstract description 68
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 38
- 201000011510 cancer Diseases 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 7
- -1 hydroxy, amino Chemical group 0.000 claims description 164
- 150000001875 compounds Chemical class 0.000 claims description 158
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 77
- 125000000217 alkyl group Chemical group 0.000 claims description 70
- 229910052757 nitrogen Inorganic materials 0.000 claims description 63
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 59
- 125000002947 alkylene group Chemical group 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 40
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 39
- 229910052760 oxygen Inorganic materials 0.000 claims description 39
- 125000005842 heteroatom Chemical group 0.000 claims description 38
- 229910052717 sulfur Chemical group 0.000 claims description 38
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 36
- 239000001301 oxygen Chemical group 0.000 claims description 34
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 32
- 239000002246 antineoplastic agent Substances 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
- 125000004432 carbon atom Chemical group C* 0.000 claims description 29
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 28
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 26
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 239000011593 sulfur Chemical group 0.000 claims description 26
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 22
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 22
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 21
- 125000002950 monocyclic group Chemical group 0.000 claims description 19
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 150000003857 carboxamides Chemical class 0.000 claims description 14
- 125000001153 fluoro group Chemical group F* 0.000 claims description 14
- QKDCLUARMDUUKN-XMMPIXPASA-N 6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3r)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide Chemical compound N1=C(O[C@H]2CN(CC2)C(=O)C=C)C(CC)=NC(C(N)=O)=C1NC(C=C1)=CC=C1N(CC1)CCC1N1CCN(C)CC1 QKDCLUARMDUUKN-XMMPIXPASA-N 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 230000010261 cell growth Effects 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 9
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 7
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 5
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 5
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 5
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 3
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims description 2
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004419 alkynylene group Chemical group 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 2
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 2
- AFEDACCGNQKVGZ-LLVKDONJSA-N n-[5-amino-2-[(3r)-3-aminopiperidin-1-yl]phenyl]-1h-imidazole-2-carboxamide Chemical compound C1[C@H](N)CCCN1C1=CC=C(N)C=C1NC(=O)C1=NC=CN1 AFEDACCGNQKVGZ-LLVKDONJSA-N 0.000 claims 2
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 claims 2
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 claims 2
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 claims 1
- 101150043850 Amtn gene Proteins 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 abstract description 7
- 230000001594 aberrant effect Effects 0.000 abstract description 3
- 230000019491 signal transduction Effects 0.000 abstract description 3
- 101001117144 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) [Pyruvate dehydrogenase (acetyl-transferring)] kinase 1, mitochondrial Proteins 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 180
- 239000000203 mixture Substances 0.000 description 117
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
- 239000002904 solvent Substances 0.000 description 88
- 238000003786 synthesis reaction Methods 0.000 description 84
- 230000015572 biosynthetic process Effects 0.000 description 79
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 77
- 229910001868 water Inorganic materials 0.000 description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 71
- 235000019439 ethyl acetate Nutrition 0.000 description 63
- 239000007787 solid Substances 0.000 description 55
- 238000002360 preparation method Methods 0.000 description 53
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 52
- 235000002639 sodium chloride Nutrition 0.000 description 52
- 238000011097 chromatography purification Methods 0.000 description 51
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 49
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 44
- 239000010410 layer Substances 0.000 description 42
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 40
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 39
- 239000012044 organic layer Substances 0.000 description 38
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 35
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 30
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 28
- 150000001408 amides Chemical class 0.000 description 26
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 25
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 0 CC1N(C)C(NC)=NC(N(C2)[C@](*)CC[C@@]2*(NC2CCCCC2)=O)=C1 Chemical compound CC1N(C)C(NC)=NC(N(C2)[C@](*)CC[C@@]2*(NC2CCCCC2)=O)=C1 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- 125000003118 aryl group Chemical group 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 229910021529 ammonia Inorganic materials 0.000 description 20
- 239000012230 colorless oil Substances 0.000 description 19
- 239000012453 solvate Substances 0.000 description 18
- 239000000543 intermediate Substances 0.000 description 17
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 17
- 239000000758 substrate Substances 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 125000004122 cyclic group Chemical group 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 15
- 229910001873 dinitrogen Inorganic materials 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 125000006413 ring segment Chemical group 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 229940002612 prodrug Drugs 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 12
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 229910052763 palladium Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 9
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 9
- 239000007821 HATU Substances 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000003710 aryl alkyl group Chemical group 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000006260 foam Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 8
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 8
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 125000004434 sulfur atom Chemical group 0.000 description 8
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 7
- IXIJRPBFPLESEI-UHFFFAOYSA-N 1,2-difluoro-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(F)=C1F IXIJRPBFPLESEI-UHFFFAOYSA-N 0.000 description 7
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 108091008611 Protein Kinase B Proteins 0.000 description 7
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 150000007942 carboxylates Chemical class 0.000 description 7
- 238000002875 fluorescence polarization Methods 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- KOHZFXXRPRNGCF-SNVBAGLBSA-N n-[5-amino-2-[(3r)-3-aminopiperidin-1-yl]phenyl]-5-bromo-1h-imidazole-2-carboxamide Chemical compound C1[C@H](N)CCCN1C1=CC=C(N)C=C1NC(=O)C1=NC(Br)=CN1 KOHZFXXRPRNGCF-SNVBAGLBSA-N 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 229960001302 ridaforolimus Drugs 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- KYWMCFOWDYFYLV-UHFFFAOYSA-N 1h-imidazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=CN1 KYWMCFOWDYFYLV-UHFFFAOYSA-N 0.000 description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
- 108090000315 Protein Kinase C Proteins 0.000 description 5
- 102000003923 Protein Kinase C Human genes 0.000 description 5
- 150000003927 aminopyridines Chemical class 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
- JNDJTVKQFZTPST-SECBINFHSA-N n-[2-[(3r)-3-aminopiperidin-1-yl]-3-fluorophenyl]-5-bromo-1h-imidazole-2-carboxamide Chemical compound C1[C@H](N)CCCN1C1=C(F)C=CC=C1NC(=O)C1=NC(Br)=CN1 JNDJTVKQFZTPST-SECBINFHSA-N 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 4
- GCCWZUCZBCTRHY-UHFFFAOYSA-N 1h-imidazole-2-carboxamide;pyridine Chemical compound C1=CC=NC=C1.NC(=O)C1=NC=CN1 GCCWZUCZBCTRHY-UHFFFAOYSA-N 0.000 description 4
- AXHRGVJWDJDYPO-UHFFFAOYSA-N 2-bromo-1h-imidazole Chemical compound BrC1=NC=CN1 AXHRGVJWDJDYPO-UHFFFAOYSA-N 0.000 description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000002877 alkyl aryl group Chemical group 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 229940124302 mTOR inhibitor Drugs 0.000 description 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- QVOXSFXDMPVAKS-CYBMUJFWSA-N n-[2-[(3r)-3-aminopiperidin-1-yl]-3-fluorophenyl]-5-(1-methylpyrazol-4-yl)-1h-imidazole-2-carboxamide Chemical compound C1=NN(C)C=C1C1=CNC(C(=O)NC=2C(=C(F)C=CC=2)N2C[C@H](N)CCC2)=N1 QVOXSFXDMPVAKS-CYBMUJFWSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000003197 protein kinase B inhibitor Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 229940126638 Akt inhibitor Drugs 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 239000012824 ERK inhibitor Substances 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000534944 Thia Species 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 125000005518 carboxamido group Chemical group 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- PFHGNIMWELIXGP-UHFFFAOYSA-N 1-nitropiperidine Chemical compound [O-][N+](=O)N1CCCCC1 PFHGNIMWELIXGP-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 description 2
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- FWHRLKTXFMRLDV-UHFFFAOYSA-N 4-(methylamino)piperidine-4-carboxamide Chemical compound CNC1(C(N)=O)CCNCC1 FWHRLKTXFMRLDV-UHFFFAOYSA-N 0.000 description 2
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- LFYOZCBFOSSLNJ-UHFFFAOYSA-N 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2h-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;hydrochloride Chemical compound Cl.C=1C=C(C=2C(=CC=3C4=NN=C(O)N4C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 LFYOZCBFOSSLNJ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 241000907681 Morpho Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 2
- RQLWUWIOLMUPRZ-UHFFFAOYSA-N benzyl 4-[2-(methylamino)-6-[2-[(2-piperazin-1-ylphenyl)carbamoyl]-1h-imidazol-5-yl]pyrimidin-4-yl]piperazine-1-carboxylate Chemical compound N=1C(NC)=NC(N2CCN(CC2)C(=O)OCC=2C=CC=CC=2)=CC=1C(N=1)=CNC=1C(=O)NC1=CC=CC=C1N1CCNCC1 RQLWUWIOLMUPRZ-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000007819 coupling partner Substances 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000006345 epimerization reaction Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 102000048810 human PDK1 Human genes 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- XLWNLCSWRLEMJR-UHFFFAOYSA-N n-benzylpyrimidin-2-amine Chemical compound C=1C=CC=CC=1CNC1=NC=CC=N1 XLWNLCSWRLEMJR-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003230 pyrimidines Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- AEIHOUCJAIZEFV-UHFFFAOYSA-N tert-butyl n-(4-fluoro-3-nitrophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(F)C([N+]([O-])=O)=C1 AEIHOUCJAIZEFV-UHFFFAOYSA-N 0.000 description 2
- WUOQXNWMYLFAHT-MRVPVSSYSA-N tert-butyl n-[(3r)-piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCCNC1 WUOQXNWMYLFAHT-MRVPVSSYSA-N 0.000 description 2
- SAAGMIHGVLKZBC-UHFFFAOYSA-N tert-butyl n-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]carbamate Chemical compound C1=NC(NC(=O)OC(C)(C)C)=CC(B2OC(C)(C)C(C)(C)O2)=C1 SAAGMIHGVLKZBC-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- UFYBTLOLWSABAU-UHFFFAOYSA-N (2-methylpyridin-4-yl)boronic acid Chemical compound CC1=CC(B(O)O)=CC=N1 UFYBTLOLWSABAU-UHFFFAOYSA-N 0.000 description 1
- PAORVUMOXXAMPL-SECBINFHSA-N (2s)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 1
- BWLAJCGCLPFOIK-UHFFFAOYSA-N (4-fluoro-3-nitrophenyl)carbamic acid Chemical compound OC(=O)NC1=CC=C(F)C([N+]([O-])=O)=C1 BWLAJCGCLPFOIK-UHFFFAOYSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- ARCACZWMYGILNI-UHFFFAOYSA-N 1,2,3-trifluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1F ARCACZWMYGILNI-UHFFFAOYSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- BKFLUXBQUHVWRH-UHFFFAOYSA-N 1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxamide Chemical compound C[Si](C)(C)CCOCN1C=CN=C1C(N)=O BKFLUXBQUHVWRH-UHFFFAOYSA-N 0.000 description 1
- 125000005851 1-(N-(alkoxycarbonyl)amino)ethyl group Chemical group 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- FPODMAKMVPTWFP-UHFFFAOYSA-N 1-[4-amino-2-(1h-imidazole-2-carbonylamino)phenyl]-4-(methylamino)piperidine-4-carboxamide Chemical compound C1CC(NC)(C(N)=O)CCN1C1=CC=C(N)C=C1NC(=O)C1=NC=CN1 FPODMAKMVPTWFP-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- DGHHQBMTXTWTJV-BQAIUKQQSA-N 119413-54-6 Chemical compound Cl.C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 DGHHQBMTXTWTJV-BQAIUKQQSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- ACNJVZRFVRLNEC-UHFFFAOYSA-N 2-(1-tert-butyl-2,9-diazaspiro[5.5]undecan-9-yl)-3-fluoroaniline Chemical compound C(C)(C)(C)C1NCCCC12CCN(CC2)C2=C(C=CC=C2F)N ACNJVZRFVRLNEC-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- KHCXGFNZZRXOND-UHFFFAOYSA-N 3-(bromomethyl)pyridine Chemical compound BrCC1=CC=CN=C1 KHCXGFNZZRXOND-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ANSBFDYOIUZSNT-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(thiophen-2-ylmethyl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC=2SC=CC=2)N=C1 ANSBFDYOIUZSNT-UHFFFAOYSA-N 0.000 description 1
- SARWEPUHGNIVNJ-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carbonitrile Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NC(C#N)=C1 SARWEPUHGNIVNJ-UHFFFAOYSA-N 0.000 description 1
- WDVAQDDJRRNKQM-UHFFFAOYSA-N 4-(4-phenylbutan-2-yl)piperidine Chemical compound C1CNCCC1C(C)CCC1=CC=CC=C1 WDVAQDDJRRNKQM-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- UQEANKGXXSENNF-UHFFFAOYSA-N 4-bromo-1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1F UQEANKGXXSENNF-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- LLIOADBCFIXIEU-UHFFFAOYSA-N 4-fluoro-3-nitroaniline Chemical compound NC1=CC=C(F)C([N+]([O-])=O)=C1 LLIOADBCFIXIEU-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ZLWMWGLWSFVWIW-UHFFFAOYSA-N 5-bromo-1h-imidazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=C(Br)N1 ZLWMWGLWSFVWIW-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- WGGFJKKCAFNBGH-UHFFFAOYSA-N 6-methylpiperidine-3-carboxamide Chemical compound CC1CCC(C(N)=O)CN1 WGGFJKKCAFNBGH-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000019050 90-kDa Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 108010012196 90-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 229940125431 BRAF inhibitor Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- PYMDEDHDQYLBRT-DRIHCAFSSA-N Buserelin acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 PYMDEDHDQYLBRT-DRIHCAFSSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- BNNKXMDZDWLJIY-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)C(C2)C1CCN2c(c(F)ccc1)c1[N+]([O-])=O)=O Chemical compound CC(C)(C)OC(N(CC1)C(C2)C1CCN2c(c(F)ccc1)c1[N+]([O-])=O)=O BNNKXMDZDWLJIY-UHFFFAOYSA-N 0.000 description 1
- PFIMABNVCKRKTD-UHFFFAOYSA-N CC(C)(C)OC(NCC(CC1)CCN1c(c(F)ccc1)c1[N+]([O-])=O)=O Chemical compound CC(C)(C)OC(NCC(CC1)CCN1c(c(F)ccc1)c1[N+]([O-])=O)=O PFIMABNVCKRKTD-UHFFFAOYSA-N 0.000 description 1
- AFXNUZZYIHEKHR-LLVKDONJSA-N CC(C)(C)OC(N[C@H](CCC1)CN1c(c(F)ccc1)c1N)=O Chemical compound CC(C)(C)OC(N[C@H](CCC1)CN1c(c(F)ccc1)c1N)=O AFXNUZZYIHEKHR-LLVKDONJSA-N 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- VCWNUMXQBNTHJS-JTQLQIEISA-N C[C@@H](c1ccccc1)Nc1cc(C)nc(N)n1 Chemical compound C[C@@H](c1ccccc1)Nc1cc(C)nc(N)n1 VCWNUMXQBNTHJS-JTQLQIEISA-N 0.000 description 1
- 101100351314 Caenorhabditis elegans pdk-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- WTWUEYTUSBENSX-UHFFFAOYSA-N Cc1nc(NC)nc([N]2(C)CCOCC2)c1 Chemical compound Cc1nc(NC)nc([N]2(C)CCOCC2)c1 WTWUEYTUSBENSX-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102100039262 Glycogen [starch] synthase, muscle Human genes 0.000 description 1
- 101710141660 Glycogen synthase 1 Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- IVDFJHOHABJVEH-UHFFFAOYSA-N HOCMe2CMe2OH Natural products CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101000691459 Homo sapiens Serine/threonine-protein kinase N2 Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- IILIWMYCMJDYBU-UHFFFAOYSA-N NCC(CC1)CCN1c(c(F)ccc1)c1N Chemical compound NCC(CC1)CCN1c(c(F)ccc1)c1N IILIWMYCMJDYBU-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 102100026379 Neurofibromin Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 101150029101 Pdk1 gene Proteins 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102100026180 Serine/threonine-protein kinase N2 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000005513 benzoazaindolyl group Chemical group 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 229960005064 buserelin acetate Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- GCUVBACNBHGZRS-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-dien-1-yl(diphenyl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.c1cc[c-](c1)P(c1ccccc1)c1ccccc1 GCUVBACNBHGZRS-UHFFFAOYSA-N 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical class CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005049 dihydrooxadiazolyl group Chemical group O1N(NC=C1)* 0.000 description 1
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 1
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- SDIXRDNYIMOKSG-UHFFFAOYSA-L disodium methyl arsenate Chemical compound [Na+].[Na+].C[As]([O-])([O-])=O SDIXRDNYIMOKSG-UHFFFAOYSA-L 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- BRMNIPUJQIHQIE-UHFFFAOYSA-N ethanol;toluene;hydrate Chemical compound O.CCO.CC1=CC=CC=C1 BRMNIPUJQIHQIE-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- UHYNYIGCGVDBTC-UHFFFAOYSA-N ethyl 1h-imidazole-2-carboxylate Chemical compound CCOC(=O)C1=NC=CN1 UHYNYIGCGVDBTC-UHFFFAOYSA-N 0.000 description 1
- CYPZPQKFCFTIHH-UHFFFAOYSA-N ethyl 4-bromo-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxylate Chemical compound CCOC(=O)C1=NC(Br)=CN1COCC[Si](C)(C)C CYPZPQKFCFTIHH-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960002011 fludrocortisone Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000002373 hemiacetals Chemical group 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- NIZHERJWXFHGGU-UHFFFAOYSA-N isocyanato(trimethyl)silane Chemical compound C[Si](C)(C)N=C=O NIZHERJWXFHGGU-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- FCUOHYLGXZINJK-UHFFFAOYSA-N methyl 1-(2-fluoro-6-nitrophenyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C1=C(F)C=CC=C1[N+]([O-])=O FCUOHYLGXZINJK-UHFFFAOYSA-N 0.000 description 1
- DQNQNLWKAGZNIT-UHFFFAOYSA-N methyl 2,6-dichloropyrimidine-4-carboxylate Chemical compound COC(=O)C1=CC(Cl)=NC(Cl)=N1 DQNQNLWKAGZNIT-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- RZVWBASHHLFBJF-UHFFFAOYSA-N methyl piperidine-4-carboxylate Chemical compound COC(=O)C1CCNCC1 RZVWBASHHLFBJF-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- LSNOAQQZECGQNS-UHFFFAOYSA-N morpholine-2-carboxamide Chemical compound NC(=O)C1CNCCO1 LSNOAQQZECGQNS-UHFFFAOYSA-N 0.000 description 1
- 125000005858 morpholino(C2-C3)alkyl group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DVCKFUQPCLOZDG-UHFFFAOYSA-N n-ethyl-1-[2-fluoro-6-[[5-(2-methylpyridin-4-yl)-1h-imidazole-2-carbonyl]amino]phenyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NCC)CCN1C1=C(F)C=CC=C1NC(=O)C1=NC(C=2C=C(C)N=CC=2)=CN1 DVCKFUQPCLOZDG-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
- GMCGYLIRFCDMPS-UHFFFAOYSA-N piperidin-3-ylcarbamic acid Chemical compound OC(=O)NC1CCCNC1 GMCGYLIRFCDMPS-UHFFFAOYSA-N 0.000 description 1
- ILUDPPGBUXWYAU-UHFFFAOYSA-N piperidine-3-carboxamide Chemical compound NC(=O)C1CCCNC1.NC(=O)C1CCCNC1 ILUDPPGBUXWYAU-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- VHYXAWLOJGIJPC-UHFFFAOYSA-N tert-butyl n-(piperidin-4-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCNCC1 VHYXAWLOJGIJPC-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 201000009825 uterine corpus cancer Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 125000005853 β-dimethylaminoethyl group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Definitions
- This invention relates to certain N-phenyl imidazole carboxamide compounds of Formula (I) as inhibitors of 3-phosphoinositide-dependent protein kinase (PDK-1).
- the compounds are useful in inhibiting the
- Certain kinases that belong to the serine/threonine kinase family are located intracellularly and are involved in the transmission of biochemical signals such as those that affect ceil proliferation and survival.
- One such serine/threonine kinase is PDK1 , which is a regulator of at least 23 protein kinases that belong to the AGC kinase family (cAMP-dependent, cGMP- dependent, and protein kinase C).
- Signal transduction pathways downstream of PDK1 include the serine/threonine kinases protein kinase B (PKB/Akt), p70 ribosomal S6 kinase (p70S6K1), serum- and glucocorticoid-tnduced protein kinase (SGK), p90 ribosomal S6 kinase (RSK), and protein kinase C (PKC).
- PBB/Akt protein kinase B
- p70S6K1 p70 ribosomal S6 kinase
- SGK serum- and glucocorticoid-tnduced protein kinase
- RSK p90 ribosomal S6 kinase
- PKC protein kinase C
- PI3K phosphoinositide-3 kinase
- PIP2 phosphoinositidylinositol- ⁇ S-triphosphate
- PIP3 phosphoinositidy[mositol-3,4,5-triphosphate
- PIP3 phosphoinositidy[mositol-3,4,5-triphosphate
- PIP3 binds to both PDK1 and PKB/Akt, which are believed to co-localize at the cell membrane as a consequence.
- PDK1 In addition to its interaction with PKB/Akt, PDK1 also phosphorylates and activates p70S6K1 , SGK, RSK and PKC, which influences cell growth, proliferation, and survival, and regulates metabolism. Bayascas, J.R., Cell Cycle, 7, 2978-2982 (2008).
- PD 1 function is critical to downstream signaling that results from activation of cells by growth factors because PKB/Akt, p70S6K, and RSK cannot be activated in cells lacking PDK1. Indeed, disrupting the PDK1 gene in mouse embryonic cells prevents activation of PKB/Akt, p70S6K, and RSK. Williams et ai, Current Biology 10, 439-447 (2000). Additionally, in an in vivo model, reducing the expression of PDK1 protects mice from developing tumors under conditions where PIP3 is elevated due to the deletion of PTEN.
- inhibiting PDK1 function is expected to mitigate tumor cell proliferation by abrogating cell signaling.
- the present invention provides compounds of Formula (I) (herein referred to as the "Imidazole Carboxamide Compounds” or “compounds of Formula (I)”) or pharmaceutically acceptable salts thereof:
- T is R A , H, halo, C C 6 alky!, (C 2 -C 3 alkynylene)-(CrC e aikyl), or
- R A is selected from the group consisting of:
- heterocyclyl of R A contains at least one ring nitrogen atom ring member, and optionally one additional heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur;
- heterocyclenyl of R A contains one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur;
- R A is unsubstituted or substituted by one to three moieties selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halo, C1-C3 fluoroalkyi, hydroxy, amino, Ci-C 6 alkyiamino,
- Y is a bond, d-C 3 aikyiene, -0-, -N(H)-, or -N(H)-(Ci-C 3
- heteroaryi of R 9 contains one to two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; or
- R 9 is unsubstituted or substituted by one to two
- each R 1 is independently H, Ci-C 6 alkyl,
- R B is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, wherein said R B is unsubstituted or substituted by one to two C1-C3 alkyl, C1-C3 aikoxy, halo, or C1-C3 fluoroalkyi;
- R 6 is H, 2 H, d-C 3 alkyl, C1-C3 aikoxy, or halogen;
- heterocyclyl moiety is a 5- to 6-membered ring containing one to two nitrogen atoms, and is unsubstituted or substituted by one to two C1-C3 alkyl, C1-C3 aikoxy, halo, or phenyl;
- n 0, 1 , or 2;
- R 4 , R 5 and R 10 are independently H r CrC 3 alkyl, fiuoro, hydroxy, amino, C C 3 alkylamino, Ci-C 3 dialkylamino, ureido, azetidinyl, pyrroiidinyl, piperidino, pyrazolyi, -(Ci-C 3 )aikylene-
- R 7 and R 8 are independently selected from the group
- R 4 , R 5 , or R 10 is -M-IM(R 7 ) ⁇ R 8 ), R 7 and R 8 together with the nitrogen atom to which it is attached form (i) R c , wherein R c is a 4- to 10-membered mono- or bicyclic heterocyclyl containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein R c is unsubstituted or substituted by 1 to 4 R 15 moieties; or
- R D is a 4- to 10-membered mono- or bicyclic heterocyc!y! containing one nitrogen atom and wherein R D is substituted by R 6 , and wherein R D is optionally and additionally substituted by 1 to 3 R 15 ;
- each R 15 is independently selected from the group consisting of C1-C3 alkyl, f!uoro, C C 3 trifluoroalkyl, (C C 3 alkylene)-OH, (Ci-C 3 alkylene)-NH 2 , and (CrC 3 aikylene)- C(0)NH 2 , or optionally two R 15 moieties together with the carbon atom to which they are attached form a carbonyl;
- R S is selected from the group
- R 4 , R 5 and R 0 together with the carbon atom(s) to which they are attached form a 5- or 6-membered cycloalkyi or heterocyclyl ring containing one to two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
- R 14 is H or C C 3 alkyi;
- R 2 and R 3 are independently selected from the group consisting of H, 2H, halo, Ci-C 3 alkyl, amino, C1-C3 alkyiamino, CrC 3 dialkylamino, carbamyl, hydroxy, cyano, trifluoromethyl, C 3 -C 7 cycloalkyi, and 5- to 6- membered heteroaryl containing one two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.
- the invention provides a pharmaceutical composition comprising an Imidazole Carboxamide Compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the invention provides an Imidazole Carboxamide Compound or a pharmaceutically acceptable salt thereof for use in therapy.
- the invention provides an Imidazole Carboxamide Compound or a pharmaceutically acceptable salt thereof for use in treating a disease or disorder characterized by excessive or pathologically elevated celi growth.
- the disease or disorder is cancer.
- the invention provides a combination comprising an Imidazole Carboxamide Compound or a pharmaceutically acceptable salt thereof and an additional anti-cancer agent for simultaneous, separate or sequential use in treating cancer.
- the present invention provides Imidazole Carboxamide Compounds and pharmaceutical compositions comprising an Imidazole Carboxamide
- the present invention provides methods of using the Imidazole Carboxamide Compounds in treating a disease or disorder characterized by excessive or pathologicaliy elevated cell growth, e.g., cancer, in a patient in need of such treatment.
- Patient includes both human and animals.
- “Mammal” means humans and other mammalian animals.
- Alky means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain.
- Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower aikyl” means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched.
- Non-!imiting examples of suitable alkyl groups include methyl, ethyl, n-propy!, isopropyl and t-butyl.
- the term "Ci-C 3 alkyl" refers to an alkyl group having from 1 to 6 carbon atoms.
- Alkenyl means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain.
- Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain.
- Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain.
- “Lower alkenyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched.
- alkenyl may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, aryl, cycloalkyl, cyano, alkoxy and -S(alkyl).
- substituents include halo, aryl, cycloalkyl, cyano, alkoxy and -S(alkyl).
- suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3- methylbut-2-enyl, n-pentenyl, octeny! and decenyl.
- Alkylene means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above.
- alkylene groups include methylene, ethylene and propylene.
- an alkylene group has from 1 to 6 carbon atoms, in one embodiment, an alkylene is branched. In another embodiment, the alkylene is linear.
- Alkynyl means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain.
- Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain.
- Lower alkynyl means about 2 to about 6 carbon atoms in the chain which may be straight or branched.
- suitable a!kynyl groups include ethynyl, propynyi, 2-butynyl and 3- methylbutynyl.
- the "alkynyl” may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of aryl and cycloalkyl.
- Aryl means an aromatic monocyclic or multicyclic ring system
- aryl group comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms.
- the aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein.
- suitable aryl groups include phenyl and naphthyl.
- Heteroaryl means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms.
- the "heteroaryl” can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
- the prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom.
- heteroaryl A nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide (indicated herein as "N(O)' '), "Heteroaryl” may also include a heteroaryl as defined above fused to an aryl as defined above.
- Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazoiyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrroly!, pyrazolyl, triazoty!, 1 ,2,4-thiadiazolyl, pyrazinyl, pyridazinyi,
- heteroaryl also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquino!yl and the like.
- heteroatoms contained in the heteroaryl group the expressions, "having one to x heteroatoms selected from the group of N, O, and S” or “having one to x heteroatoms selected from the group of N, N(O), O, and S" (wherein x is an a specified integer), for example, mean that each heteroatom in the specified heteroaryl is independently selected from the specified selection of heteroatoms.
- Aralkyl or “arylalkyl” means an ary -alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alky! group. Non-limiting examples of suitable aralkyl groups include benzyl, 2- phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
- Alkylaryl means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkyiaryis comprise a lower alkyl group. A non- limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
- Cycloalkyi means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyi rings contain about 5 to about 7 ring atoms.
- the cycloalkyi can be optionally substituted with one or more "ring system substttuents" which may be the same or different, and are as defined above.
- suitable monocyclic cyc!oalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- suitable multicyclic cycloalkyts include 1-decaiinyl, norbornyl, adamantyl and the like. ⁇
- Cycloalkylalkyl means a cycloalkyl moiety as defined above linked via an alky! moiety (defined above) to a parent core.
- suitable cycloaiky!a!kyls include cyclohexylmethyl, adamantylmethyl and the like.
- Cycloalkenyi means a non-aromatic mono or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms which ring system contains at least one carbon-carbon double bond. Preferred cycloalkenyi rings contain about 5 to about 7 ring atoms.
- the cycloaikenyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above.
- suitable monocyclic cycloalkenyis include
- cyclopentenyl cyctohexenyl, cyclohepta-1 ,3-dienyl, and the iike.
- a non-limiting example of a suitable multicyclic cycloaikenyl is norbornylenyl.
- Cycloalkenylalkyl means a cycloaikenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.
- suitable cycloa!kenyla!kyls include cyclopentenylmethyl, cyclohexenylmethyl and the iike.
- Halogen means fluorine, chlorine, bromine, or iodine. Preferred halogens are fluorine, chlorine and bromine.
- Fluoroalkyf means an alky! as defined above wherein one or more hydrogen atoms on the alkyl is replaced by a fluoro atom.
- fluoroalkyl include trifluoromethyl and 2,2,2-trifluoroethyl.
- Ring system substituent means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system.
- Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, afkenyl, alkynyl, aryl, heteroaryl, aralkyt, alkylaryl, heteroaralkyl,
- alkoxycarbonyl aryioxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroary!thio, aralkylthio,
- heteroaralkyithio, cycloalkyl, heterocyclyl, -SF 5 , -OSF 5 (for aryl), ⁇ 0-C(0)-alkyi, -0-C(0)-aryl, -0-C(0)-cycloalkyl, -C( N-CN)-NH 2 ,
- Y 1 and Y 2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryi, cycloalkyl, and aralkyl.
- Ring system substituent may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such a moiety are methylenedioxy, ethylenedioxy, - C(CH 3 > 2 - and the like which form moieties such as, for example:
- Heteroarylalkyl means a heteroaryi moiety as defined above linked via an alkyl moiety (defined above) to a parent core.
- suitable heteroaryis include 2-pyridinylmethyi, quinoiinylmethyl and the like.
- Heterocyclyi means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example, nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system.
- Preferred heterocyclyls contain about 5 to about 6 ring atoms.
- the prefix aza, oxa or thia before the heterocyclyi root name means that at least a nitrogen, oxygen or sulfur atom, respectively, is present as a ring atom.
- Any -NH in a heterocyclyi ring may exist in protected form such as, for example, as an -N(Boc), -N(CBz), -N(Tos) group and the like; such protections are also considered part of this invention.
- the heterocyclyi can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
- the nitrogen or sulfur atom of the heterocyclyi can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
- Non-limiting examples of suitable monocyclic heterocyclyi rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyi, thiazolidinyl, 1 ,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like.
- pyrrolidone In describing the heteroatoms contained in a specified heterocyclyl group, the expression, "having one to x heteroatoms selected from the group of N, O, and S" (wherein x is an a specified integer), for example, means that each heteroatom in the specified heterocyclyl is independently selected from the specified selection of heteroatoms.
- Heterocyclylalkyl means a heterocyclyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.
- suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.
- Heterocycleny means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond. There are no adjacent oxygen and/or sulfur atoms present in the ring system.
- Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms.
- the prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom.
- the heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein "ring system substituent" is as defined above.
- the nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
- Non- limiting examples of suitable heterocyclenyl groups include 1 ,2,3,4- tetrahydropyridinyl, 1 ,2-dihydropyridinyl, 1 ,4-dihydropyridinyI, 1 ,2,3,6- tetrahydropyridinyi, 1 ,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyi, 2- imidazolinyl, 2-pyrazolinyl, dihydroimidazoly!, dihydrooxazolyl,
- An example of such a moiety is pyrrolidinone:
- the expression, "having one to x heteroatoms selected from the group of N, O, and S" (wherein x is an a specified integer), for example, means that each heteroatom in the specified heterocyclenyl is independently selected from the specified selection of heteroatoms.
- Heterocyclenyialkyl means a heterocyclenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.
- heteroatom-containing ring systems of this invention there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom.
- Heteroaralky means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described.
- Preferred heteroaralky is contain a lower alkyl group.
- suitable aralkyl groups include
- Hydroxyalkyl means a HO-alkyl- group in which alkyl is as previously defined. Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
- acyl means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the various groups are as previously described.
- the bond to the parent moiety is through the carbonyl.
- Preferred acy!s contain a lower alkyl.
- suitable acyl groups include formyl, acetyl and propanoyl.
- Aroyl means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl.
- suitable groups include benzoyl and 1- naphthoyl.
- Alkoxy means an alkyi-O- group in which the alkyl group is as previously described.
- suitable aikoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy.
- the bond to the parent moiety is through the ether oxygen.
- Aryloxy means an aryl-O- group in which the aryl group is as previously described.
- suitable aryloxy groups include phenoxy and naphthoxy.
- the bond to the parent moiety is through the ether oxygen.
- Alkyloxy means an aralkyl-O- group in which the aralkyl group is as previously described.
- suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.
- the bond to the parent moiety is through the ether oxygen.
- Alky!thto means an alkyl-S- group in which the alkyl group is as previously described.
- suitable alkylthio groups include methylthio and ethylthio.
- the bond to the parent moiety is through the sulfur.
- Aminthio means an ary!-S- group in which the aryl group is as previously described.
- suitable aryithio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the su!fur.
- Alkylthio means an aralkyl-S- group in which the aralkyl group is as previously described.
- a non-limiting example of a suitable aralkylthio group is benzylthio.
- the bond to the parent moiety is through the sulfur.
- Alkoxycarbonyl means an alkyl-O-C(O)- group.
- suitable alkoxycarbonyl groups include methoxycarbonyl and
- Aryloxycarbonyl means an aryl-O-C(O)- group.
- suitable aryloxycarbonyl groups include phenoxycarbonyl and
- Alkoxycarbonyl means an aralkyl-O-C(O)- group.
- a suitable aralkoxycarbonyl group is benzy!oxycarbony!.
- the bond to the parent moiety is through the carbonyl.
- Alkylsulfonyi means an alkyl-S(0 2 )- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.
- Arylsulfonyl means an aryI-S(0 2 ) ⁇ group. The bond to the parent moiety is through the sulfonyl.
- substituted means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound.
- purified means optional substitution with the specified groups, radicals or moieties.
- purified means optional substitution with the specified groups, radicals or moieties.
- purified means optional substitution with the specified groups, radicals or moieties.
- purified means optional substitution with the specified groups, radicals or moieties.
- purified means optional substitution with the specified groups, radicals or moieties.
- purified means optional substitution with the specified groups, radicals or moieties.
- purified form or isolated and purified form for a compound refers to the physical state of said compound after being isolated from a synthetic process ⁇ e.g., from a reaction mixture), or natural source or combination thereof.
- purified refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan (e.g., chromatography, recrystallization and the like), in sufficient purity to be characterized by standard analytical techniques described herein or well known to the skilled artisan.
- any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.
- any one or more of these hydrogen atoms can be deuterium.
- protecting groups When a functional group in a compound is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in Organic Synthesis (1991 ), Wiley, New York.
- variable e.g., aryl, heterocycle, R 2 , etc.
- its definition on each occurrence is independent of its definition at every other occurrence.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- Prodrugs and solvates of the compounds of the invention are also contemplated herein.
- a discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S.
- prodrug means a compound (e.g., a drug precursor) that is transformed in vivo to yield a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in biood.
- prodrugs are provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible
- a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (Ci- Cajalkyl, (C 2 -Ci 2 )alkanoyloxymethyi, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyI-1-(alkanoyioxy)-ethyi having from 5 to 10 carbon atoms, alkoxycarbonyloxymethy! having from 3 to 6 carbon atoms, 1- (alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1 ⁇
- alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N- (alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N- (alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthaiidyl, 4- crotonolactonyl, gamma ⁇ butyrolacton-4-yl, di-N,N-(Ci-C 2 )aikyIamino(C 2 -C 3 )alkyl (such as ⁇ -dimethylaminoethyl), carbamoyl-(CrC 2 )alkyl, N,N-di (C-i-
- a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (Ct-Cejalkanoyloxymethyl, 1-((Ci-C 6 )alkanoyloxy)ethyl, 1-methyl-1-((Ci-C 6 )alkanoyloxy)ethyl, (Ci- C 6 )a!koxycarbonyloxymethyl, N-(Ci ⁇ C 6 )alkoxycarbony!aminomethyi, succinoyl, (CrC 6 )atkanoyi, a-amino(Ci-C 4 )alkanyl, arylacyl and a-aminoacyl, or a- aminoacyl- a -aminoacyl, where each a -aminoacyl group is independently selected from the naturally occurring L-amino acids, -P(0)(OH) 2
- a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbony!,
- R and R' are each independently (Ci-Cio)alkyl, (C 3 -C 7 ) cycloalkyl, benzyl, or R-carbonyl is a natural a-aminoacyl or natural a - aminoacyl,
- Ceiaikyl amino(Ci-C 4 )alkyl or mono-N— or di-N,N-(Ci-C 6 )alkylaminoalkyl, ⁇ C(Y 4 )Y 5 wherein Y 4 is H or methyl and Y 5 is mono-N— or di-N,N-(C r
- One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.
- “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covending bonding, including hydrogen bonding, in certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
- “Solvate” encompasses both solution- phase and isolatable solvates.
- suitable solvates include ethanolates, methanolates, and the like.
- “Hydrate” is a solvate wherein the solvent molecule is H 2 O.
- One or more compounds of the invention may optionally be converted to a solvate.
- Preparation of solvates is generally known.
- M. Caira ef al, J. Pharmaceutical Sci Surf 93(3), 601-61 1 (2004) describes the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water.
- Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et at, AAPS PharmSciTech., 5(1), article 12 (2004); and A. L. Bingham et al, Chem. Commun., 603-604 (2001).
- a typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods.
- Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
- Effective amount or “therapeutically effective amount” is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
- PDK1 is meant to refer to wild type PDK1.
- PDK1 variant or “variant of PDK1" is meant to refer to PDKI having at least one point mutation, insertion, or deletion.
- the compounds of Formula (I) can form salts which are also within the scope of this invention.
- Imidazole Carboxamide Compound herein is understood to include reference to salts thereof, unless otherwise indicated.
- a compound of Formula (i) contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term "salt(s)" as used herein.
- Salts of the compounds of Formula (I) may be formed, for example, by reacting a compound of Formula (I) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
- Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromtdes, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesu!fonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like.
- Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexyiamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
- alkali metal salts such as sodium, lithium, and potassium salts
- alkaline earth metal salts such as calcium and magnesium salts
- salts with organic bases for example, organic amines
- organic amines such as dicyclohexyiamines, t-butyl amines
- salts with amino acids such as arginine, lysine and the like.
- Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides ⁇ e.g., methyl, ethyl, and butyl chlorides, bromides and iodides), diaikyl sulfates (e.g., dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g., decy!, lauryl, and steary! chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.
- agents such as lower alkyl halides ⁇ e.g., methyl, ethyl, and butyl chlorides, bromides and iodides), diaikyl sulfates (e.g., dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g., decy!
- esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxy methyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethy!), aryl (for example, phenyl optionally substituted with, for example, halogen, C- alkyl, or or amino); (2) sulfonate esters, such as alkyl- or aralkyisuifonyi (for example, methanesulfonyl); (3) amino acid esters (for example, L-valy!
- phosphate esters may be further esterified by, for example, a C 1-2 o alcohol or reactive derivative thereof, or by a 2,3-di (C 6-24 )acyl glycerol.
- the compounds of Formula (I), and salts thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
- the compounds of Formula (I) may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomers forms. It is intended that all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures, form part of the present invention.
- the present invention embraces all geometric and positional isomers. For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
- Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
- Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiraf alcohol or Mosher's acid chloride), separating the diastereomers and
- All stereoisomers for example, geometric isomers, optical isomers and the like
- of the present compounds including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs
- those which may exist due to asymmetric carbons on various substituents including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
- a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
- all keto-enol and imine-enamine forms of the compounds are included in the invention.
- Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
- the chiral centers of the present invention can have the S or R configuration as defined by the lUPAC 1974
- the present invention also embraces isotopically-labe!led compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine and iodine, such as 2 H, 3 H, 1 C, 13 C, 14 C, 15 N, 8 0, 17 0, 31 P, 32 P, 35 S, 18 F, 36 C! and 123 l, respectively.
- Certain isotopically-labe!led compounds of Formula (I) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability.
- Certain isotopically-iabeiled compounds of Formula (I) can be useful for medical imaging purposes. For instance those compounds labeled with positron- emitting isotopes like 1 C or 18 F can be useful for application in Positron
- Emission Tomography PET
- those labeled with gamma ray emitting isotopes like 123 1 can be useful for application in Single Photon Emission
- Computed Tomography SPECT
- substitution of compounds with heavier isotopes such as deuterium i.e., 2 H
- isotopic substitution of a compound at a site where epimerization occurs may slow or reduce the epimerization process and thereby retain the more active or efficacious form of the compound for a longer period of time.
- Isotopicalty labeled compounds of Formula (I) in particular those containing isotopes with longer half lives (T1/2 >1 day), can generally be prepared by foiiowing procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an appropriate isotopicaliy labeled reagent for a non-isotopically labeled reagent.
- the present invention further includes the compounds of Formula (I) in all their isolated forms.
- the above-identified compounds are intended to encompass all forms of the compounds such as, any solvates, hydrates, stereoisomers, and tautomers thereof.
- the compounds according to the invention have pharmacological properties; in particular, the compounds of Formula (i) can be inhibitors of PDK- 1.
- the present invention provides Imidazole Carboxamide Compounds having the Formula (I), or pharmaceutically acceptable salts thereof, wherein D, T, R 1 , R 2 , R 3 , and R 6 are as defined above for the compound of Formula (I).
- the compounds of Formulas (la) and (lb), as are described in detail below, are embodiments of the compound of Formula (I).
- R 6 is H. tn other embodiments, R 6 is 2 H.
- D is selected from the group consisting of:
- D is
- M is a direct bond, -C(O)-, or methylene
- R 4 and R 6 are independently selected from the group consisting of H, C1-C3 alkyl, and fluoro
- R 7 and R 8 are independently selected from the group consisting of H, d-C 3 alkyi, -CH 2 CH 2 NH 2 , -CH 2 CH 2 NHCH 2 CH 3 , -CH 2 CH 2 CH 2 CH 2 NHCH 3 , cyclohexylamino,
- R c is a 4- to 10-membered mono- or bicyclic heterocyclyl containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein R c is unsubstituted or substituted by 1 to 4 R 15 moieties; or
- R D is a 4- to 10-membered mono- or bicyclic
- each R 5 is independently selected from the group consisting of C1-C3 alkyl, fluoro, C1-C3 trifluoroalkyl, (C C 3 alkylene)-OH, (C C 3 alkylene)-NH 2) and (Ci-C 3 atkylene)-C(0)NH 2t or optionally two R 15 moieties together with the carbon atom to which they are attached form a carbonyl;
- R 16 is selected from the group consisting of (C C 3 a!kylene)- OH, (Ci-C 3 alkylene)-NH 2 , and (C C alkylene)-C(0)NH 2 .
- R 7 , and R 8 are as described above, M is -C(O)-.
- T is selected from the group consisting of
- R A wherein R A is selected from the group consisting of cyclopropyl, phenyl, pyrazolyl, thienyl, pyridinyi, pyrimidinyi, pyridazinyl, indolyl, piperidinyl, piperazinyl, and dihydropyranyl, wherein R A is unsubstituted or substituted by one to three moieties selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halo, trifluoromethyl, hydroxy, amino, Ci-C 6 alkylamino, C C 6 dialkylamino, Ci-C 6 hydroxyalkyl, cyano, ⁇ C(0)-(CrC 6 alkyl),
- T is selected from the group consisting of
- R A is selected from the group consisting of phenyl, pyrazotyl, thienyi, pyridinyl, pyrimidinyl, tndolyl, and dihydropyranyl, wherein said cyclic moiety of T is unsubstituted or substituted by 1 to 2 moieties selected from the group consisting of methyl, ethyl, fiuoro, chloro, methoxy, cyc!opropyl, amino, methylamino, dimethylamtno, cyclopropylamino, benzylamino, cyano, hydroxymethyl, 2-hydroxyethyl, sulfonamido, acetamido, acetyl, trifluoromethyl, pyrazolyl, benzyl, thienylmethyl, and pyridinylmethyl.
- T is selected from the group consisting of:
- T is selected from the group consisting of:
- T is R A , wherein R A is selected from the group consisting of substituted or unsubstituted cyclopropyl, phenyl, pyrazolyl, pyridinyl, pyrimidinyl, indolyl, piperidinyl, piperazinyl, and dihydropyranyi, wherein R A is unsubstituted or substituted by one to three moieties selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halo, trifluoromethyl, hydroxy, amino, Ci-C 6 alkylamino, Ci-C 6 diaikylamino, C Ce hydroxyalkyl, sulfonamide,
- R 4 and R 5 are independently selected from the group consisting of H,
- R 7 and R 8 are independentiy selected from the group consisting of H,
- R c is a 4- to 10-membered mono- or bicyclic
- heterocyclyl containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein R c is unsubstituted or substituted by 1 to 4 R 15 moieties; or
- R D is a 4- to 10-membered mono- or bicyclic
- each R 5 is independently selected from the group consisting of C1-C3 alkyl, fiuoro, d-C 3 trif!uoroalkyl, (C C 3 alkylene)-OH, (C1-C3 alkylene) ⁇ NH 2 , and (Ci ⁇ C 3 alkylene)-C(0)NH 2 , or optionally two R 15 moieties together with the carbon atom to which they are attached form a carbonyl;
- R 16 is selected from the group consisting of (C-t-C 3 alkylene)- OH, (C1-C3 alkylene)-NH 2j and (C C 3 alkylene)-C(0)NH 2 ;
- R 6 is H
- R 1 , R 2 , and R 3 are independently selected from the group consisting of H, fiuoro, and pyrazolyl.
- M is a direct bond, -C(O)-, or methylene
- R 4 and R 5 are independently selected from the group consisting of H,
- R 7 and R 8 are independently selected from the group consisting of H,
- R c is a 4- to 10-membered mono- or bicyciic
- heterocyclyl containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein R c is unsubstituted or substituted by 1 to 4 R 15 moieties; or
- R D is a 4- to 10-membered mono- or bicyciic heterocyclyl containing one nitrogen atom and wherein R D is substituted by R 16 , and wherein R D is optionally and additionally substituted by 1 to 3 R 16 ;
- each R 15 is independently selected from the group consisting of C1-C3 aikyl, f!uoro, d-C 3 trifluoroalkyi, (C C 3 alkylene)-OH,
- R 16 is selected from the group consisting of (C1-C3 alkylene)-
- R s is H
- R 1 , R 2 , and R 3 are independently selected from the group consisting of H, fluoro, and pyrazoiyi.
- R , R 2 , and R 3 are independently selected from the group consisting of H, halo, and pyrazoiyi.
- X is CH or N
- R 12 and R 13 are independently selected from the group consisting of H, Ci- C 3 alkyl, amino, Ci-C3 ⁇ 4 alkylamino, and hydroxymethyl;
- R 1 is H or halo; M is a direct bond or methylene; and
- R 7 and R 8 are independently H or C 1 --C3 alkyi.
- X is CH or N
- R 12 is C -C3 alkylamino
- R 3 is a 4- to 7-membered monocyclic heterocyclyl wherein said
- heterocyclyl contains at least one ring nitrogen atom ring member, and optionally one additional heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur; wherein said monocyclic heterocyclyl is unsubstituted or substituted by one to three moieties selected from the group consisting of C1-C3 alkyi, C 1 -C3 alkoxy, halo, C 1 -C3 fluoroalkyl, hydroxy, amino, Ci-C 6 alkylamino,
- d-Ce dialkytamino C C 6 hydroxyalky!, Ci-C 6 alkylamino, cyano, -C(0)-(Ci-C 6 alkyi), -C(0)-0-(Ci-C 6 alkyi), suifonamido,
- Y is a bond, d-C 3 alkylene, -0-, -N(H)-, or -N(H)-(C C 3
- heteroaryl of R 9 contains one to two heteroatoms selected from the group consisting of nitrogen,
- R 9 is unsubstituted or substituted by one to two C1-C3 alkyl, C 1 -C3 alkoxy, halo, or C1-C3 fluoroalkyl;
- each R 1 is independently H, Ci-C 6 alkyl, (C3-C7) cycloalkyl, (C 6 -Cio) aryl, -(C1-C3 alkylene Nid-Cs alkyl) 2> -(C C 3 alkylene)-R B , or optionally, the R 11 groups together with the nitrogen atom to which they are attached, form a 5- to 6- membered heterocyclyl containing one to two nitrogen atoms, which is heterocyciy! is optionally substituted by C-r C 3 alkyl;
- R B is phenyl, pyridinyl, pyrimidinyl, pyraztnyl, or pyridazinyl, wherein said R B is unsubstituted or substituted by one to two C 1 -C3 alkyl, C 1 -C3 alkoxy, halo, or C1-C3 fluoroalkyl;
- R is H or halo
- M is a direct bond or methylene
- R 7 and R 8 are independently H or C 1 -C3 alkyl.
- R 1 is fluoro
- the moiety is selected from the group consisting of
- the moiety is selected from the group consisting of
- the compound of Formula (I) has the Formula (lb):
- X is CH or N
- R 12 and R 3 are independently selected from the group consisting of H, C C 3 alkyl, amino, C 1 -C3 alkylamino, carbamyl, hydroxymethyl, benzylamino, 4- fluorobenzylamino, 3,4-difluorobenzylamino, 4-trifluorobenzylamino, 3,4- dimethoxybenzylamino, and 2-hydroxy-1-phenylethylamino;
- R 1 is H or halo;
- R 7 and R 8 are independently H, C1-C3 alky!, (C C 6 alkylene)-NH 2 , (C C 6 alkylene)-N(H)(CrC 3 alkyl), (C C 6 alkytene)-N(C C 3 alkyl) 2 ,
- R c is a 4- to 10-membered mono- or bicyciic heterocyciyi containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein R c is unsubstituted or substituted by 1 to 2 R 15 moieties; or
- R D is a 4- to 10-membered mono- or bicyciic
- heterocyciyi containing one nitrogen atom and wherein R D is substituted by R 16 , and wherein R D is optionally and additionally substituted by 1 to 2 R 5 moieties;
- each R 15 is independently selected from the group consisting of Ci-C 3 alkyl, fluoro, C 1 -C3 trifluoroalkyl, (C C 3 alkyiene)-OH, (C C 3 aikylene)-NH 2) and (C C 3 aikylene)-C(0)NH 2 ; and
- R 16 is selected from the group consisting of (Ci-C 3 alkylene)- OH, (Ci-C 3 alkylene)-NH 2 , and (C C 3 alkylene)-C(0)NH 2 .
- X is CH
- R 2 is H
- R 13 is CH 3 ;
- the invention provides also provides compounds 1-96 as set forth be!ow, and pharmaceutically acceptable salts thereof:
- the compounds according to the invention have pharmacological properties; in particular, the compounds of the present invention can be inhibitors, regulators or modulators of protein kinases, such as PDK1.
- the compounds of Formula (i) can be prepared from known or readily prepared starting materials, following methods known to one skilled in the art of organic synthesis. Methods useful for making the compounds of Formula (I) are set forth in the Examples below. Alternative synthetic pathways and analogous structures will be apparent to those skilled in the art of organic synthesis. Ail stereoisomers and tautomeric forms of the compounds are contemplated.
- the description indicates the reaction mixture was purified by HPLC, the description refers to using a preparative Agilent 1100 Series LC/MSD SL system: Column Reverse Phase- Varian Pursuit XRs 10pC-18 250 X 21.2mm; elution with gradient
- pH concentration of hydronium ions in a solution
- DIPEA diisopropylethylamine
- HATU 0-(7-azabenzo ⁇ riazoi-1 -yl)-N,N,N ⁇ N ⁇ etramethyluronium
- CDI N,N'-carbonyldiimidazole
- HMDS hexamethyldisilazane
- UV ultraviolet
- Step B Synthesis of Ethyl 4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- imidazole-2-carboxylate (lnt-1b)
- Step E (R)-tert-butyl 1-(2-(4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl) ⁇ 1H ⁇ imidazole-2-carboxamido)phenyl)piperidin-3-ylcarbamate (lnt-1e)
- Step G N-[2-(3(R)-amino-1 ip ⁇ ridinyl) ⁇ 3-fluorophenyl]-4 ⁇ [1-(2 h ⁇
- Step B Synthesis of: tert-butyl (1-(2-amino-6-fluorophenyi)piperidin-4- yl)methylcarbamate (lnt-2b)
- Step D Synthesis of tert-butyl (1-(2-(4-(2-methylpyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-ca ⁇ o
- Step E N-[2-[4-(aminomethyl)-1 ⁇ iperidiny ⁇ ] ⁇ 3-fluoro ⁇
- Step B Synthesis of Lithium 4 ⁇ (1 ⁇ benzyl-1H-pyrazol-4-yl)-1-((2- (trimeth lsil l)ethoxy)methyl)-1H-imidazole-2-carboxylate (lnt ⁇ 5b)
- Step B Synthesis of (R)-tert-butyl 1-(2-fluoro-6-(4-(1-(pyridin-3-ylmethyl) ⁇ 1H- pyrazol-4 ⁇ yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imM ⁇
- Step C N-[2-(3(R)-amino-1 ⁇ iperidinyl)-3jluorophenyl]-4-[1-(3-
- Step A Synthesis of(R)-tert-butyl 1-(2-(4-(2-chloro-6-methylpyridin ⁇ 4 ⁇ yl)-1-((2- (trimethylsilyl)ethoxy)methyl) ⁇ 1H-imidazole-2 ⁇ ca
- Step B Synthesis of 4-(2-amino-6-methyl ⁇ 4-pyridinyl)-N-[2-(3(R)-amino-1- piperidinyl)-3 ⁇ fluorophenyl]-1H-imidazole-2-carboxamide (24)
- Step A (R)-met yl 4-(2-(2-(3-(tert-butoxycarbonylamino)piperidin-1-yl)-3- fluorophenylcarbamoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)- ⁇
- Tetrakistriphenylphosphorous palladium (17 mg, 0.015 mmol) was added. The mixture was heated in a microwave reactor at 1 0 °C for 1 h. Water and ethyl acetate were added and layers were separated. The separated aqueous layer was extracted with ethyl acetate. The separated organic layer was dried (MgS0 4 ) and filtered. The solvents were removed in vacuo and
- Methyl ester lnt-8a (20 mg, 0.046 mmol) was stirred in tetrahydrofu an (2 mL) at 0 °C. Lithium aluminum hydride (0.1 mL, 1 M in tetrahydrofuran) was added. The mixture was allowed to warm to r.t. and was quenched with a saturated solution of potassium sodium tartrate. Methanol and silica were added and the solvents were removed in vacuo. Chromatographic purification [dichloromethane -methanol (7 N ammonia)] of the residue gave
- Step C Synthesis of N-[5-amino ⁇ 2-(3(R)-amino-1-piperidinyl)phenyl]-1 H- imidazoie-2-carboxamide (1)
- Step B Synthesis of N-[5-amino-2 ⁇ (3(R)-amino-1-piperidinyl)phenyl]-4-bromo- 1 H ⁇ imidazoIe-2 ⁇ carboxamide (16)
- lnt-11a was prepared using procedures similar to those described in Step D of Example 1.
- Step C Synthesis ofN-[2-[4-(aminomethyl) ⁇ 1 ⁇ iperidinyl]-3 -difluorophenyl] ⁇ 4-(2-amino ⁇ 4 ⁇ yridinyl)-1H-imidazole-2-carboxamide (28)
- Aminopyridine lnt-12b (46 mg, 0.097 mmol) was stirred in 4 N hydrochloric acid in 1 ,4-dioxane (2 mL) and methanol (2 mL) at 50 °C for 2 h. The solvents were removed in vacuo. Chromatographic purification
- lnt-13b was prepared using procedures similar to those described in Steps D and E of Example 1.
- Step B Synthesis of tert-butyl 4-(2 ⁇ (2-(4-((dimethylamino)methyl)piperidin ⁇ 1 ⁇ yl)phenylcarbamoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-im ⁇
- Step C 4 ⁇ (2-amino ⁇ 4 ⁇ yrid yl)-N-l2 ⁇ [4 ⁇ [(dimet y
- Step B Synthesis of tert-butyi 4-(4-carbamoyl-4-(methylamino)piperidin-1 ⁇ yl) ⁇ 3-( 1 H-imidazote-2-carboxamido)phenylcarbamate (lnt-14b)
- Step A Synthesis of 4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2 ⁇ yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1 t-15a)
- Step B Synthesis of tert-butyl (1-(4-bromo-2-nitrophenyl)piperidin-4 ⁇ yl)methylcarbamate (lnt ⁇ 15b)
- Nitrobenzene lnt-15b was prepared by following similar procedures to those described in Step A of Example 2 using 4-bromo-1-fluoro-2-nitrobenzene and ferf-butyl piperidin-4-yImethyicarbamate as starting materials.
- Step C Synthesis of tert-butyl (1-(2-nitro-4-(1-((2- (trimethyls ⁇ lyl)ethoxy)methyl)-1H yrazol ⁇ 4 ⁇ yl) henyl) iperidin-4- yl)methylca
- Step D Synthesis of tert-butyl (1-(2-a ino-4-(1 ⁇ ((2- (trimethylsilyl)ethoxy)methyl)-1H ⁇ yrazol-4-yi)phenyl)piperidin ⁇
- Aniline lnt-15d was prepared from pyrazole Int-15c by following a similar procedure as that described in Example 2, Step B.
- Step E Synthesis of tert-butyl (1-(2-(4-bromo-1-((2- (trimethylsilyl)ethoxy)methyl)-1H ⁇ imidazole ⁇ 2-carboxam
- Step F Synthesis of tert-butyl (1-(4-(1 ⁇ (2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazol-4-yl) ⁇ 2-(1-((2-(trimethylsilyl)ethoxy)meth ⁇
- Amide lnt-15f was prepared from lnt-15e and lnt-15a by following a similar procedure to that described in Example 1 , Step F.
- LCMS m/e (M + H + ) 923.4.
- Step G Synthesis of N ⁇ [2-[4-(aminomethyl) ⁇ 1-piperidinyl]-5-(1 H-pyrazol-4- yl)phenyl]-4-(1H ⁇ pyrazol-4-yl)-1H-imidazole-2-carboxamide (51)
- Step B 4-(2-methylpyridin-4-yl)-1-((2-(trimethylsiW
- Step D Synthesis of Benzyl-2-(piperidin-4-yl)propan ⁇ 2 ⁇ ylcarbamate (lnt-16e)
- Step E Synthesis ofBenzyl-2-(1-(2 luoro ⁇ 6 ⁇ nitrophenyl)piperidin-4-yl)propan- 2-ylca
- Step F Synthesis of Benzyl 2-(1-(2-amino-6-fluorophenyl)piperidin ⁇ 4 ⁇ yl)prop -2-ylcarbamate (lnt-16g)
- Step G Sythesis of Benzyl2-(1-(2 luoro-6-(4-(2-methylpyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxam
- Step H Synthesis of N-(2-(4 ⁇ (2 ⁇ aminopropan-2-yl)piperdin-1-yl)-3- fluouophenyl)-4-(2-methylpyridin-4-yl) 1 -((2-(trimethylsilyl)ethoxy)methyl)-1H- imidazole-2-carboxamide (Int- 16i)
- Step I Synthesis of N-[2-[4-(1-amino-1-methyiethyl)-1-piperidinyl]-3- fluorophenyl]-4 ⁇ (2 ⁇ methyl-4-pyridinyl)-1H-imidazole-2-carboxam ⁇ (67)
- Step B Synthesis of teii-Butyl (1-(2-fluoro-6-nitrophenyl)piperidin-4- yl)methyl(methyl)carbamate (lnt-17b)
- amine lnt-18a (920 mg, 4.1 mmol) (prepared according to Le Huerou, Y. et al. WO 2009/140320), difluoro-nitr (678 mg, 4.1 mmol), and DIPEA (1.05 g, 8.2 mmol) in acetonitriie (12 mL) was stirred at 80 °C overnight. After cooling to room temperature, the mixture was diluted with ethyl acetate (60 mL), washed with water (20 mL) and brine (20 mL), dried over sodium sulfate, filtered, and the solvent removed in vacuo to give lnt-18b ( .5 g, >99%) as an orange foam.
- Step B Synthesis of tert-butyl 6-(2-amino-6-fiuorophenyt)octahydro-1H- pyrrolo -c]pyridine- 1 -carboxyla te (lnt-18c)
- Step C Synthesis of tert-butyl6-(2-fluoro-6-(4 ⁇ (2-methylpyridin-4 ⁇ yl) ⁇ 1-((2 ⁇ (trimethylsilyl)ethoxy)methyl)-1H-imidazole ⁇ 2 ⁇ carboxamido)
- Step D Synthesis ofN-[3-fluoro-2-(octahydro-6H-pyrrolo[2,3-c]pyridin-6- yl)ph ⁇ -4-(2-methyl-4 ⁇ yridinyl)-1H-imidazole ⁇ 2-carboxamide (43)
- Step B Synthesis of tert-butyl 9-(2-amino-6-fluorophenyl)-2,9- diazaspiro[5.5]undecane ⁇ 2-carboxylate (lnt-19c)
- Step C Synthesis of tert-butyl 9 ⁇ (2-fIuoro ⁇ 6 ⁇ (4-(2 ⁇ methylpyridin ⁇ 4-yl)-1-((2- (t methylsilyl)ethoxy)methyl)- 1 H-imidazole-2 ⁇ carboxamido)phenyI)-2, 9- diazaspiro[5.5]undecane ⁇ 2-carbox late (lnt-19d)
- Step D Synthesis ofN-[2-(2,9-diazaspiro[5.5]undec-9-yl)-3-fluorophenyl]-4-(2- methyl- -pyridinyl)- 1 H-imidazole-2-carboxami
- Step C Synthesis of Methyl 1-(2-fluoro-6-(4 ⁇ (2 ⁇ methylpyridin-4-yl)-1-((2- (tnmethyisilyi)ethoxy)methyl)-1H-imidazole-2-carboxamido)p ⁇
- Step D Synthesis of 1 ⁇ (2-fluoro ⁇ 6-(4-(2-methylpyridin-4-yl)-1 ⁇ ((2 ⁇
- Methyl ester lnt-20c (71 mg, 0.13 mmo!) was dissolved in MeOH/THF (2 mL each), and water (0.5 mL) was added to the round-bottomed fiask.
- Sodium hydroxide (4 pellets) was added to the round-bottomed flask, and the mixture was stirred vigorously at r.t. overnight.
- the solvents were concentrated in vacuo and 4 N HCI was slowly added to the solid until a neutral pH was reached.
- the solid product that crashed out was filtered and dried under vacuum to give lnt-20d (50 mg, 72%) as a white solid.
- Step E Synthesis of /V-ethy!-1-(2-fluoro-6-(4-(2-methylpyridin-4-yl)-1 -((2- (trimethyls ' !lyl)ethoxy)methyl)- H-imidazole-2-carboxamido)phenyl)piperidine-4- carboxamide (lnt-20e)
- Step F Synthesis of N-ethyl-1 -[2-fluoro-6-[[[4 ⁇ (2-methyl-4-pyridinyl)-1 H- imidazol-2 ⁇ yl]carbonyl]amino]phenyl]-4 ⁇ piperidinecarboxamide (60)
- Step A Synthesis of 4-(1-benzyl-1H-pyrazol-4-yl)-N-(2-(2- (dimethylamino)ethy!amino)phenyl)-1 ⁇ ((2 ⁇ (trimethylsilyl) ⁇
- Step A Synthesis of 4 ⁇ bromo-N-(2-(2 ⁇ (dimethylamino)ethylamino)phenyl)-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H ⁇ imidazole ⁇ 2-carboxam (lnt-22a)
- Step B Synthesis of N-(2 ⁇ (2-(dimethylamino)ethoxy)phenyl)-4-(1- (phenylsuifonyl)- 1 H-in doi ⁇ 3-yl)- 1-((2 ⁇ ( trimethylsilyl) e thoxy)methyl) ⁇ 1 H- imidazole-2-carboxamide (lnt-22b)
- Tetrakistriphenylphosphorous palladium was added. The mixture was heated in a microwave reactor at 110 °C for 1 h. Water and ethyl acetate were added, and the layers were separated. The separated aqueous layer was extracted with ethyl acetate. The separated organic layer was dried (MgS0 ) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave indole lnt-22b (112 mg, 84%) as a colorless oil.
- Step C Synthesis of N-(2 ⁇ (2 ⁇ (dimethylamino)ethoxy)phenyl)-4-(1 ⁇
- Step D Synthesis of N-[2 ⁇ [2-(dimethylamino)ethoxy]phenyl]-4-(1 H-indol-3-yl) ⁇ 1 H-imidazole-2-carboxamide (17)
- Pd(dppf)CI 2 .CH 2 CI 2 (10 mg, 0.013 mmol) in 1 ,4-dioxane (5 mL) at r.t. was purged with nitrogen gas for 5 min in a sealed-tube. The mixture was heated at 85 °C overnight. The mixture was cooled to r.t. and transferred to a microwave vial. Chloropyrimidine lnt-23a (87 mg, 0.25 mmol), sodium carbonate (67 mg, 0.64 mmol) in ethanol (2 mL), toluene (2 mL) and water (1 mL) and Pd(PPh 3 ) (15 mg, 0.013 mmol) were added.
- Step B Synthesis ofN-[2 ⁇ [4 ⁇ (aminomethyt)-1 ⁇ piperidinyl]-3-fluorophenyl]-4-(2- amino ⁇ 'methyl-4 ⁇ yrimidinyl)'1H-im ⁇ dazole-2-ca ⁇ oxamid ⁇ (47)
- R 6 is H
- T is a substituted pyrimidine moiety
- D is The preparation is illustrated by the preparation of compound
- lnt-25a was prepared using similar procedures as described in Step A of Example 24.
- lnt-25b was prepared using similar procedures as described in Step A of Example 24.
- Step C Synthesis ofN-[2-[4 ⁇ (ammQmethyl)-1 ⁇ iperidinylJ-3-fluoroph
- lnt-26a was prepared using similar procedures as described in Step A of Example 24.
- Imidazole Carboxamide Compounds can be prepared which bear 2 H substituents. This example describes a method useful for preparing Imidazole Carboxamide Compounds wherein R 6 is 2 H. lnt-27c
- lnt-27a is heated with palladium on carbon in the presence of 2 H 2 0 to provide the deuterium-containing intermediate lnt-27b.
- lnt-27b is prepared by treating lnt-27a with N-bromosuccinimide followed by hydrogenation with deuterium gas.
- int-27b is converted to Int-27c using procedures similar to those described in Steps A and B of Example 1.
- Int-27c is saponified as described in Step C of Example 1 to provide Int
- This example describes a method useful for preparing Imidazole Carboxamide Compounds wherein R is 2 H.
- nitrobenzene lnt-28a is displaced with the substituted piperidine using conditions such as those described above in Step A of Example 2 to provide lnt-28b.
- Hydrogenation of lnt-28b with Pd/C in deuterium gas provides aniline lnt-28c.
- Int-28c can be condensed with various imidazole carboxylic acid intermediates and deprotected as described above to provide Imidazole Carboxamide Compounds wherein R 1 is 2 H.
- phosphorylation of a substrate by PDK1 uses the IMAP® technology system available from Molecular Devices (Silicon Valley, CA, United States).
- the technology enables the detection of the phosphorylation of protein substrates by PDK1 and does not require the addition of antibodies to detect substrate phosphorylation.
- the technology is based on the high-affinity interaction of triva!ent metal containing nanoparticles (beads) with phospho-groups on the substrate of interest.
- the readout for the assay was fluorescence polarization (FP) which increased once the fluorescently labeled substrate was
- Addition of the IMAP® Binding System (available from Molecular Devices) stopped the kinase reaction and specifically bound the phosphorylated substrates. Phosphorylation and subsequent binding of the substrate to the beads was detected by FP.
- the PDK1 IMAP assay utilized recombinant human PDK1 produced in Sf9 insect cells and containing amino acids 51-556 of the human PDK1 enzyme.
- the assay measured the change in fluorescence polarization caused by phosphorylation of a peptide substrate by PDK1. Addition of smali molecule PDK1 inhibitors results in the reduction of peptide phosphorylation changing the fluorescence polarization which is measured using a fluorescence plate reader.
- the assay was performed in a 384-well plate with 10 nM PDK1 enzyme, 100 nM peptide substrate 1 (SEQ ID NO:1 ), 100 nM activated peptide PIFtide and 2.5 uM ATP for 1.5 hours. PIFtide is added separately to the IMAP reaction at 100 nM.
- the peptide sequence of PIFtide is
- RREPRILSEEEQEMFRDFDYIADWC SEQ ID NO:2.
- PIFtide is a peptide sequence that interacts with PDK-1 and is derived from PRK2 kinase, a PDK-1 substrate. This sequence is present in the hydrophobic motif present in PDK-1 substrates and binds to the kinase domain of PDK-1. It is thought to act as a docking site for PDK-1 on the substrate and in vitro has been shown enhance PDK-1 phosphorylation of substrates by approximately 4-fold. See Biondi et al., EMBO 19, 979-988 (2000).
- the detection beads were then added and allowed to incubate for 1 hour at room temperature and the fluorescence was then read.
- Staurosporine a broad spectrum kinase inhibitor, was used as a positive control for the assay resulting in typical tCsos of 3 nM.
- Test compounds in 100% DMSO at a range of concentrations were added at 0.5 ⁇ 15 minutes prior to ATP addition.
- the fluorescence polarization units (mP) generated with 1 uM stauroporine is considered to be background mP and the mP units generated with DMSO is considered to be total mP for each assay.
- the IC 5 o value is calculated based on fitting the mP units to the total and background mP and the concentration required to inhibit the mP units by 50% is reported to be the IC50.
- Table 6 below lists representative compounds of the invention with activity data whereby the IC 50 values are rated “A”, “B,” “C,” or “D.”
- the IC 50 values are rated “A” for IC 50 values in the range of 1 nM to 50 nM, "B” for 1C 50 values in the range from 51 nM to 250 nM, “C” for IC50 values in the range from 251 nM to 1 ⁇ , and “D” for IC 50 values in the range from 1-5 ⁇ .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention provides Imidazole Carboxamide Compounds of Formula (I): wherein D, T, R1, R2, R3, and R6 are as defined herein, and pharmaceutically acceptable salts of such Imidazole Carboxamide Compounds. The Imidazole Carboxamide Compounds are useful in the treatment of cancer and other aberrant conditions that result from overstimulation of the PDK-1 signaling pathway.
Description
-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF
3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1
FIELD OF THE INVENTION
This invention relates to certain N-phenyl imidazole carboxamide compounds of Formula (I) as inhibitors of 3-phosphoinositide-dependent protein kinase (PDK-1). The compounds are useful in inhibiting the
proliferation of cancer cells, and other aberrant conditions where the PDK-1 signaling pathway is overstimulated.
BACKGROUND OF THE INVENTION
Certain kinases that belong to the serine/threonine kinase family are located intracellularly and are involved in the transmission of biochemical signals such as those that affect ceil proliferation and survival. One such serine/threonine kinase is PDK1 , which is a regulator of at least 23 protein kinases that belong to the AGC kinase family (cAMP-dependent, cGMP- dependent, and protein kinase C). Signal transduction pathways downstream of PDK1 include the serine/threonine kinases protein kinase B (PKB/Akt), p70 ribosomal S6 kinase (p70S6K1), serum- and glucocorticoid-tnduced protein kinase (SGK), p90 ribosomal S6 kinase (RSK), and protein kinase C (PKC). Peifer et al,, ChemMed Chem 3, 1810-1838 (2008).
The binding of growth factors to the cell surface receptors activates phosphoinositide-3 kinase (PI3K), which phosphorylates the substrate, phosphoinositidylinositol-^S-triphosphate (PIP2) to form the second
messenger, phosphoinositidy[mositol-3,4,5-triphosphate (PIP3). PIP3 binds to both PDK1 and PKB/Akt, which are believed to co-localize at the cell membrane as a consequence. In addition to its interaction with PKB/Akt, PDK1 also phosphorylates and activates p70S6K1 , SGK, RSK and PKC, which influences cell growth, proliferation, and survival, and regulates metabolism. Bayascas, J.R., Cell Cycle, 7, 2978-2982 (2008).
Cancer cells of common human tumor types, including breast, lung, gastric, prostate, haemotological and ovarian cancers, have gene mutations that result in abnormally high levels of PIP3. High levels of PIP3 cause overstimulation of PDK1 which result in constitutive activation the members of the AGC kinase family. As a consequence, tumor ceil proliferation, reduced apoptosis and angiogenesis occur. In addition, cells lacking functioning PTEN, a lipid phosphatase that reduces cellular PIP3, are associated with a variety of human tumours including breast, prostate, endometrial cancers along with melanomas and glioblastomas. Steck et ai, Nat Genetics, 15, 356-362
(1997).
PD 1 function is critical to downstream signaling that results from activation of cells by growth factors because PKB/Akt, p70S6K, and RSK cannot be activated in cells lacking PDK1. Indeed, disrupting the PDK1 gene in mouse embryonic cells prevents activation of PKB/Akt, p70S6K, and RSK. Williams et ai, Current Biology 10, 439-447 (2000). Additionally, in an in vivo model, reducing the expression of PDK1 protects mice from developing tumors under conditions where PIP3 is elevated due to the deletion of PTEN.
Bayascas et ai., Current Biology 15, 1839- 846 (2005). Thus, while not being bound by any specific theory, inhibiting PDK1 function is expected to mitigate tumor cell proliferation by abrogating cell signaling.
Accordingly, there exists a need in the art for small-molecule inhibitors of PDK1 that are useful for treating cancer and other disorders associated with aberrant PDK1 activity. SUMMARY OF THE INVENTION
In one aspect, the present invention provides compounds of Formula (I) (herein referred to as the "Imidazole Carboxamide Compounds" or "compounds of Formula (I)") or pharmaceutically acceptable salts thereof:
wherein:
T is RA, H, halo, C C6 alky!, (C2-C3 alkynylene)-(CrCe aikyl), or
(C2-C3 alkynylene)-cyclopropyl;
wherein RA is selected from the group consisting of:
(i) 5- to 10-membered mono- or bicyclic heteroaryl wherein said heteroaryl of RA contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
(ii) 4- to 7-membered monocyclic heterocyclyl wherein said
heterocyclyl of RA contains at least one ring nitrogen atom ring member, and optionally one additional heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur;
(iii) 4- to 7-membered monocyclic heterocyclenyi wherein said
heterocyclenyl of RA contains one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur;
(iv) phenyl;
(v) C3-C7 cyc!oalkyl; and
(vi) C3-C7 cycloalkenyl;
wherein said RA is unsubstituted or substituted by one to three moieties selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halo, C1-C3 fluoroalkyi, hydroxy, amino, Ci-C6 alkyiamino,
C1-C6 dialkyiamino, C-i-Ce hydroxyalkyi, C1-C6 alkyiamino, cyano, -C(0)~(C -C6 alkyl), -C(0)-0-(C C6 alkyl), sulfonamido,
-N(H)-C(0)-(Ci-C6 alkyi), benzylamino, -Y-R9, and -C(0)-N(R 1)2;
Y is a bond, d-C3 aikyiene, -0-, -N(H)-, or -N(H)-(Ci-C3
alkylene), wherein said C1-C3 aikyiene or -N(H)-(Ci-C3
alkyiene) of Y is unsubstituted or substituted by C1-C3 hydroxyalkyi;
R9 is
(i) phenyl;
(ii) 5- to 6-membered heteroaryl, wherein said
heteroaryi of R9 contains one to two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; or
(iii) C3-C7 cycloaikyl;
wherein said R9 is unsubstituted or substituted by one to two
C 1-C3 alkyl, C1--C3 aikoxy, halo, or C1-C3 fluoroalkyi;
each R1 is independently H, Ci-C6 alkyl,
-(C1-C3 alkylene)-N(Ci-C3 alkyl)2t -(C C3 alkylene)-RB, or optionally, the R11 groups together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclyl containing one to two nitrogen atoms, which is heterocyclyl is optionally substituted by C1-C3 alkyl;
wherein RB is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, wherein said RB is unsubstituted or substituted by one to two C1-C3 alkyl, C1-C3 aikoxy, halo, or C1-C3 fluoroalkyi;
R6 is H, 2H, d-C3 alkyl, C1-C3 aikoxy, or halogen;
D is
(i) -(C1-C3 dialky!amino)-(Ci-C3 aikoxy);
(ii) -C(0)-N(H)-heterocyclyl wherein said heterocyclyl moiety is a 5- to 6-membered ring containing one to two nitrogen atoms, and is unsubstituted or substituted by one to two C1-C3 alkyl, C1-C3 aikoxy, halo, or phenyl;
n is 0, 1 , or 2;
R4, R5 and R10 are independently Hr CrC3 alkyl, fiuoro, hydroxy, amino, C C3 alkylamino, Ci-C3 dialkylamino, ureido, azetidinyl, pyrroiidinyl, piperidino, pyrazolyi, -(Ci-C3)aikylene-
OH,
- -N{R7){R8), or -N(R7)-C(0)(R8);
M is
(i) a direct bond;
00 -C(O)-;
(iii) -(C1-C3 alkylene)-C(O)-;
(iv) C1-C3 a!kylene; or
(v) a rin of the formula E
E, wherein o is 1 , 2, 3, or 4; wherein ring E or said aikylene of M is unsubstituted or substituted by one to two C1-C3 alkyl;
R7 and R8 are independently selected from the group
consisting of H, C C3 alkyl, (C C6 alkylene)-NH2, (Ci-C6 alkylene)-N(H)(CrC3 alkyl), (C C6 alkyIene)-N(C C3 alkyl)2, {C3-C6 cyc!oa!kyl)-NH2, (C C3 alkylene)-(C3-C6 cycloalkyi)-NH2, (3,3,3-trifluoro-2-hydroxy)propylt and Cr C3 alkanoyl;
or optionally, wherein R4, R5, or R10 is -M-IM(R7)<R8), R7 and R8 together with the nitrogen atom to which it is attached form (i) Rc, wherein Rc is a 4- to 10-membered mono- or bicyclic heterocyclyl containing one nitrogen atom and one additional heteroatom selected from the
group consisting of nitrogen, oxygen and sulfur, and wherein Rc is unsubstituted or substituted by 1 to 4 R15 moieties; or
(ii) RD, wherein RD is a 4- to 10-membered mono- or bicyclic heterocyc!y! containing one nitrogen atom and wherein RD is substituted by R 6, and wherein RD is optionally and additionally substituted by 1 to 3 R15;
wherein each R15 is independently selected from the group consisting of C1-C3 alkyl, f!uoro, C C3 trifluoroalkyl, (C C3 alkylene)-OH, (Ci-C3 alkylene)-NH2, and (CrC3 aikylene)- C(0)NH2, or optionally two R15 moieties together with the carbon atom to which they are attached form a carbonyl;
wherein R S is selected from the group
consisting of (Ci-C3 alkylene)-OH, (CrC3 aikylene)-NH2, and (Ci-C3 alkylene)- C(0)NH2;
or two of R4, R5 and R 0 together with the carbon atom(s) to which they are attached form a 5- or 6-membered cycloalkyi or heterocyclyl ring containing one to two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; R14 is H or C C3 alkyi;
, R2 and R3 are independently selected from the group consisting of H, 2H, halo, Ci-C3 alkyl, amino, C1-C3 alkyiamino, CrC3 dialkylamino, carbamyl, hydroxy, cyano, trifluoromethyl, C3-C7 cycloalkyi, and 5- to 6- membered heteroaryl containing one two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.
In another aspect, the invention provides a pharmaceutical composition comprising an Imidazole Carboxamide Compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
In still another aspect, the invention provides an Imidazole Carboxamide Compound or a pharmaceutically acceptable salt thereof for use in therapy.
In another aspect, the invention provides an Imidazole Carboxamide Compound or a pharmaceutically acceptable salt thereof for use in treating a disease or disorder characterized by excessive or pathologically elevated celi growth. In some embodiments, the disease or disorder is cancer.
In yet another aspect, the invention provides a combination comprising an Imidazole Carboxamide Compound or a pharmaceutically acceptable salt thereof and an additional anti-cancer agent for simultaneous, separate or sequential use in treating cancer. DETAILED DESCRIPTION OF THE INVENTION
The present invention provides Imidazole Carboxamide Compounds and pharmaceutical compositions comprising an Imidazole Carboxamide
Compound. In addition, the present invention provides methods of using the Imidazole Carboxamide Compounds in treating a disease or disorder characterized by excessive or pathologicaliy elevated cell growth, e.g., cancer, in a patient in need of such treatment.
Definitions
As used above, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
"Patient" includes both human and animals.
"Mammal" means humans and other mammalian animals.
"Alky!" means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain.
Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain.
More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower aikyl" means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched. "Alkyl" may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently sefected from the group consisting of halo, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, oxime (e.g., =N-OH),
-NH(alkyl), -NH(cycloalkyl), -N(aikyl)2, -0-C(0)-alkyl, -0-C(0)-aryl,
-0-C(0)-cycloalkyi, -SF5, carboxy and -C(0)0-aikyl. Non-!imiting examples of suitable alkyl groups include methyl, ethyl, n-propy!, isopropyl and t-butyl. The term "Ci-C3 alkyl" refers to an alkyl group having from 1 to 6 carbon atoms.
"Alkenyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. "Lower alkenyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. "Alkenyl" may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, aryl, cycloalkyl, cyano, alkoxy and -S(alkyl). Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3- methylbut-2-enyl, n-pentenyl, octeny! and decenyl.
"Alkylene" means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above. Non-limiting examples of alkylene groups include methylene, ethylene and propylene. In one embodiment, an alkylene group has from 1 to 6 carbon atoms, in one embodiment, an alkylene is branched. In another embodiment, the alkylene is linear.
"Alkynyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain. "Lower alkynyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable a!kynyl groups include ethynyl, propynyi, 2-butynyl and 3- methylbutynyl. The "alkynyl" may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of aryl and cycloalkyl.
"Aryl" means an aromatic monocyclic or multicyclic ring system
comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl.
"Heteroaryl" means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms. The "heteroaryl" can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. A nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide (indicated herein as "N(O)' '), "Heteroaryl" may also include a heteroaryl as defined above fused to an aryl as defined above. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazoiyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl,
pyrroly!, pyrazolyl, triazoty!, 1 ,2,4-thiadiazolyl, pyrazinyl, pyridazinyi,
quinoxaliny!, phthalazinyl, oxindoiyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyi, azaindolyi, benzimidazoly!, benzothienyl, quinoliny!, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyi, pyrrolopyridyl, imidazopyridy!, isoquinolinyl, benzoazaindolyl, 1 ,2,4-triazinyl, benzothiazolyl and the like. The term "heteroaryl" also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquino!yl and the like. In
describing the heteroatoms contained in the heteroaryl group the expressions, "having one to x heteroatoms selected from the group of N, O, and S" or "having one to x heteroatoms selected from the group of N, N(O), O, and S" (wherein x is an a specified integer), for example, mean that each heteroatom in the specified heteroaryl is independently selected from the specified selection of heteroatoms.
"Aralkyl" or "arylalkyl" means an ary -alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alky! group. Non-limiting examples of suitable aralkyl groups include benzyl, 2- phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
"Alkylaryl" means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkyiaryis comprise a lower alkyl group. A non- limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
"Cycloalkyi" means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyi rings contain about 5 to about 7 ring atoms. The cycloalkyi can be optionally substituted with one or more "ring system substttuents" which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cyc!oalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyts include 1-decaiinyl, norbornyl, adamantyl and the like.
π
"Cycloalkylalkyl" means a cycloalkyl moiety as defined above linked via an alky! moiety (defined above) to a parent core. Non-!imiting examples of suitable cycloaiky!a!kyls include cyclohexylmethyl, adamantylmethyl and the like.
"Cycloalkenyi" means a non-aromatic mono or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms which ring system contains at least one carbon-carbon double bond. Preferred cycloalkenyi rings contain about 5 to about 7 ring atoms. The cycloaikenyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkenyis include
cyclopentenyl, cyctohexenyl, cyclohepta-1 ,3-dienyl, and the iike. A non-limiting example of a suitable multicyclic cycloaikenyl is norbornylenyl.
"Cycloalkenylalkyl" means a cycloaikenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloa!kenyla!kyls include cyclopentenylmethyl, cyclohexenylmethyl and the iike.
"Halogen" means fluorine, chlorine, bromine, or iodine. Preferred halogens are fluorine, chlorine and bromine.
"Fiuoroalkyf means an alky! as defined above wherein one or more hydrogen atoms on the alkyl is replaced by a fluoro atom. Non-limiting examples of fluoroalkyl include trifluoromethyl and 2,2,2-trifluoroethyl.
"Ring system substituent" means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, afkenyl, alkynyl, aryl, heteroaryl, aralkyt, alkylaryl, heteroaralkyl,
heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryi, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy,
alkoxycarbonyl, aryioxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroary!thio, aralkylthio,
heteroaralkyithio, cycloalkyl, heterocyclyl, -SF5, -OSF5 (for aryl),
~0-C(0)-alkyi, -0-C(0)-aryl, -0-C(0)-cycloalkyl, -C(=N-CN)-NH2,
-C(=NH)-NH2, -C(=NH)-NH(aikyl), oxime (e.g., =N-OH), -NY1Y2, -alkyl-NY1Y2, -C(0)NY1Y2, -S02NY1Y2 and -S(0)NYiY2, wherein Y1 and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryi, cycloalkyl, and aralkyl. "Ring system substituent" may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such a moiety are methylenedioxy, ethylenedioxy, - C(CH3>2- and the like which form moieties such as, for example:
"Heteroarylalkyl" means a heteroaryi moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heteroaryis include 2-pyridinylmethyi, quinoiinylmethyl and the like.
"Heterocyclyi" means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example, nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyi root name means that at least a nitrogen, oxygen or sulfur atom, respectively, is present as a ring atom. Any -NH in a heterocyclyi ring may exist in protected form such as, for example, as an -N(Boc), -N(CBz), -N(Tos) group and the like; such protections are also considered part of this invention. The heterocyclyi can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyi can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyi rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyi, thiazolidinyl, 1 ,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam,
lactone, and the like. "Heterocyclyl" also includes heterocyclyl rings as described above wherein =0 replaces two available hydrogens on the same ring carbon atom. An example of such a moiety is pyrrolidone:
In describing the heteroatoms contained in a specified heterocyclyl group, the expression, "having one to x heteroatoms selected from the group of N, O, and S" (wherein x is an a specified integer), for example, means that each heteroatom in the specified heterocyclyl is independently selected from the specified selection of heteroatoms.
"Heterocyclylalkyl" means a heterocyclyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.
"Heterocycleny!" means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. The heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein "ring system substituent" is as defined above. The nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non- limiting examples of suitable heterocyclenyl groups include 1 ,2,3,4- tetrahydropyridinyl, 1 ,2-dihydropyridinyl, 1 ,4-dihydropyridinyI, 1 ,2,3,6-
tetrahydropyridinyi, 1 ,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyi, 2- imidazolinyl, 2-pyrazolinyl, dihydroimidazoly!, dihydrooxazolyl,
dihydrooxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyi, dihydrofuranyl, fiuorodihydrofuranyl, 7-oxabicycio[2.2.1 ]heptenyl, dihydrothiophenyl, dihydrothiopyranyl, and the like. "Heterocyclenyl" also includes heterocyclenyl rings as described above wherein =0 replaces two available hydrogens on the same ring carbon atom. An example of such a moiety is pyrrolidinone:
in describing the heteroatoms contained in a specified heterocyclenyl group, the expression, "having one to x heteroatoms selected from the group of N, O, and S" (wherein x is an a specified integer), for example, means that each heteroatom in the specified heterocyclenyl is independently selected from the specified selection of heteroatoms.
"Heterocyclenyialkyl" means a heterocyclenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.
It should be noted that in heteroatom-containing ring systems of this invention, there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom. Thus, for example,
there is no -OH attached directly to carbons marked 2 and 5.
It should also be noted that tautomeric forms such as, for example, the moieties:
are considered equivalent in certain embodiments of this invention.
"Heteroaralky!" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyis contain a lower alkyl group. Non-limiting examples of suitable aralkyl groups include
pyridylmethyl, and quino!in-3-yimethyl. The bond to the parent moiety is through the alkyl.
"Hydroxyalkyl" means a HO-alkyl- group in which alkyl is as previously defined. Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
"Acyl" means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl. Preferred acy!s contain a lower alkyl. Non-limiting examples of suitable acyl groups include formyl, acetyl and propanoyl.
"Aroyl" means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl. Non-limiting examples of suitable groups include benzoyl and 1- naphthoyl.
"Aikoxy" means an alkyi-O- group in which the alkyl group is as previously described. Non-limiting examples of suitable aikoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.
"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.
"Aralkyloxy" means an aralkyl-O- group in which the aralkyl group is as previously described. Non-limiting examples of suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.
"Alky!thto" means an alkyl-S- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur.
"Aryithio" means an ary!-S- group in which the aryl group is as previously described. Non-limiting examples of suitable aryithio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the su!fur.
"Aralkylthio" means an aralkyl-S- group in which the aralkyl group is as previously described. A non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.
"Alkoxycarbonyl" means an alkyl-O-C(O)- group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and
ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.
"Aryloxycarbonyl" means an aryl-O-C(O)- group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and
naphthoxycarbony!. The bond to the parent moiety is through the carbonyl.
"Aralkoxycarbonyl" means an aralkyl-O-C(O)- group. Non-limiting example of a suitable aralkoxycarbonyl group is benzy!oxycarbony!. The bond to the parent moiety is through the carbonyl.
"Alkylsulfonyi" means an alkyl-S(02)- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.
"Arylsulfonyl" means an aryI-S(02)~ group. The bond to the parent moiety is through the sulfonyl.
The term "substituted" means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound.
Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. A reference to a "stable compound' or "stable structure" means that the compound is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and to survive formulation into an efficacious therapeutic agent.
The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties.
The term "purified", "in purified form" or "in isolated and purified form" for a compound refers to the physical state of said compound after being isolated from a synthetic process {e.g., from a reaction mixture), or natural source or combination thereof. Thus, the term "purified", "in purified form" or "in isolated and purified form" for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan (e.g., chromatography, recrystallization and the like), in sufficient purity to be characterized by standard analytical techniques described herein or well known to the skilled artisan.
It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences. In addition, any one or more of these hydrogen atoms can be deuterium.
it should also be noted that in case of a discrepancy between the chemical name and structural formula for a specified compound, the description provided by the structural formula will be controlling.
When a functional group in a compound is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in Organic Synthesis (1991 ), Wiley, New York.
When any variable (e.g., aryl, heterocycle, R2, etc.) occurs more than one time in any constituent or in Formula (I), its definition on each occurrence is independent of its definition at every other occurrence.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
Prodrugs and solvates of the compounds of the invention are also contemplated herein. A discussion of prodrugs is provided in T. Higuchi and V.
Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S.
Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term "prodrug" means a compound (e.g., a drug precursor) that is transformed in vivo to yield a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in biood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible
Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
For example, if a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (Ci- Cajalkyl, (C2-Ci2)alkanoyloxymethyi, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyI-1-(alkanoyioxy)-ethyi having from 5 to 10 carbon atoms, alkoxycarbonyloxymethy! having from 3 to 6 carbon atoms, 1- (alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1~
(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N- (alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N- (alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthaiidyl, 4- crotonolactonyl, gamma~butyrolacton-4-yl, di-N,N-(Ci-C2)aikyIamino(C2-C3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(CrC2)alkyl, N,N-di (C-i-
C2)alkylcarbamoyl-(CrC2)alkyl and piperidino-, pyrroiidino- or morpholino(C2- C3)alkyl, and the like.
Similarly, if a compound of Formula (1) contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (Ct-Cejalkanoyloxymethyl, 1-((Ci-C6)alkanoyloxy)ethyl, 1-methyl-1-((Ci-C6)alkanoyloxy)ethyl, (Ci- C6)a!koxycarbonyloxymethyl, N-(Ci~C6)alkoxycarbony!aminomethyi, succinoyl,
(CrC6)atkanoyi, a-amino(Ci-C4)alkanyl, arylacyl and a-aminoacyl, or a- aminoacyl- a -aminoacyl, where each a -aminoacyl group is independently selected from the naturally occurring L-amino acids, -P(0)(OH)2, -P(0)(0(Cr C6)alkyl)2 or glycosyi (the radical resulting from the removal of a hydroxy! group of the hemiacetal form of a carbohydrate), and the like.
If a compound of Formula (1) incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbony!,
NRR'-carbonyl where R and R' are each independently (Ci-Cio)alkyl, (C3-C7) cycloalkyl, benzyl, or R-carbonyl is a natural a-aminoacyl or natural a - aminoacyl,
— C(OH)C(0)OY1 wherein Y1 is H, (C C6)alkyl or benzyl,
— C(OY2)Y3 wherein Y2 is (C C4) alkyl and Y3 is (C C6)alkyl, carboxy (d-
Ceiaikyl, amino(Ci-C4)alkyl or mono-N— or di-N,N-(Ci-C6)alkylaminoalkyl, ~~C(Y4)Y5 wherein Y4 is H or methyl and Y5 is mono-N— or di-N,N-(Cr
C6)aikylamino morphoiino, piperidin-1-y! or pyrrolidin-1-yi, and the like.
One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. "Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covaient bonding, including hydrogen bonding, in certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution- phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent molecule is H2O.
One or more compounds of the invention may optionally be converted to a solvate. Preparation of solvates is generally known. Thus, for example, M. Caira ef al, J. Pharmaceutical Sci„ 93(3), 601-61 1 (2004) describes the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well
as from water. Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et at, AAPS PharmSciTech., 5(1), article 12 (2004); and A. L. Bingham et al, Chem. Commun., 603-604 (2001). A typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods. Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
"Effective amount" or "therapeutically effective amount" is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
"PDK1 " is meant to refer to wild type PDK1.
"PDK1 variant" or "variant of PDK1 " is meant to refer to PDKI having at least one point mutation, insertion, or deletion.
The compounds of Formula (I) can form salts which are also within the scope of this invention. Reference to a compound of Formula (I) or an
Imidazole Carboxamide Compound herein is understood to include reference to salts thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula (i) contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Pharmaceutically acceptable (i.e., nontoxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of Formula (I) may be formed, for example, by reacting a compound of Formula (I) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromtdes, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesu!fonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like.
Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahi et al, Camille G. (eds.) Handbook of Pharmaceutical Salts, Properties, Selection and Use. (2002) Zurich: Wiley-
VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexyiamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides {e.g., methyl, ethyl, and butyl chlorides, bromides and iodides), diaikyl sulfates (e.g., dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g., decy!, lauryl, and steary! chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.
All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
Pharmaceutically acceptable esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion
of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxy methyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethy!), aryl (for example, phenyl optionally substituted with, for example, halogen, C- alkyl, or
or amino); (2) sulfonate esters, such as alkyl- or aralkyisuifonyi (for example, methanesulfonyl); (3) amino acid esters (for example, L-valy! or L-isoleucyl); (4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C1-2o alcohol or reactive derivative thereof, or by a 2,3-di (C6-24)acyl glycerol.
The compounds of Formula (I), and salts thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
The compounds of Formula (I) may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomers forms. It is intended that all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiraf alcohol or Mosher's acid chloride), separating the diastereomers and
converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers {e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC column.
It is also possible that the compounds of Formula (!) may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds included in the invention.
All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention. Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the lUPAC 1974
Recommendations. The use of the terms "salt", "solvate", "ester", "prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
The present invention also embraces isotopically-labe!led compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine and iodine, such as 2H, 3H, 1C, 13C, 14C, 15N, 80, 170, 31P, 32P, 35S, 18F, 36C! and 123l, respectively.
Certain isotopically-labe!led compounds of Formula (I) (e.g., those labeled with 3H and 4C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and detectability. Certain isotopically-iabeiled compounds of Formula (I) can be useful for medical imaging purposes. For instance those compounds labeled with positron- emitting isotopes like 1 C or 18F can be useful for application in Positron
Emission Tomography (PET) and those labeled with gamma ray emitting isotopes like 1231 can be useful for application in Single Photon Emission
Computed Tomography (SPECT). Further, substitution of compounds with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo haif-!ife or reduced dosage requirements) and hence may be preferred in some circumstances. Additionally, isotopic substitution of a compound at a site where epimerization occurs may slow or reduce the epimerization process and thereby retain the more active or efficacious form of the compound for a longer period of time. Isotopicalty labeled compounds of Formula (I), in particular those containing isotopes with longer half lives (T1/2 >1 day), can generally be prepared by foiiowing procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an appropriate isotopicaliy labeled reagent for a non-isotopically labeled reagent.
Polymorphic forms of the compounds of Formula (I), and of the salts, of the compounds of Formula (I), are intended to be included in the present invention.
The present invention further includes the compounds of Formula (I) in all their isolated forms. For example, the above-identified compounds are intended to encompass all forms of the compounds such as, any solvates, hydrates, stereoisomers, and tautomers thereof.
The compounds according to the invention have pharmacological properties; in particular, the compounds of Formula (i) can be inhibitors of PDK- 1.
Compounds of Formula i\)
The present invention provides Imidazole Carboxamide Compounds having the Formula (I), or pharmaceutically acceptable salts thereof, wherein D, T, R1, R2, R3, and R6 are as defined above for the compound of Formula (I). The compounds of Formulas (la) and (lb), as are described in detail below, are embodiments of the compound of Formula (I).
In some embodiments of the compound of Formula (I), R6 is H. tn other embodiments, R6 is 2H.
In certain embodiments of the compound of Formula (I), D is selected from the group consisting of:
In some embodiments of the com ound of Formula (t), D is
M is a direct bond, -C(O)-, or methylene;
R4 and R6 are independently selected from the group consisting of H, C1-C3 alkyl, and fluoro, and
R7 and R8 are independently selected from the group consisting of H, d-C3 alkyi, -CH2CH2NH2, -CH2CH2NHCH2CH3, -CH2CH2CH2CH2NHCH3, cyclohexylamino,
or optionally R7 and R8 together with the nitrogen atom to which it is attached form:
(i) Rc, wherein Rc is a 4- to 10-membered mono- or bicyclic heterocyclyl containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein Rc is unsubstituted or substituted by 1 to 4 R15 moieties; or
(ii) RD, wherein RD is a 4- to 10-membered mono- or bicyclic
heterocyclyl containing one nitrogen atom and wherein RD is substituted by R16, and wherein RD is optionally and additionally substituted by 1 to 3 R15;
wherein each R 5 is independently selected from the group consisting of C1-C3 alkyl, fluoro, C1-C3 trifluoroalkyl, (C C3 alkylene)-OH, (C C3 alkylene)-NH2) and (Ci-C3 atkylene)-C(0)NH2t or optionally two R15 moieties together with the carbon atom to which they are attached form a carbonyl;
wherein R16 is selected from the group consisting of (C C3 a!kylene)- OH, (Ci-C3 alkylene)-NH2, and (C C alkylene)-C(0)NH2.
R7, and R8 are as described above, M is -C(O)-.
In some embodiments of the compound of Formula (I), T is selected from the group consisting of
H, and Br; and
RA, wherein RA is selected from the group consisting of cyclopropyl, phenyl, pyrazolyl, thienyl, pyridinyi, pyrimidinyi, pyridazinyl, indolyl, piperidinyl, piperazinyl, and dihydropyranyl, wherein RA is unsubstituted or substituted by
one to three moieties selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halo, trifluoromethyl, hydroxy, amino, Ci-C6 alkylamino, C C6 dialkylamino, Ci-C6 hydroxyalkyl, cyano, ~C(0)-(CrC6 alkyl),
-C(0)-0-(Ci-C6 alkyl), sulfonamido, -N(H)-C(0)-(Ci-C6 alkyl), benzylamino, -Y-R9, and -C(0)N(R1 )2.
In specific embodiments of the compound of Formula (I), T is selected from the group consisting of
H, Br; and
RA, wherein RA is selected from the group consisting of phenyl, pyrazotyl, thienyi, pyridinyl, pyrimidinyl, tndolyl, and dihydropyranyl, wherein said cyclic moiety of T is unsubstituted or substituted by 1 to 2 moieties selected from the group consisting of methyl, ethyl, fiuoro, chloro, methoxy, cyc!opropyl, amino, methylamino, dimethylamtno, cyclopropylamino, benzylamino, cyano, hydroxymethyl, 2-hydroxyethyl, sulfonamido, acetamido, acetyl, trifluoromethyl, pyrazolyl, benzyl, thienylmethyl, and pyridinylmethyl.
In specific embodiments of the compound of Formula (I), T is selected from the group consisting of:
H, Br,
In certain embodiments of the compound of Formula (I):
T is RA, wherein RA is selected from the group consisting of substituted or unsubstituted cyclopropyl, phenyl, pyrazolyl, pyridinyl, pyrimidinyl, indolyl, piperidinyl, piperazinyl, and dihydropyranyi, wherein RA is unsubstituted or substituted by one to three moieties selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halo, trifluoromethyl, hydroxy, amino, Ci-C6 alkylamino, Ci-C6 diaikylamino, C Ce hydroxyalkyl, sulfonamide,
-N(H)-C(0)-(Ci-C3 alkyl), benzylamino, -Y-R9, and -C(0)N(R11)2; D is
I direct bond, -C(O)-, or methylene;
R4 and R5 are independently selected from the group consisting of H,
C1-C3 alkyl, and fiuoro;
R7 and R8 are independentiy selected from the group consisting of H,
C1-C3 alkyl, -CH2CH2NH2l -CH2CH2NHCH2CH3l -
CH2CH2CH2CH2NHCH3, cyclohexylamino,
or optionally R7 and R8 together with the nitrogen atom to which it is
attached form:
(i) Rc, wherein Rc is a 4- to 10-membered mono- or bicyclic
heterocyclyl containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein Rc is unsubstituted or substituted by 1 to 4 R15 moieties; or
(ii) RD, wherein RD is a 4- to 10-membered mono- or bicyclic
heterocyclyl containing one nitrogen atom and wherein RD is substituted by R16, and wherein RD is optionally and additionally substituted by 1 to 3 R15;
wherein each R 5 is independently selected from the group consisting of C1-C3 alkyl, fiuoro, d-C3 trif!uoroalkyl, (C C3 alkylene)-OH, (C1-C3 alkylene)~NH2, and (Ci~C3 alkylene)-C(0)NH2, or optionally two R15 moieties together with the carbon atom to which they are attached form a carbonyl;
wherein R16 is selected from the group consisting of (C-t-C3 alkylene)- OH, (C1-C3 alkylene)-NH2j and (C C3 alkylene)-C(0)NH2;
R6 is H; and
R1, R2, and R3 are independently selected from the group consisting of H, fiuoro, and pyrazolyl.
D is
M is a direct bond, -C(O)-, or methylene;
R4 and R5 are independently selected from the group consisting of H,
C1-C3 alkyl, and fluoro;
R7 and R8 are independently selected from the group consisting of H,
C1-C3 alkyl, ~CH2CH2NH2, -CH2CH2NHCH2CH3, -
CH2CH2CH2CH2NHCH3, cyc!ohexylamino,
or optionally R7 and R8 together with the nitrogen atom to which it is attached form:
(i) Rc, wherein Rc is a 4- to 10-membered mono- or bicyciic
heterocyclyl containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen,
oxygen and sulfur, and wherein Rc is unsubstituted or substituted by 1 to 4 R15 moieties; or
(ii) RD, wherein RD is a 4- to 10-membered mono- or bicyciic heterocyclyl containing one nitrogen atom and wherein RD is substituted by R16, and wherein RD is optionally and additionally substituted by 1 to 3 R16;
wherein each R15 is independently selected from the group consisting of C1-C3 aikyl, f!uoro, d-C3 trifluoroalkyi, (C C3 alkylene)-OH,
(C C3 alkylene)-NH2, and (C1-C3 atkylene)-C(0)NH2l or optionally two R15 moieties together with the carbon atom to which they are attached form a carbonyl;
wherein R16 is selected from the group consisting of (C1-C3 alkylene)-
OHt (d-C3 alkylene)-NH2) and (C C3 atkylene)-C(0)NH2;
Rs is H; and
R1 , R2, and R3 are independently selected from the group consisting of H, fluoro, and pyrazoiyi.
In specific embodiments of the compound of Formula (I), R , R2, and R3 are independently selected from the group consisting of H, halo, and pyrazoiyi.
In another asp the Formula (la):
X is CH or N;
R12 and R13 are independently selected from the group consisting of H, Ci- C3 alkyl, amino, Ci-C¾ alkylamino, and hydroxymethyl;
R1 is H or halo;
M is a direct bond or methylene; and
R7 and R8 are independently H or C1--C3 alkyi.
In another asp the Formula (la):
X is CH or N;
R12 is C -C3 alkylamino;
R 3 is a 4- to 7-membered monocyclic heterocyclyl wherein said
heterocyclyl contains at least one ring nitrogen atom ring member, and optionally one additional heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur; wherein said monocyclic heterocyclyl is unsubstituted or substituted by one to three moieties selected from the group consisting of C1-C3 alkyi, C1-C3 alkoxy, halo, C1-C3 fluoroalkyl, hydroxy, amino, Ci-C6 alkylamino,
d-Ce dialkytamino, C C6 hydroxyalky!, Ci-C6 alkylamino, cyano, -C(0)-(Ci-C6 alkyi), -C(0)-0-(Ci-C6 alkyi), suifonamido,
-N(H)-C(0)-(Ci-C6 alkyi), benzylamino, -Y-R9, and -C(0)-N(R11)2;
Y is a bond, d-C3 alkylene, -0-, -N(H)-, or -N(H)-(C C3
alkylene), wherein said C C3 alkylene or -N(H)-(Ci-C3 alkylene) of Y is unsubstituted or substituted by C1-C3 hydroxyalkyl;
R9 is
(i) phenyl;
(ii) 5- to 6-membered heteroaryl, wherein said
heteroaryl of R9 contains one to two heteroatoms
selected from the group consisting of nitrogen,
oxygen, and sulfur; or
(iii) C3-C7 cycloalkyl;
wherein said R9 is unsubstituted or substituted by one to two C1-C3 alkyl, C1-C3 alkoxy, halo, or C1-C3 fluoroalkyl;
each R 1 is independently H, Ci-C6 alkyl, (C3-C7) cycloalkyl, (C6-Cio) aryl, -(C1-C3 alkylene Nid-Cs alkyl)2> -(C C3 alkylene)-RB, or optionally, the R11 groups together with the nitrogen atom to which they are attached, form a 5- to 6- membered heterocyclyl containing one to two nitrogen atoms, which is heterocyciy! is optionally substituted by C-r C3 alkyl;
wherein RB is phenyl, pyridinyl, pyrimidinyl, pyraztnyl, or pyridazinyl, wherein said RB is unsubstituted or substituted by one to two C1-C3 alkyl, C1-C3 alkoxy, halo, or C1-C3 fluoroalkyl;
R is H or halo;
M is a direct bond or methylene; and
R7 and R8 are independently H or C1-C3 alkyl.
In specific embodiments of the compound of Formula (la), R1 is fluoro.
In certain embodiments of the compound of Formula (la), the moiety
in specific embodiments of the compound of Formula (la), the moiety
is selected from the group consisting of
In specific embodiments of the compound of Formula (ia), the moiety
is selected from the group consisting of
In stiil another aspect, the compound of Formula (I) has the Formula (lb):
wherein:
X is CH or N;
R12 and R 3 are independently selected from the group consisting of H, C C3 alkyl, amino, C1-C3 alkylamino, carbamyl, hydroxymethyl, benzylamino, 4- fluorobenzylamino, 3,4-difluorobenzylamino, 4-trifluorobenzylamino, 3,4- dimethoxybenzylamino, and 2-hydroxy-1-phenylethylamino;
R1 is H or halo;
R7 and R8 are independently H, C1-C3 alky!, (C C6 alkylene)-NH2, (C C6 alkylene)-N(H)(CrC3 alkyl), (C C6 alkytene)-N(C C3 alkyl)2,
(C3-C6 cycioalkyl)-NH2, (C C3 alky!ene)-(C3-C6 cycloalkyl)-NH2l
or, optionally, R7 and R8 together with the nitrogen atom to which it is attached form
(i) Rc, wherein Rc is a 4- to 10-membered mono- or bicyciic heterocyciyi containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein Rc is unsubstituted or substituted by 1 to 2 R15 moieties; or
(ii) RD, wherein RD is a 4- to 10-membered mono- or bicyciic
heterocyciyi containing one nitrogen atom and wherein RD is substituted by R16, and wherein RD is optionally and additionally substituted by 1 to 2 R 5 moieties;
wherein each R15 is independently selected from the group consisting of Ci-C3 alkyl, fluoro, C1-C3 trifluoroalkyl, (C C3 alkyiene)-OH, (C C3 aikylene)-NH2) and (C C3 aikylene)-C(0)NH2; and
wherein R16 is selected from the group consisting of (Ci-C3 alkylene)- OH, (Ci-C3 alkylene)-NH2, and (C C3 alkylene)-C(0)NH2.
In some embodiments of the compound of Formula (lb), the group
X is CH,
R 2 is H;
R13 is CH3; and
The invention provides also provides compounds 1-96 as set forth be!ow, and pharmaceutically acceptable salts thereof:
N-[5-amino-2-(3(R)-amino-1-piperidinyl)phenyl]-1H-tmidazole-2- carboxamide (1);
1-[4-amino~2-[(1 H-imidazol-2-yicarbonyl)amino]phenyl]-4-(methylamino)-4- piperidinecarboxamide (2);
N-[5-amino-2 4-(aminomethyl)-1-piperidinyl]phenyl]-1 H-imidazole-2- carboxamide (3);
N-[2-(3(R)-amino-1 -piperidinyl)-3-fluorophenyl|-4~[1 -(phenyimethy!)-l H- pyrazoi-4-yl]-1 H-imidazole-2-carboxamide (4);
N-t2-(3(R)-amino-1 -piperidiny!)-3-fluorQphenyl]-4-[1 -(2-thienylmethyl)-1 H- pyrazol-4-yl]-1 H-imidazole-2-carboxamide (5);
N-[2-[2-(dtmethylamino)ethoxy]phenyl]-4-[1-{phenylmethyl)-1 H-pyrazol-4-y!]- 1 H-imidazole-2-carboxamide (6);
N-[2-(3(R)-amino-1 -piperidinyl)-3-f!uorophenyl]-4-[1 -(2-pyridinylmethyl)-1 H- pyrazol-4-yl]-1 H-imidazQle-2-carboxamide (7);
N-[2-(3(R)-amino-1~piperidinyi)-3-fluorophenyl]-4-(2-methyl-4-pyridinyt)~1 H- imidazoie-2-carbQxamide (8);
N-[2-(3(R)-amino-1-piperidinyl)-3-fluQrQphenyi]-4-t5-(trifluoromethyi)-3- pyridinyl]-1 H-imidazole-2-carboxamide (9);
N-[2-(3(R)-amino-1-piperidinyl)-3 luorophenyl]-4-(4-pyridinyl)-lH-imidazole- 2-carboxamide (10);
N-[2-(3{R)-amino-1 -piperidinyl)-3-f luoropheny!]-4-(1 H-pyrazol-4-yl)-1 H- imidazole-2-carboxamide (11);
N-[2-(3(R)-amino-1-piperidinyl)-3 fuorophenyl]-4-bromo-1H-imidazole-2- carboxamide (12);
N-[2-(3(R)-amino-1 -piperidinyl)-3-fluQrophenyl]-4-J1 -(3-pyridinylmethyl)-1 H- pyrazol-4-yl]-1 H-imidazQie-2-carboxam'ide (13);
N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-(1-methyl-1 H-pyrazol-4- yl)-1 H-imidazole-2-carboxamide (14);
N-[2-[3(R)-E(aminocarbonyl)amino]-1-piperidinyl]-3--fluorophenyl]-4-brQmo- 1 H-imidazoSe-2-carboxamide (15);
N-[5-amtno-2-(3(R)-amino-1-piperidinyl)phenyll-4-bromo~1H-imidazole-2- carboxamide (16);
N 2-[2-(dimethylamino)ethoxy]phenyl]-4-(1 H-indoi-3-yl)-1 H-imid
carboxamtde (17);
N-[2-[4-(aminomethyl)-1-piperidinyl]-3 fuorophenyi]-4-(2-methyl-4-pyridinyl)- 1 H-imidazole-2-carboxamide (18);
N-[2-(3(R)-amino-1-piperidtnyl)-3-fluorophenyl]-4-i2-(trifluoromethyi)-4- pyridinyl]-1 H-imidazole-2-carboxamide (19);
N-[2-(-3(R)-amina-1i3!peridinyi)-3-¾
irnidazole-2-carbQxamide (20);
N-[2-(3(R)-amino-1-pipendinyl)~3 luorophenyl]-4-(2-methoxy-4-pyridinyl)- 1 H-imidazole-2-carboxamide (21);
N-[2-(3(R)-amino-1-piperidinyl)-3 luorophenyil-4-(3,6-dihydro-2h-pyran-4- yl)-1 H-imidazo!e-2-carbQxamide (22);
-[2-(3(R)-amino~1-piperidinyl)-3-fluorQphenyl]-4-(2-cyclopropyl-4~pyridinyi)- 1 H-imidazQle-2-carboxamide (23);
4-(2-amino-6-methyM-pyridinyl)-N-[2-(3(R)-amino-1-piperidinyl)-3- fluorophenyl]-1 H-tmidazole-2-carboxamide (24);
N-[2-(3(R)-amino»1-piperidinyi)-3-fluQrophenyl]-4-(2-hydrQxy-4-pyridinyl)-1 H- imidazoIe-2-carboxamide (25);
N-[2-(3(R)-amino-1-piperidinyl)-3-fiuorophenyl]-4-[2-(hydroxymethyl)-4- pyridinyl]-1 H-imidazole-2-carboxamide (26);
N-[2-[4-(aminomethy!)-1-piperidinyl]-3~fluorophenyl]-4-(2-amino-4-pyri 1 H-imidazole-2-carboxamide (27);
N-[2-[4-(aminomethyl)-1-piperidmyl3-3!4-difluorophenyl]-4-(2-amino-4-- pyridinyl)-1 H-imidazole-2-carboxamide (28);
4-(2-amino~6-methyl-4-pyrimidinyl)-N-[2™(3(R)-amino-1-piperidinyl)-3- fluorophenyl]-1 H-tmidazoie-2-carboxamide (29);
N-[2-[4-(aminomethy!)-1 -piperidinyl]-3-fiuoropheny!]-4-(2-ethyl-4-pyridinyl)- 1 H-imidazole-2-carboxamide (30);
N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4~ 3- (aminosuifonyl)phenyl]-1 H-imidazole-2-carboxamide (31 );
N-[2-[4-(aminomethy[)-1-piperidiny[]-3-fluorophenyl]-4-[2-(methyiarnino)-4- pyridinylJ-1 H-imidazoie-2-carboxarnide (32);
4-[2-(acetylamino)-4-pyridinyt]-N-[2-[4-(arn!nomethyl)-1-piperidtnyl]--3- fluorophenyl]-1 H-imidazole-2-carboxamide (33);
N-[2-i4-(aminomethyl)-1-piperidinyt]-3-fluorophenyl]-4-(3-chlorophenyl)-1 H- imidazole-2-carboxarnide (34);
N-[2-[4~(aminomethyl)-1-piperidtnyl3-3-fluorophenyl]-4-[2- [(phenylmethyl)aminoH-pyridinyl]-1H-imidazote-2-carboxamide (35);
N-[2-[4-(aminomethyl)-1-piperidinyl]-3 luoropheny!H 2-(dimethylamino)-4- pyridinyl]-1 H-imidazole-2-carboxamide (36);
lv|.[2-[4-(aminomethyi)-1-piperidinyl]-3 luorophenyl]-4-(2,5-dimQthylphenyi)- 1 H~imtdazoie-2-carboxamide (37);
N-t2-(3(R)-amino-1-piperidinyl)-3-fluorophenyil-4-(2.4-difluorophenyl)-1 H- imtdazole-2-carboxamide (38);
N-[2-(3(R)-amino~1 -piperidinyl)-3-fluorophenyl]-4-[2-(1 H-pyrazol-1 -yl)-4- pyridiny!]~1 H-imidazole-2-carboxamide (39);
4-(2-amino-4-pyridiny!)-N-[2-[4-[(dimethylamino)methylJ-1- piperidinyi]phenyl]-1 H-imtdazo!e-2-carboxamide (40);
N-[2-[4-(aminomethyl)-1-piperid!nyl]-3-fluorophenyl]-4-[3-(2- hydroxyethyl)phenyl]-1 H-imidazole-2-carboxamide (41 );
N 2-t4-(aminomethyt)-1-piperidinyl]-3-f!uorophenylH-E2- (cyclopropylamino)-4-pyridinyl]-1H-imtdazQle-2-carboxamide (42);
N-[3 luoro-2^ctahydro-6h~pyrrolot2,3-c]pyridin-6-yl)phenyl]-4-(2-methyl-4- pyridinyl)-1 H~imidazole-2-carboxamide (43);
N^2 4-(aminomethyl)-1-piperidinyl3-3-fluorophenyl]-4-(6-cyano-2--pyridinyl)- 1 H-imidazole-2-carboxamide (44);
4-(5-acetyl-24hienyI)-N-[2-[4-(aminomethyl)"1-piperidinyl]-3--fluorophenyl]- 1 H-imidazole-2-carboxamide (45);
N 2-(2,9-diazaspiro[5,5]undec-9-yl)-3 !uorophenyl]-4-(2-rnethyl-4-pyridmyl)- 1 H-imidazole-2-carboxamide (46);
N_[2-t4-(aminomethyl)-1-piperidinyl]-3-fluorophenyi3-4-(2-amino-6-meth pyrimidinyi)-1 H-imida2ole-2-carboxamide (47);
N-P-[4-(aminomethyl)-1-piperid^
1 H-pyrazol-S-yl]-1 H-lmidazole-2-carboxamide (48);
N 2^4-(aminomethyl)-1-piperidinyl]^
pyrimidinyl)-1 H-imidazole-2-carboxamide (49);
N-[2-[4-[(dimethylamino)methyi^
pyridinyl)-1 H-imidazole-2-carboxamide (50);
N 2-[4-(aminomethyl)~1-piperidinyil-5-(1H-pyrazoM-yi)phenyl]-4~(1 H- pyrazo!-4~yl)-1 H-tmidazole-2-carboxamide (51);
N-[2-[4-(aminQmethyI)-4-ethyl-1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4- pyridinyf)-1 H-imidazole-2-carboxamide (52);
N-[2-[4-(aminomethyl)-1 -piperidinyi]-3-f luorophenyll-4-(l H-pyrazol-4-yl)-1 H- imidazole-2-carboxarnide (53);
N-[2-(3,8-dtazabicyclo[3.2.1]oct-3-yl)-3-fluorophenyl]-4-(2-methyi-4- pyridinyl)-1 H-imidazole-2-carboxamide (54);
N-[2-[4-(aminomethyl)-4-methyi-1-p^
pyridinyl)-1 H-imidazole-2-carboxamide (55);
methyl 3-[2-ttI2-t4-{aminomethyl)-1 -piperidinylJ-S- fluorophenyl]amino]carbonyl]-1 H-im!dazol-4-yl]benzoate (56);
N-[3-fluoro-2-[4-[(methylamino)methyl]~1-piperidinyl]phenyl]-4-(2-methy!-4- pyridinyt)-1 H-imidazoie-2-carboxamide (57);
N~[3-fluoro-2-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yi)phenyl]-4-(2-methyt-4- pyridinyl)-1 H-imidazole-2-carboxamide (58);
1 ~[2-f !uoro-6-[[[4-(2-methyl-4-pyridiriyl)-1 H-irnidazol-2- yi]carbonyl}aminolphenyl]-N-methyi-4-piperidinecarboxamide (59);
N-ethyl-1-[2 luoro-6-[[i4-(2-methyl-4-pyridinyl)-1H-imidazo!-2- yl]carbonyl]amino]phenyi]-4-piperidinecarbQxamide (60);
1 -[2-fluorQ-6-[[[4-(2-methyl-4-pyridtnyl)-1 H-imidazot-2- yl]c¾rbonyl]amino]phenyl]-N,N-dirnethyl- -piperidtnecarboxarnide (61);
1-[2-fluoro-6-[it4-(2-methyl-4-pyridinyl)~1H-imidazol-2- yUcarbonyljaminoJphenyQ-N-iS.S.S-trifluoro^-hydroxyprQpyi)^- piperidinecarboxamide (62);
N 2-t4-(aminomethyl)-1-piperidinyi]-3-ftuorophenyt]-4-(5-pyrimidiny!)-1H- imidazole-2-carboxamide (63);
N-[3-fluoro-2-[4-[(3(S)-fluoro-1-pyrro!idinyl)carbonyl]-1-piperidinyl]phenyl3-4- (2-methyl-4-pyridinyl)-1 H-imidazole-2-carboxamide (64);
1 -[2-f luoro-6-[[[4-(2-methyl-4-pyridinyl)-1 H-imidazol-2- yl]carbonyl]amino]phenyl]-N-(1(R)-phenylethyl)- -piperidinecarboxamide (65);
N-[2-[4-(1 -azetidinylcarbanyl)-1
1 H-imtdazoie-2-carboxamide (66);
N-[2-[4-(1 -amino-1 -methytethyt)-1 -piperidinyt]-3-f luorQphenyl]-4-(2-methyl-4- pyridinyl)-1 H-im!dazoIe-2-carboxamide (67);
6-[2-[P-[4-(aminomethyl)-1-pipertdinyll-3-fluorophenyl]amino]carbonyl]-1 H- imidazol-4~yi]-2-hydrQxy-4-pyrim!dinecarboxamide (68);
N-[2-j;4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[2-amino-6- [(phenylmethyi)amino]-4-pyrimidinyl]-1 H-imidazo!e-2-carboxamtde (69);
N- 2-[4-(aminomethyl)-1-piperidiny^^
(trifluoromethyl)phenyl]methyl]amino]-4~pyrimidinyl]-1H-imida
carboxarnide (70);
4-[2-amino-6-[[(4-fluorophenyl)met yl]aminoH-pyrimidinyl|-N-[2-[4- (aminomethyl)-l -piperidiny!}-3-fluoropheny!]-1 H-imtdazole-2-carboxamide (71 );
4-[2-amino-6-[[2-hydroxy-1(R)-phenylethyl]amino]-4-pyrimidinyl]-N-[2-[4- (aminomethyl)-l -piperidinyl]-3-f iuorophenyl]-1 H-imidazole-2-carboxamide (72);
N-[2-[4-(aminomethyl)-1-piperidinyl]-3-f!uorophenyl]-4-t6-[[(4- fluorophenyi)methyl]amino]-4-pyrimidinyl]-1 H-imidazole-2-carboxamide (73);
-^-^-iaminomethy -l- i eridinyll-S-fluorophenyll^-ie-^iS^- difluorophenyl)methyl]amino]-4-pyrimidinyl]-1H-imidazQle-2-carboxamide (74);
4-[2-amino-6-[[(3l4-difluorophenyl)methyl]amino]-4-pyrimidinyl3-N-[2-[4- (aminomethyl)-1-piperidinyl]-3-fluorop enyl]-1H-imidazole-2-carboxamide (75);
4-[2-amino-6-ft(3^-dimethoxyphenyl)methyl]amino]-4-pyrimidinyl]-N-[2--[4- (aminomethyl)-l -piperldinyl]-3-fluorQphenyi]-1 H-imidazoIe-2-carboxamide (76);
4-[2-amino-6~t(2-hydroxy-1(S)-phenylethyl)amino]-4-pyrimidinyl3-N-[2-[4- (aminomethyl)-l -piperidinyl]-3-fluorophenyl]-1 H-imidazQle-2-carboxamide (77);
N-[3-fluoro-2-[4-(8-oxa-3-azabicyclo[3.2.13oct-3-ytcarbonyl)-1- piperidinyl]phenylH-(2-methyl-4-pyridinyi)-1 H-imidazole-2-carboxamide (78);
N-[3-fluoro-2-[4-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylcarbonyl)-1- piperidinyl]phenylH-(2-methyl-4-pyridinyl)-1 H-imidazole-2~carboxamide (79);
N-[3-f!uoro-2-[4-[ 3-(hydroxymet yl)-4-morpholinyl]carbonyl]-1- ptperidinyl]phenyl]-4-(2-methyl-4-pyridinyl)-1 H-irnidazole-2-carboxamide (80);
N-[2-[4-i[3-(amtnomethyl)-4-morpholinyl]carbQnyl]-1-ptpericlinyl]-3- fluorophenyl]-4-(2-methyl-4-pyridinyl)-1 H-imidazole-2-carboxamide (81 );
l-[2-fluoro-6-n[4-(2-methyt-4-pyridinyl)-1 H-imidazol-2- yi]carbonyl3aminQ]phenyl]-4~piperidinecarboxamide (82);
N-(2-aminoethyl)-1-[2-fluoro-6-[[[4-(2-methyM"pyridinyl)-1 H-imidazol-2- yiJcarbonyl]aminoJphenyl]-4-piperjdinecarboxamide (83);
N-(2-aminocyclohexyl)-1-[2-fluoro-6-[[[4-(2-methyl-4-pyridinyl)-1H-imidazol~ 2-yl]carbonyl]amino]phenyl]-4-ptperidinecarboxamide (84);
1 ~[2-f luoro-6-[[i4-(2-methyl-4-pyridinyl)-1 H-imidazol-2- yl]carbonyl]amino]phenyl]-N-[4-(methylamino)butyl]^-piperidinecarboxamide (85);
N-[2-(ethyiamino)ethy!]-H2-fluoro^
2-yl]carbonyllamino]pheny!]- -piperidinecarboxamide (86);
N-[2-[4-(3,8-diazabicyclo[3.2.1]oct-8-ylcarbQnyl)-1-piperidinyl]-3- fluorophenyl3-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxarnide (87);
N-[(1 -aminocyclopentyl)methy!]-1 -E2-fluoro-6-[[E4-(2-methyl-4-pyridinyi)-1 H- imidazol-2-yl]carbonyl]amino}phenyl]-4-piperidinecarboxamide (88);
N-[2-[4-[[2-(aminomethyl)-4-morpholinyl]carbonyl]-1-piperidinyl]-3- fluorophenylH 2-methyW-pyridinyl)-1H-imidazoJe-2-carboxamide (89);
N-[3-f!uorQ-2-[4-E[2-(2-hydroxyethyl)-4-morpholinyl]carbonyi]-1- pipe rid i nyl]phenyll-4-(2-methyl-4-pyrid inyl)- 1 H-imidazole-2-carboxamide (90) ;
N-[2-[4-(3,6-diazabicyclo|3.2.1 ]oct-3-ylcarbonyl)-1 -piperidinyl]-3- fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide (91);
N-[3 luGro-2-[4-[(3(R)-fluG^
(2-methy!-4-pyridinyl)-1 H-imidazole-2-carboxamtde (92);
N-[3-fluoro-2-|4-[(3-oxo-2,8-diazaspiro[4.5]dec-8-yl)carbonyl]-1- piperidinyl]phenylH~(2-niethyl-4-pyridinyl)-1 H-imidazole-2-carboxamid (93);
N-E2-[4-(2,7-diazaspiro[3.5]noN-7-ylcarbonyl)-1-piperidtnyl}-3-fluorophenyl]- 4-(2-methyl-4-pyridinyl)-1 H»imidazoie-2-carboxamide (94);
N-[2-[4-[[2-(1-aminoethyl)-4-rnorpholinyl]carbonyl3-1-piperidinyl]-3- fluorophenyl]-4-(2-methyM~pyridinyl)-1H-imidazo!e-2-carboxarnide (95);
N-[3-fluoro-2 4-[[4-hydrox^
piper!diny!]pheny!]-4-{2-methyi-4~pyridinyi)-1H-imtdazole-2-carboxamide (96);
N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(1-(difiuoromethyl)-6- oxo-1 ,6-dihydropyridin~3-yi)-1 H-imidazoie-2-carboxamide (97);
(R)-N-(2"(3-aminopiperidin-1-y})-3 luorophenyl)-4-(2-chloro-6-methylpyridin- 4-yi)-1 H-imidazole-2-carbQxamide (98);
4-(2-amino-6-morpho!inopyrimidin-4-yl)-N-(2~(4-(aminomethyl)pipendt yl)~3-fluorophenyl)-1 H-imidazole-2-carboxamide (99);
methyl 4-(6-(2-(2-(4-{aminomethyl)piperidin-1-yt)-3-fluorophenylcarbarnoyl)- 1 H-imidazol-4-yl)-2-(methylamino)pyr^
(100) ;
4-(6-(4-acetylpiperazin-1-yi)-2-(methylamino)pyrimidin-4-yl)-N-(2-(4- (aminomethyl)piperidin-1-yl)-3-fluorophenyl)-1H-imidazole-2-carboxamide
(101) ;
N-cyclohexyl-6-methyl-1-(2-(methylamino)-6-(2-(2-(piperazin-1- yl)phenylcarbamoyl)-1H4midazol-4-yl)pyrimidin^-yl)piperidine-3-carboxami
(102) ;
4-(6-(4-acetylpiperazin-1-yl)-2-(methylaminQ)pyrimidin-4-yl)-N-(2-(piperazin- 1-yl)phenyl)-1 H-imidazole-2-carboxamide ( 03);
N-cyclohexyl-6-methyl-1~(2-(methylamino)-6-(2~(2-(piperazin-1- yl)phenylcarbamoyl)-1 H-imidazol-4-yl)pyrimidin-4-yl)piperidtne-3-carboxamide (104);
benzyl 4-(2-(methylamino)-6-(2-(2-(piperazin-1 -yl)phenylcarbamoyl)-1 H- imidazol-4-yl)pyrimidin-4-yl)piperazine-1 -carboxylate (105);
N-cyclohexyi-4-(2-(methylamino)-6-(2-(2-(piperazin-1-yl)phenylcarbamoyl)- 1 H-imidazoi-4-yl)pyrimidin-4~yl)morpholine-2-carboxamide (106);
1 -(6-(2-(2-(4~(aminomethyl)piperidin-1 -yi)-3-f luorophenylcarbamoyl)-1 H- imida2ol-4-y!)-2-(methylamino)pyrim^
3-carboxamide ( 07);
N-cyclohexyl-6-methyl-l-(2-(methylamino)-6-(2-(2-(piperidin-4- yloxy)phenylcarbamQyi)-1H-imidazol-4-yl)pyrim!din-4-yi)piperidine-3- carboxamide (108);
N-cyclohexy!-1-(6-{2-(3-fluoro-2-m
-yl)-2-{methy!amino)pyrimidin-4-yl)-6-m (109);
1-(6-{2-(2-((S)-2-(aminomet yl)morpholino)-3-fluorophenylcarbamoyl)-1 H- imidazol-4-yi)-2-(methylamino)pyrimidm^^
3-carboxamide (110);
1-(6-(2-(2-((R)-2-(aminomethyl)morpholino)-3-fluoropheny!carbamoyl)-1H- imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-N-cyclohexyl-6-methyiplperidin 3-carboxamide (1 1);
1-(2-amino-6-(2-(5-amino-2-(2,9-diazasplro[5.5lundecan-9- yl)phenylcarbamoyl)-1H-imidazol-4-yl)pyrimidin-4-yl)-N-cyclohexyi-6- meihylpiperidine-3-carboxamide ( 12);
1 -(6-(2-(2-(1 ,4-dioxa-8~azaspirot4.5]decan-8-yi)phenylcarbamoyl)-1 H- imidazol-4-yl)-2-(methylamino)pyrimidin-4~yl)-N-cyclohexyl-6-meih
3-carboxamide (113);
1 -(S-(2-(2-((R)-3-aminopiperidin-1 -yl)-3-fiuorophenylcarbamoyl)-1 H- imidazoi-4-yl)-2-(methylaminQ)pyrimidin-4-yl)-N-cyclQhexyl-6-methylpiperidi 3-carboxamide (114);
(3S,6R)-1 -(6-(2-(2-(4-(aminomethyi)piperidin-1 -yl)-3- fluorophenylcarbamQyl)-1 H-imidazol-4-yi)-2-(methylamino)pyrimidin-4-yl)-N- cyclohexy!-6-methylpiperidine-3-carbQxamide (115);
(3R,6S)-1 -(6-(2-(2-(4-(aminomethy!)piperidin-1 -yI)-3- fluorophenylcarbamoyl)-1H-imidazol-4-yi)-2-(methylamino)pyrimidin-4-yl)-N- cyclohexyl-6-methyipiperidine-3-carboxamide (116);
{3S,6R)-1-(6-(2-(2-((S)-2-(aminomethyl)morpholino)-3- fluorophenylcarbamoyl)-1 H-imidazol-4-yl)-2-(methylaminQ)pyrimidin-4-yl)-N- cyclohexyl~6-methylpiperidine-3-carboxamide (1 7);
N-cyclohexyi-1-(6-{2-(3-fluoro-2-(2,7-diazaspiro[3.5]nonan-7- yl)pheny!carbamoyl)-1 H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yI)-6- methylpiperidine-3-carboxamide (118);
N-cyclohexyl-1-(6-(2-(3-fluoro-2-(2,8-diazaspiro[4.5]decan-8- yl)phenylcarbamoyi)-1 H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yt)-6- methylpiperidine-3-carboxamide (119);
( )-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(2- (met ylamtno)-6-(2-methylpiperazin-1-yl)pyrimidin-4-yl)-1 H-im!dazole-2- carboxamide (120);
(R)-N-(2-(4-(aminomethyI)pipendin-1-y!)-3-fluorophenyi)-4-(2- (methylaminQ)-6-(3-methylmorpho!ino)pyrimidin-4-yl)-1H-imidazole-2- carboxamide (121);
N-cyc!ohexyl-1 ~(6-(2-(3-fluoro-2-((R)-3-^
1H-imidazoi-4-y!)-2-(methylamino)pyrim^
carboxamide (122);
(R)-4-(6-(2-(aminomethyl)morpho!inG^
(4-(aminomethy!)piperidin-1-yl)-3-fluorophenyl)-1H-imidazole-2-carboxamide (123);
(S)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(2-(methylarnino)- 6-(3-methylpiperazin-1 -yl)pyrimidin-4-yl)-1 H-imidazoie-2-carboxamide (124);
4-(6-(4-(aminamethyl)piperidin^
(aminomethyl)piperidin-1-yi)-3-fluorophenyl)-1H-imidazoIe-2-carboxamide (125);
(R)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(6-(3- aminopiperidin-1-yl)-2-(methylamino)pyrimidin^-yl)-1H-imidazole-2- carboxamide (126);
1-(6-(2-(2-(4-(aminomethyl)piperidin-1-y!)-3-fluorophenylcarbamoyl)-1 H- imidazGl-4-yl)-2-(methyiamino)pyrim^
carboxamide (127);
(S)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorQphenyl)-4-(6-(3--carbamoyi-
3- methoxypyrrotidin-1-yi)-2-(methylamino)pyr!midin-4-yl)-1 H-imidazole-2- carboxamide (128);
(S)-N-(2-(4-(aminomethyl)piperidin-1-yi)-3-fiuorophenyl)-4-(6-(3- (cyc!ohexylcarbamoyl)-3-methoxypy
yl)-1 H-imidazole-2-carboxamide (129);
(R)-N-(2-(4-(aminomethyl)piperidiri-1-yl)-3-fluorophenyi)-4-(6-(3- (benzylcarbamoyl)-3-(methoxymethy!)pyrrolidin-1-yl)-2-(methylamino)pyrimi
4- yl)-1 H-imidazoIe-2-carboxamide (130);
(R)-N-(2-(4-(aminomethyl)piperidtn-1-yl)-3-fIuorophenyl)-4-(6-(3- (cyclopropylcarbamoyl)-3-(methoxymethyl)pyrrolidin-1-yl)-2- (methyiamino)pyrimidin-4-yl)-1 H-imidazole-2-carboxamide (131); and
(R)-N-(2-(4-(arninomethyl)piperidin-1-yl)-3-fluorQphenyl)-4-(6-(3- (cyclohexylcarbamoyl)-3-(rnethoxymethyl)pyrrolidin-1-yl)-2- (methylarnino)pyrimidin-4-yl)-1 H-imidazole-2-carbQxamide (132).
The compounds according to the invention have pharmacological properties; in particular, the compounds of the present invention can be inhibitors, regulators or modulators of protein kinases, such as PDK1.
Methods for Making the Compounds of Formula (\)
The compounds of Formula (i) can be prepared from known or readily prepared starting materials, following methods known to one skilled in the art of organic synthesis. Methods useful for making the compounds of Formula (I) are set forth in the Examples below. Alternative synthetic pathways and analogous structures will be apparent to those skilled in the art of organic synthesis. Ail stereoisomers and tautomeric forms of the compounds are contemplated.
EXAMPLES
Solvents, reagents, and intermediates that are commercially available were used as received. Reagents and intermediates that are not commercially available were prepared in the manner as described below. 1H NMR spectra were obtained on a Varian spectrometer (400 MHz and 500 MHz) are reported as ppm down field from Me4Si with number of protons, multiplicities, and coupling constants, in Hertz indicated parenthetically. Where LC/MS data are presented, analyses was performed using an Agilent 1100 Series LC w/ MicroMass Quattro MS Varian Pursuit XRs C18, Smicron, 150mm x 4.6mm ID gradient flow (0.1% TFA or 0.2% FA): 0 min - 5% ACN, 7.5 min - 100% ACN, 8.5 min -100 ACN, 8.51 min - 5% ACN, 10 min - stop 3 ml/min. The retention time and observed parent ion are given. Where the description indicates the
reaction mixture was purified by HPLC, the description refers to using a preparative Agilent 1100 Series LC/MSD SL system: Column Reverse Phase- Varian Pursuit XRs 10pC-18 250 X 21.2mm; elution with gradient
Acetonitrile/water with 0.1%TFA or 0.2% formic acid. The desired product was detected and collected by a mass-triggered automatic sample collector. Flash column chromatography was performed using pre-packed normal phase silica from Biotage, Inc.
The following solvents, reagents and reaction conditions may be referred to by their abbreviations:
Aq: aqueous
rac BINAP: racemic 2,2'-bis(diphenylphosphino)-1 ,1'-binaphthyl
g or gm: grams
psi: pounds per square inch
pH: concentration of hydronium ions in a solution
°C: degrees Celsius
h: hours
THF: tetrahydrofuran
Et20: diethyl ether
SEM: 2-(trimethylsilyl)ethoxymethyl
LCMS: Liquid chromatography mass spectrometry
DCM: dichloromethane
N: Normal
mL: milliliter
NBS: N-Bromosuccinimide
NCS: N-Chlorosuccinimide
NIS: N-iodosuccinimide
r.t.: room temperature
MeOH: methanol
DIEA: diisopropylethylamine
DIPEA: diisopropylethylamine
DMAP: dimethylaminopyridine
EtOAc: ethyl acetate
EtOH: ethanol
DMF: dimethylformamide
wt%: weight percent
m/z: mass per charge
LiOH: lithium hydroxide
DMSO: dimethylsulfoxide
HATU: 0-(7-azabenzo†riazoi-1 -yl)-N,N,N\N^etramethyluronium
hexafluorophosphate
HOBT: 1-hydroxybenzotriazole
I PA: isopropanol
NMM: 4-methylmorpholine
Rt: retention time
RP: reverse phase
SEM: p-(trimethy]silyl)ethoxyjmethyl
SEMCI: p-(trimethylsilyl)ethoxy]methyl chloride
ACN: acetonitrile
CH3CN: acetonitrile
MeCN: acetonitrile
Mel: iodomethane
r.t: room temperature
pTSA: para-toluene sulfonic acid
CDI: N,N'-carbonyldiimidazole
mg: milligram
PMA: phosphomolybdic acid
UHMDS: Lithium bis(trimethylsilyl)amide
HMDS: hexamethyldisilazane
Pd/C: palladium on carbon
H2: hydrogen gas
PdCI2(dppf): [1 ,1'-b'is(diphenylphosphino)ferrocene] dichloropaliadium(ll) μιηοΙ: micromole
TFA: trifluoroacetic acid
MP: N-methyl-2-pyrrolidone
min: minute
D E: dimethylethane
AcOH: acetic acid
BOC: tertiary-butyioxycarbonyi
M: Molar
mmoi: miliimoiar
Pd[P(t-Bu)3]2: bis(tributyl)Phosphine) palladium
Pd(PPh3)4-' tetrakis(triphenylphosphine) palladium
EDCI: 1-ethyl-3-(3-dimethyiaminopropyl)-carbodiimide
UV: ultraviolet
LDA: lithium diisopropy!amide
Tf: trifluoromethanesulfonyl Representative Imidazole Carboxamide Compounds 1-96 were prepared as described in Examples 1 -26 below. Other Imidazole Carboxamide
Compounds can be readily prepared by those skilled in the art of organic synthesis using readily obtained starting materials and using synthetic routes similar to those described in the examples below.
EXAMPLE 1
This example describes the preparation of Imidazole Carboxamide
Compounds wherein the group
Preparation of N-[2-(3(R)-amino-1^iperidinyl)~3-fluorophenyl]~4-[1-(2-- thienylmethyl)~1H-pyrazol-4-yl]~ 1 H-imidazole-2-carboxamide (5)
Step A -Synthesis of Ethyl 1~((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2- carboxylate (lnt~1a)
ci
InMa
2-(Trimethylsilyl)ethoxymethyi chloride (12.8 g, 0.077 mol) was added to a stirred solution of ethyl imidazole-2-carboxylate (9.0 g, 0.064 mol) and potassium carbonate (17.7 g, 0.128 mol) in NtN-dimethylformamide (50 mL) at 0 °C. The mixture was allowed to stir from 0 °C to r.t. overnight. Water and ethyl acetate were added and the layers were separated. The separated aqueous layer was extracted with ethyl acetate (X2). The combined organic layers were washed with water (X2). The separated organic layer was dried (MgS04) and filtered. The solvents were removed in vacuo and
chromatographic purification (ethyl acetate - hexane) of the residue gave imidazole InMa (12 g, 70%) as a colorless oil. LCMS m/e (M + H+) - 271.1.
Step B - Synthesis of Ethyl 4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- imidazole-2-carboxylate (lnt-1b)
InMa int-1 b
A mixture of imidazole InMa (6.3 g, 0.023 mol) and N- bromosuccinimide (6.2 g, 0.035 mol) was stirred in a mixture of
dichioromethane (30 mL) and N,N-dimethylformamide (30 mL) at r.t. overnight. Dichioromethane and water were added, and the layers were separated. The separated aqueous layer was extracted with dichioromethane (X2)t dried ( gS04) and filtered. The solvents were removed in vacuo and
chromatographic purification (ethyl acetate - hexane) of the residue gave bromoimidazole In b (5.2 g, 64%) as a white solid.
Step C - Synthesis of Lithium 4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- imidazole-2-carboxyIate (lnt-1c)
A solution of lithium hydroxide (94 mg, 2.23 mol) in water (5 ml_) was added to a stirred solution of bromoimidazole lnt-1 b (0.65 g, 1.86 mmol) in 1 ,4- dioxane (10 ml_) at r.t. The mixture was stirred at r.t. for 2 days and solvents were removed in vacuo to give bromoimidazolecarboxylate lnt-1c as a white solid. The solid was used in the next step without further purification.
Step D - Synthesis of Preparation of (lnt-1d)
lnt-1d
A mixture of 1 ,2-difluoro-3-nitrobenzene (2.38 g, 0.015 mmol), (R)-tert- butyl piperidin-3-ylcarbamate (3.0 g, 0.015 mmol) and N,N- diisopropylethylamine (5.2 ml, 0.030 mmol) was heated in acetonitrile (20 mL) at 80 °C overnight. The solvents were removed in vacuo, and chromatographic purification (ethyl acetate-hexanes) of the residue gave a nitropiperidine as orange oil (3.7 g, 72%).
A mixture of the nitropiperidine (3.51 g, 10.3 mmol), 10% palladium on carbon (2.2 g, 1.03 mmol, 50%wet) was stirred in methanol (100 mL) at r.t. under hydrogen (balloon) for 2 h. The solids were filtered through Ceiite®, and the solvents were removed in vacuo to give lnt-1d as a grey foam (3.0 g, 94%),
Step E - (R)-tert-butyl 1-(2-(4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)~1H~ imidazole-2-carboxamido)phenyl)piperidin-3-ylcarbamate (lnt-1e)
A mixture of carboxylate lnt-1c (421 mg, 1.31 mmol), aniline lnt-1d (406 mg, 1.31 mmol), 1-hydroxybenzotriazole hydrate (HOBt) (354 mg, 2.62 mmol), N-(3-dimethylaminopropyl)-N'-ethyl carbodiimide hydrochloride (EDCI) (500 mg, 2.62 mmol) and 4-methylmorpholine (NMM) (66 mg, 0.66 mmol) was stirred in N.N-dimethylformamide (10 mL) at 50 °C overnight. Water and ethyl acetate were added and the layers were separated. The separated organic layer was washed with water. The separated organic layer was dried (MgS0 ) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyi acetate - hexane) of the residue gave amide lnt-1e (609 mg, 76%) as a white solid.
Step F- Synthesis of (R)-tert-butyl 1-(2-fluoro-6-(4-(1-(thiophen-2-ylmethyl)~ 1H yrazol·4-yl)-1-((2-(trimethylsiIyl)ethoxy)methyl)-1M
carbox
A mixture of bromide lnt-1e (60 mg, 0.098 mmol), 4-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)-1-(thiophen-2-ylmethyl)-1 H-pyrazole (28 mg, 0.098 mmol) and sodium carbonate (31 mg, 0.30 mmol) in ethanol (1 mL), toluene (1 mL) and water (0.5 mL) at r.t. was purged with nitrogen gas for 5 min in a microwave vial. Tetrakistriphenylphosphorous palladium (12 mg, 0.0098 mmol) was added. The mixture was heated in a microwave reactor at 1 0 °C for 1 h. Water and ethyl acetate were added and the layers were separated. The
separated aqueous layer was extracted with ethyl acetate. The separated organic layer was dried (MgS04) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave thiophene lnt-1f as a colorless oil.
Step G - N-[2-(3(R)-amino-1 ipθridinyl)~3-fluorophenyl]-4~[1-(2 h^
1 H-pyrazol-4-yl]~ 1 H~imidazole-2-carboxamide (5)
Thiophene lnt-1f from above was stirred in 4 N hydrochloric acid in 1 ,4- dioxane and methanol at 60 °C for 3 h. The solvents were removed in vacuo. Chromatographic purification [dichloromethane -methanol (3% ammonia)] of the residue gave imidazole 5. Imidazole 5 was dissolved in MeOH and excess hydrochloride acid (1 M, in ether) was added. The solvents were removed to give hydrochloride salt of 5 (30 mg) as a yellow solid. LCMS m/e (M + H+) = 466.3.
Aniline lnt-1e was coupled with the coupling partners listed in Table 1 below using the coupling procedures similar to that described in Step F. The intermediate coupling product was deprotected using procedures similar to that described in Step G. Thus, compounds 5, 7, 8, 10-14, 16, 19-23, 25-27, 38, and 39 were prepared from aniline lnt-1b using procedures similar to those described above for Steps F and G.
Table 1
Λ fluorophenyI]-4-(1 H-
N-NH pyrazoi~4-yl)-1 H-imidazole-
H 2-carboxamide
11
384.2 N-[2-(3(R)-amino-1- piperidinyl)-3-
Λ f!uorophenyl]-4-{1-methyl-
N-N 1H-pyrazol-4-yl)-1H-
\
\ imidazole-2-carboxamide
14
449.1 N-[2-(3{R)-amino-1- piperidinyl)-3- fluoraphenyl]-4~[2-
4 // ^ "NH2 (trif!uoromethyl)-4- CF3 pyridinylj-1 H-imidazole-2-
19 carboxamide
396.1 N-[2-(-3(R)-amino-1- piperidiny!)-3- fluorophenyl]-4-(2-amino- /> 'NH2 4-pyridinyl)-1 H-imidazole-
N NHBoc
NH2 2-carboxamide
20
411 .1 N-[2-(3(R)-amino-1- piperidinyl)-3- fluorophenyl]- -(2-
4 // ^ 'NH2 methoxy-4-pyridinyl)-1 H- OMe imidazo!e-2-carboxamide
386.1 N-[2-(3(R)-amino-1- o,„,o piperidirtyi)-3-
B
fluoropheny!]-4-(3,6-
EXAMPLE 2
This example describes the preparation of Imidazole Carboxamide
Compounds wherein the group
is The preparation is specifically described for N-[2-[4-(aminomethyl)-1-piperidinyl]-3- f luorophenyl]-4-(2-methyl-4-pyridinyl)-1 H-imidazole-2-carboxamide (18).
Step A - Synthesis of tert-butyl (1-(2-fluoro-6-nitrophenyl)piperidin-4~ yl)methylcarbamate (lnt-2a)
To a solution of 2,3-difluoronitrobenzene (5.0 g, 31 mmol) in EtOH (25 mL) were added ieri-butyl piperidin-4-ylmethylcarbamate (8.1 g, 38 mmol), and A/,/V-diisopropyiethylamine (6.6 mL, 38 mmol). The reaction was irradiated to 110 °C for 20 min by microwave. The crude reaction mixture was diluted with EtOAc, washed with 1 N HCI and brine, dried over MgS04 and concentrated to yield nitrobenzene lnt-2a ( 1.2 g, 99%) as yellow crystals. The crude product was used without further purification.
Step B - Synthesis of: tert-butyl (1-(2-amino-6-fluorophenyi)piperidin-4- yl)methylcarbamate (lnt-2b)
To a solution of nitrobenzene lnt-2a (5.2 g, 14.7 mmol) in EtOAc (40 mL) was added 10% Pd/C ( 50 mg). The flask was evacuated and filled with H2 three times. Then the reaction mixture was stirred at r.t. under 1 atm of H2 overnight. The reaction was filtered through a fiberglass filter paper and then concentrated to yieid aniline lnt-2b (4.9 g, quant.) as a beige solid. The crude aniline lnt-2b was used without further purification.
Step C - Synthesis of tert-butyl (1-(2-(4~bromo-1-((2~
(trimethylsilyl)ethoxy)methyl)-1H~imidazole-2-carboxamido)phen
A mixture of carboxylate fnt-1c (55 mg, 0.17 mmoi), aniline lnt-2b (55 mg, 0.17 mmoi), HOBt (46 mg, 0.34 mmoi), EDCI (65 mg, 0.34 mmoi) and NM (7 mg, 0.086 mmoi) was stirred in N,N-dimethylformamide (3 mL) at 50 °C overnight. Water and ethyl acetate were added and the layers were separated. The separated organic layer was washed with water. The separated organic layer was dried (MgS04) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave amide lnt-2c (85 mg, 79%) as an orange oil. LCMS m/e (M + H+) = 626.2.
Step D - Synthesis of tert-butyl (1-(2-(4-(2-methylpyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-caώo
yl)me
A mixture of amide lnt-2c (74 mg, 0.12 mmoi), 2~methySpyridine-4- boronic acid ptnacol ester (31 mg, 0.14 mmoi) and sodium hydrogen phosphate (50 mg, 0.35 mmoi) in 1 ,4-dioxane (2 mL) and water (1 mL) at r.t. was purged with nitrogen gas for 5 min in a microwave vial. Tetrakistnphenylphosphorous palladium ( 4 mg, 0.012 mmoi) was added. The mixture was heated in a microwave reactor at 110 °C for 1 h. Water and ethyl acetate were added and layers were separated. The separated aqueous layer was extracted with ethyl acetate. The separated organic layer was dried (MgS04) and filtered. The
solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave pyridine lnt-2d (62 mg, 82%) as a colorless oil. LCMS m/e (M + H*) = 639.3.
Step E - N-[2-[4-(aminomethyl)-1^iperidiny}]~3-fluoro^
pyridin -1H-imidazole-2-carboxamide (18)
Pyridine lnt-2d (62 mg, 0.097 mmol) was stirred in 4 N hydrochloric acid in 1 ,4-dioxane (1 mL) and methanol (4 mL) at 50 °C for 2 h. The solvents were removed in vacuo. Chromatographic purification [dichloromethane -methanol (7 N ammonia)] of the residue imidazole 18 (35 mg, 88%) as a white solid. LCMS m/e (M + H+) = 409.2.
Aniline lnt-2d was coupled with the coupling partners listed in Table 2 below using coupling procedures similar to that described in Step D. The intermediate coupling product was then deprotected using procedures similar to that described in Step E. Thus, compounds 18, 27, 30-37, 41 , 42, 44, 45, 48, 53, 56, and 63 were prepared from aniline lnt-2d using the procedures described above.
Table 2
EXAMPLE 3
Preparation of N-[2-(3(R)-amino- 1 -piperidinyl)-3-fluorophenyl]-4-bromo- 1 H- imidazole-2-carboxamide (12)
!nt-1e
Amide !nt-1e (51 mg, 0.083 mmol) was stirred in 4 N hydrochloric acid in 1 ,4-dioxane (5 mL) at 50 °C for 2 h. The solvents were removed in vacuo. Chromatographic purification [dichioromethane -methanol (7 N ammonia)] of the residue gave imidazole 12 (28 mg, 88%) as a colorless oil. LCMS m/e (M + H+) = 382.2.
EXAMPLE 4
Preparation of N-[2-[3(R)-[(aminocarbonyl)amino]-1-piperidinyl]-3- fluorophenyl]-4-bromo- 1 H-imidazoie-2-carbox TMS-isocyanate
12 15
A mixture of imidazole 12 (29 mg, 0.076 mmol), trimethylsilyi isocyanate (18 mg, 0.15 mmol) and triethylamine (31 mg, 0.30 mmol) in tetrahydrofuran (1 mL) was stirred at r.t. for 4 h. Methanol (1 mL) was added and the mixture was stirred at r.t for 1 h. The solvents were removed in vacuo and chromatographic purification (ethyl acetate ~ hexane) of the residue gave urea 15 (21 mg, 64%) as a colorless oil. LCMS m/e (M + H+) = 425.2.
EXAMPLE 5
Preparation of N-[2-(3(R)-amino- 1 -piperidinyl)-3-fluorophenyI]-4-[1 - (phenylmethyl)-l H-pyrazol-4-yl]-1 H-imidazole~2-carboxamide (4)
Step A - Synthesis of Ethyl 4-(1~benzyl~1H-pyrazol-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxylate (lnt-5a)
A mixture of bromoimidazole lnt-1 b (0.46 g, 1.32 mmol), 1- benzylpyrazoie-4-boronic acid pinacoi ester (0.45 g, 1.58 mmol) and sodium carbonate (420 mg, 3.96 mmol) in toluene (1 ml_), ethanol (1 ml_) and water (0.5 ml_) at r.t. was purged with nitrogen gas for 5 min in a microwave vial. Tetrakistriphenylphosphorous palladium (152 mg, 0.132 mmol) was added. The mixture was heated in a microwave reactor at 1 10 °C for 1 h. Water and ethyl acetate were added and layers were separated. The separated aqueous layer was extracted with ethyi acetate. The separated organic layer was dried (MgS04) and filtered. The solvents were removed in vacuo and
chromatographic purification (ethyi acetate - hexane) of the residue gave pyrazole lnt-5a (0.38 g, 69%) yellow oil.
Step B - Synthesis of Lithium 4~(1~benzyl-1H-pyrazol-4-yl)-1-((2- (trimeth lsil l)ethoxy)methyl)-1H-imidazole-2-carboxylate (lnt~5b)
A solution of lithium hydroxide (38 mg, 0.90 moi) in water (3 mL) was added to a stirred solution of pyrazole lnt-5a (320 mg, 0.75 mmol) in 1 ,4- dioxane (6 mL) at r.t. The mixture was stirred at r.t. overnight and solvents were removed in vacuo to give carboxylate lnt~5b as a white solid. The solid was used in the next step without further purification.
Step C - Synthesis of (R)4ert-butyl 1~(2-(4-(1-benzyl-1H~pyrazol-4-yl)-1-((2~ (trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxam
fluo
A mixture of carboxylate lnt-5b (55 mg, 0.14 mmol), aniline lnt-1d (44 mg, 0.14 mmol), HOBt (37 mg, 0.28 mmol), EDCI (53 mg, 0.28 mmol) and NMM (7 mg, 0.069 mmol) was stirred in N,N-dimethylformamide (2 mL) at 50 °C overnight. Water and ethyl acetate were added, and the layers were separated. The separated organic layer was washed with water. The separated organic layer was dried (MgSO,*) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave amide Int-5c (76 mg, 80%) as a white solid.
Step D -Synthesis of N-[2-(3(R)-amino-1-piperidinyl)-3-fiuorophenylJ-4-[1- (phen
Amide Int-5c (11 mmol) was stirred in a mixture of methanol (1 mL) and 4 N hydrochloric acid in 1 ,4-dioxane (3 mL) at r.t. overnight. The solvents were removed in vacuo. Chromatographic purification [dichloromethane -methanol (7 N ammonia)] of the residue gave imidazole 4 (45 mg, 88%) as a colorless oil. LCMS m/e (M + H+) = 460.3.
EXAMPLE 6
Preparation of N-[2-(3(R)~amino-1 -piperidinyl)-3-fluorophenyl]-4~[1 -(3- pyridinylmethyl)-1 H-pyrazol-4-yt]-1 H-imidazote-2-carboxamide ( 13) Step A - Synthesis of (R)-tert-butyl 1-(2-(4-(1H-pyrazoI-4-yl)-1-((2~
(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxamido)-6-- fluo
A mixture of bromide lnt-1e (200 mg, 0.33 mmol), 4-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaboroian-2-yl)-1 H-pyrazole (64 mg, 0.33 mmol) and sodium
carbonate (104 mg, 0.98 mmol) in ethanol (1 mL), toluene (1 mL) and water (0.5 mL) at r.t. was purged with nitrogen gas for 5 min in a microwave vial. Tetrakistriphenyl-phosphorous palladium (38 mg, 0.033 mmol) was added. The mixture was heated in a microwave reactor at 110 °C for 1 h. Water and ethyl acetate were added and layers were separated. The separated aqueous layer was extracted with ethyl acetate. The separated organic layer was dried (MgS04) and filtered. The solvents were removed in vacuo and
chromatographic purification (ethyl acetate - hexane) of the residue gave pyrazole lnt-6a (73 mg, 37%) as a white solid.
Step B - Synthesis of (R)-tert-butyl 1-(2-fluoro-6-(4-(1-(pyridin-3-ylmethyl)~1H- pyrazol-4~yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imM^
A mixture of pyrazole lnt-6a (30 mg, 0.050 mmol), 3- (bromomethyl)pyridine (14 mg, 0.055 mmol) and cesium carbonate (39 mg, 0.10 mmol) in N.N-dimethyfforrnamide (2 ml_) was stirred at r.t. overnight. Water and ethyl acetate were added, and the layers were separated. The separated aqueous layer was extracted with ethyl acetate. The separated organic layer was dried (MgS04) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave pyridine lnt-6b.
Step C - N-[2-(3(R)-amino-1^iperidinyl)-3jluorophenyl]-4-[1-(3-
Pyridine lnt-6b from above was stirred in 4 N hydrochloric acid in 1 ,4- dtoxane and methanol at r.t. overnight. The solvents were removed in vacuo. Chromatographic purification [dichloromethane -methanol (10% ammonia)] of the residue gave imidazole 13, Imidazole 13 was dissolved in MeOH and excess hydrochioric acid (1 M, in ether) was added. The solvents were removed to give hydrochloric salt of 13 (8 mg) as brown solid. LCMS m/e (M + H÷) = 461.3.
EXAMPLE 7
Preparation of 4-(2-amino-6-methyl~4^yridinyl)-N-[2~(3(R)-amino-1- piperidinyl)-3-fluorophenyl]-1H-imidazole-2-carboxamide (24)
Step A - Synthesis of(R)-tert-butyl 1-(2-(4-(2-chloro-6-methylpyridin~4~yl)-1-((2- (trimethylsilyl)ethoxy)methyl)~1H-imidazole-2~ca
fluo
A mixture of bromide lnt-1e (372 mg, 0.061 mmol), 2-chloro-6-methyl-4- (4,4,5,5-tetramethyl-1 ,3,2-dioxaboroian-2-yl)pyridine (154 mg, 0.061 mmoi) and sodium carbonate (194 mg, 1.83 mmoi) in ethanol (2 mL), toluene (2 m!_) and water (1 mL) at r.t. was purged with nitrogen gas for 5 min in a microwave vial. Tetrakistriphenyiphosphorous palladium (70 mg, 0.061 mmoi) was added. The mixture was heated in a microwave reactor at 100 °C for 1 h. Water and ethyl acetate were added and layers were separated. The separated aqueous layer was extracted with ethyl acetate. The separated organic layer was dried ( gSO and filtered. The solvents were removed in vacuo and
chromatographic purification (ethyl acetate - hexane) of the residue gave chloropyridine lnt-7a (60 mg, 15%) as white foam. LC S m/e (M + H+) = 659.2.
Step B - Synthesis of 4-(2-amino-6-methyl~4-pyridinyl)-N-[2-(3(R)-amino-1- piperidinyl)-3~fluorophenyl]-1H-imidazole-2-carboxamide (24)
A mixture of chloropyridine !nt-7a (30 mg, 0.046 mmol), palladium (II) acetate (0.5 mg, 0.0023 mmol), rac-BINAP (6 mg, 0.0091 mmol), sodium tert- butoxide (7 mg, 0.068 mmol), diphenylmethanimine (16 mg, 0.091 mmol) was stirred in toluene (2 mL) at r.t. The mixture was purged with nitrogen for 5 min. and was heated at 110 °C for 4 h. After being cooled to r.t., methanol (2 mL) and 4 N hydrochloric acid in 1 ,4-dioxane (2 mL) were added. The mixture was heated at 50 °C for 1 h. After being cooled to r.t. and solvents were removed in vacuo. Chromatographic purification [dichloromethane -methanol (7 H ammonia)] of the residue gave aminopyridine 24 (12 mg, 62%) as a white foam. LCMS m/e (M + H+) = 410.1.
EXAMPLE 8
Preparation of N-[2-(3(R)-amino- 1 -piperidinyl)-3~fluorophenyl]-4~[2- (hydroxymethyl)-4φyridinyl]-1H-imidazo^e~2-carboxarnide (26)
Step A - (R)-met yl 4-(2-(2-(3-(tert-butoxycarbonylamino)piperidin-1-yl)-3- fluorophenylcarbamoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-^
yl)picolinate (lnt~8a)
A mixture of bromide lnt-13 (90 mg, 0.15 mmo!), 4-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)picolinonitrile (37 mg, 0.16 mmol) and sodium hydrogen
phosphate (63 mg, 0.44 mmoi) in 1 ,4-dioxane (2 mL) and water (1 ml_) at r.t. was purged with nitrogen gas for 5 min in a microwave vial.
Tetrakistriphenylphosphorous palladium (17 mg, 0.015 mmol) was added. The mixture was heated in a microwave reactor at 1 0 °C for 1 h. Water and ethyl acetate were added and layers were separated. The separated aqueous layer was extracted with ethyl acetate. The separated organic layer was dried (MgS04) and filtered. The solvents were removed in vacuo and
chromatographic purification (ethyl acetate - hexane) of the residue gave a colorless oil. The colorless oil was stirred in methanol (2 mL) and 4 N hydrochloric acid in 1 ,4-dioxane (2 mL) at 50 °C overnight. After being cooled to r.t. and solvents were removed in vacuo. Chromatographic purification
[dichloromethane -methanol (7 N ammonia)] of the residue gave methyl ester lnt-8a (20 mg, 31%) as a white foam. LCMS m/e (M + H+) = 439.1. Step B - N-[2-(3(R)-amino-1^iperidinyl)~3-fluorophenyl]-4-[2-(hyd
pyridin -1H-imidazole-2-carboxa ide (26)
Methyl ester lnt-8a (20 mg, 0.046 mmol) was stirred in tetrahydrofu an (2 mL) at 0 °C. Lithium aluminum hydride (0.1 mL, 1 M in tetrahydrofuran) was added. The mixture was allowed to warm to r.t. and was quenched with a saturated solution of potassium sodium tartrate. Methanol and silica were added and the solvents were removed in vacuo. Chromatographic purification [dichloromethane -methanol (7 N ammonia)] of the residue gave
hydroxymethyipyridine 26 (10 mg, 55%) as a colorless oil. LCMS m/e (M + H*) = 411.1.
EXAMPLE 9
Preparation of N-[5-amino~2-(3(R)-amino-1-piperidinyl)phenyl]-1H- imidazole-2-carboxamide (1)
A mixture of 4-fluoro-3-nitroaniline (30 g, 0.192 mol), di-t-butylcarbonate (84 g, 0.384 mol) was stirred in ethanoi (300 mL) at r.t. for 1 week. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave tert-butyl 4-fluoro-3- nitrophenylcarbamate (43 g, 88%) as a white solid.
lnt-9a
Usint the starting materials, tert-butyl 4~fluoro-3-nitropheny!carbamate and (R)-tert-buty! piperidin-3-ylcarbamate, lnt-9a was prepared using procedures similar to those described in Step D of Example 1 .
Step B - Synthesis o†lnt~9b
A mixture of 1 H-imidazole-2-carboxylic acid (15 mg, 0.13 mmol), aniline lnt-9a (54 mg, 0.13 mmol), diisopropylethyiamine (46 μΙ_, 0.27 mmoi) and HATU (56 mg, 0.15 mmol) was stirred in N,N-dimethylformamide (3 mL) at r.t. overnight. Water and ethyl acetate were added, and the layers were separated. The separated organic layer was washed with water. The
separated organic layer was dried (MgS04) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave amide lnt-9b (21 mg, 32%) as a white solid.
Step C - Synthesis of N-[5-amino~2-(3(R)-amino-1-piperidinyl)phenyl]-1 H- imidazoie-2-carboxamide (1)
Amide Int-9b (21 mg, 0.042 mmol) was stirred in trifluoroacetic acid (3 mL) for 2 h. The solvents were removed in vacuo. Chromatographic purification [dichioromethane -methanol (7 N ammonia)] of the residue gave imidazole 1 (9 mg, 73%) as a white solid. LCMS m/e (M + H+) = 301.2.
EXAMPLE 10
Preparation of N-[5-amino-2-(3(R)-amino-1-piperidinyl)phenyl]-4-bromo-1 H- imidazole-2-carboxamide (16)
Step A - Synthesis of lnt 10a
A mixture of carboxylate lnt-1c (56 mg, 0.17 mmol), aniline lnt-9a (71 mg, 0.17 mmol), HOBt (47 mg, 0.35 mmol), EDCI (66 mg, 0.35 mmol) and NMM (9 mg, 0.087 mmol) was stirred in N,N-dimethylformamide (3 mL) at 50 °C overnight. Water and ethyl acetate were added, and the layers were separated. The separated organic layer was washed with water. The separated organic layer was dried (MgS04) and filtered. The solvents were
removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave amide int~10a (96 mg, 78%) as a white solid.
Step B - Synthesis of N-[5-amino-2~(3(R)-amino-1-piperidinyl)phenyl]-4-bromo- 1 H~imidazoIe-2~carboxamide (16)
Amide lnt-10a (25 mg, 0.035 mmol) was stirred in 4 N hydrochloric acid in 1 ,4-dioxane (2 mL) at r.t. overnight. The solvents were removed in vacuo. Chromatographic purification fdichioromethane -methanol (7 N ammonia)] of the residue gave imidazole 16 (11 mg, 83%) as a white solid. LCMS m/e (M + H+) - 489.
EXAMPLE 11
Preparation of N-[5-amino-2~[4-(aminomethyl)-1-piperidinyl]phenyl]-1H~ imidazole-2-carboxamide (3)
Step A - Synthesis oflnt-11a
Using the starting materials, tert-butyl 4-fluoro-3-nitrophenylcarbamate and tert-butyl piperidin-4-ylmethylcarbamate, lnt-11a was prepared using procedures similar to those described in Step D of Example 1.
A mixture of 1 H-imidazole-2-carboxylic acid (15 mg, 0.13 mmol), aniline Int-11a (56 mg, 0.13 mmol), HOBt (36 mg, 0.27 mmol), EDCI (51 mg, 0.27 mmol) and NMM (7 mg, 0.067 mmol) was stirred in N,N-dimethylformamide (2 mL) at r.t. overnight. Water and ethyl acetate were added, and the layers were separated. The separated organic layer was washed with water. The separated organic layer was dried (MgS04) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave amide lnt-11b (57 mg, 83%) as a white solid.
Step C - Synthesis of N-[5-amino~2-[4-(aminomethyl)-1^iperidinyl]phenyl]-1 H- imidazote~2-carboxamide (3)
lnt-11 b 3
Amide lnt-11 b (57 mg, 0.11 mmol) was stirred in trifluoroacetic acid (3 mL) for 1 h. The solvents were removed in vacuo. Chromatographic purification [dich!oromethane -methanol (7 N ammonia)] of the residue gave imidazole 3 (24 mg, 70%) as a white solid. LCMS m/e (M + H+) = 3 5.2.
EXAMPLE 12
Preparation of N-[2-[4~(aminomethyl)-1^iperidinyl]-3 -difluorophen (2-amino-4~pyridinyI)-1H-imidazole-2-carboxamide (28)
Step A - Synthesis of lnt-12a
1,2,3-trifluoro-4~niirobenzerie (R)-ferf-butyl piperidin-3-yScarbamate lnt-12a
Using the starting materials, 1 ,2,3-trifluoro-4-nitrobenzene and (R)-tert- butyl piperidin-3-ylcarbamate, lnt-12a was prepared using procedures similar to those described in Step D of Example .
Step B ~ Synthesis of lnt-12b
A mixture of bromide lnt-12a (65 mg, 0.10 mmol), tert-butyl 4-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridin-2-ylcarbamate (27 mg, 0.12 mmol) and sodium carbonate (32 mg, 0.30 mmol) in ethanol (1 rriL), toluene (1 rnl_) and water (0.5 mL) at r.t. was purged with nitrogen gas for 5 min in a microwave vial. Tetrakistriphenylphosphorous palladium (12 mg, 0.010 mmol) was added. The mixture was heated in a microwave reactor at 1 10 °C for 1 h. Water and ethyl acetate were added, and the layers were separated. The separated aqueous layer was extracted with ethyl acetate. The separated organic layer was dried ( gS04) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave aminopyridine lnt-12b (46 mg, 69%) as a colorless oil. LCMS m/e ( + H+) - 658.3.
Step C - Synthesis ofN-[2-[4-(aminomethyl)~1^iperidinyl]-3 -difluorophenyl]~ 4-(2-amino~4^yridinyl)-1H-imidazole-2-carboxamide (28)
int-12b 28
Aminopyridine lnt-12b (46 mg, 0.097 mmol) was stirred in 4 N hydrochloric acid in 1 ,4-dioxane (2 mL) and methanol (2 mL) at 50 °C for 2 h. The solvents were removed in vacuo. Chromatographic purification
[dichloromethane -methanol (7 N ammonia)] of the residue gave imidazole 28 (24 mg, 81 %) as a white solid. LCMS m/e (M + H+) = 428.1.
Preparation of 4~(2-amino-4^yridinyl)-N-[2-[4-[(dimethylam
piperidinyl]phenyl]-1H-imidazole-2-carboxamide (40)
Step A and B - Synthesis of l -13b
Starting from 1-fluoro-2-nitrobenzene and N,N-dimethyl-1-(piperidin-4- yOmethanamine (lnt~13a), lnt-13b was prepared using procedures similar to those described in Steps D and E of Example 1.
Step B - Synthesis of tert-butyl 4-(2~(2-(4-((dimethylamino)methyl)piperidin~1~ yl)phenylcarbamoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-im^
A mixture of bromide lnt-13b (55 mg, 0.10 mmol), tert-butyl 4-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridin-2-ylcarbamate (39 mg, 0.12 mmol) and sodium carbonate (33 mg, 0.31 mmol) in ethano! (1 ml_), toluene (1 mL) and water (0.5 mL) at r.t. was purged with nitrogen gas for 5 min in a microwave vial. Tetrakistriphenylphosphorous palladium (12 mg, 0.010 mmol) was added. The mixture was heated in a microwave reactor at 110 °C for 1 h. Water and ethyl acetate were added and the layers were separated. The separated aqueous layer was extracted with ethyl acetate. The separated organic layer was dried ( gS04) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave aminopyridine lnt-13c (27 mg, 41%) as a colorless oil.
Step C - 4~(2-amino~4^yrid yl)-N-l2~[4~[(dimet y
pipe
int-13c 40
Aminopyridine lnt-13c (62 mg, 0.097 mmol) was stirred in 4 N hydrochloric acid in 1 ,4-dioxane (1 mL) and methanol (4 mL) at 50 °C for 2 h. The solvents were removed in vacuo. Chromatographic purification
fdichioromethane -methanol (7 N ammonia)] of the residue gave imidazole 40 (13 mg, 77%) as a white solid. LCMS m/e ( + H÷) = 420.2.
EXAMPLE 14
Preparation of 1 -[4-amino-2-[(1 H-imidazol-2-ylcarbonyl)amino]phenyl]-4- (methylamino)-4-piperidinecarboxamide ( 2)
Step A - Synthesis oflnt-14b
Using the starting materials, 1 tert-butyi 4-fluoro-3-nitrophenylcarbamate and 4-(methylamino)piperidine-4-carboxamide, lnt-14b was prepared using procedures similar to those described in Step D of Example 1. The synthesis of 4-(methylamino)piperidine-4-carboxamide (fnt-14a) is described in U.S. Patent No. 3,155,669 and Metwally et a/., J. Medicinal Chem. 41 5084-5093 (1998).
Step B - Synthesis of tert-butyi 4-(4-carbamoyl-4-(methylamino)piperidin-1~yl)~ 3-( 1 H-imidazote-2-carboxamido)phenylcarbamate (lnt-14b)
A mixture of 1 H-imidazole-2-carboxylic acid (19 mg, 0.17 mmol), aniline lnt-14b (60 mg, 0.17 mmol), HATU (69 mg, 0.18 mmol), diisopropyiethylamine (57 pL, 0.33 mmol) was stirred in N,N-dimethylformamide (2 mL). Water and ethyl acetate were added, and the layers were separated. The separated organic layer was washed with water. The separated organic layer was dried ( gS04) and filtered. The solvents were removed in vacuo and
chromatographic purification (ethyl acetate - hexane) of the residue gave amide lnt-14c (26 mg, 35%) as a white solid.
Step C - Synthesis of 1-[4-amino-2-[(1 H-imidazol-2-ylcarbonyl)amino]phenyi]- 4-(me
lnt-14c
Amide lnt-14c (26 mg, 0.057 mmol) was stirred in trifiuoroacetic acid (3 mL) for 1 h. The solvents were removed in vacuo. Chromatographic purification [dichloromethane -methanol (7 N ammonia)] of the residue gave imidazole 2 (16 mg, 78%) as a white solid. LCMS m/e (M + H+) - 358.2.
EXAMPLE 15
Preparation of N-[2-[4-(aminomethyl)-1^iperidinyl]-5-(1H-pyrazol-4- yl)phenyl]-4-( 1 H-pyrazol-4-yl)-1H-imidazole-2-carboxamide (51)
Step A - Synthesis of 4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2~yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1 t-15a)
lnt-15a
To a solution of 4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)- H- pyrazole (8.2 g, 41 mmol) in NMP (60 mL) was added K2C03 (12 g, 82 mmoi) and 2-(trimethylsilyi)ethoxymethy! chloride (7.8 mL, 43 mmol) in sequence. The reaction mixture was stirred at r.t. under N2 for 16 h. Then, the reaction
mixture was diluted and filtered, and then the filtrate was diluted with EtOAc (300 mL). The resulting solution was washed with sat. NaHC03 (aq) (3 x 200 mL), H20 (4 x 200 mL), brine (1 x 200 mL), dried over Na2S04, filtered, concentrated and dried in vacuo to yield intermediate !nt-15a (11.4 g, 86 %) as a clear yellowish oil.
Step B - Synthesis of tert-butyl (1-(4-bromo-2-nitrophenyl)piperidin-4~ yl)methylcarbamate (lnt~15b)
Nitrobenzene lnt-15b was prepared by following similar procedures to those described in Step A of Example 2 using 4-bromo-1-fluoro-2-nitrobenzene and ferf-butyl piperidin-4-yImethyicarbamate as starting materials.
Step C - Synthesis of tert-butyl (1-(2-nitro-4-(1-((2- (trimethylsίlyl)ethoxy)methyl)-1H yrazol·4~yl) henyl) iperidin-4- yl)methylca
A mixture of nitrobenzene fnt-15b (200 mg, 0.483 mmol), boronic ester lnt-15a (235 mg, 0.724 mmol), tetrakis(triphenylphosphine)palladium (56 mg,
0.048 mmol), and potassium phosphate tribasic (310 mg, 1 .45 mmol) in DMF (3 mL) and water (1 mL) was purged with nitrogen gas for 40 min in a microwave vial. The mixture was irradiated at 120 °C for 20 min by microwave. The reaction mixture was diluted with EtOAc, washed with sat NaHC03 (aq), brine, dried over MgS04, filtered, and concentrated. The crude product was purified by column chromatography using EtOAc and hexanes as eluents to yield the pyrazole lnt-15c (227 mg, 88%) as an orange oil.
Step D - Synthesis of tert-butyl (1-(2-a ino-4-(1~((2- (trimethylsilyl)ethoxy)methyl)-1H^yrazol-4-yi)phenyl)piperidin^
yl)methylcarbamate (lnt~15d)
Aniline lnt-15d was prepared from pyrazole Int-15c by following a similar procedure as that described in Example 2, Step B.
Step E - Synthesis of tert-butyl (1-(2-(4-bromo-1-((2- (trimethylsilyl)ethoxy)methyl)-1H~imidazole~2-carboxam
(trimethylsilyl)ethoxy)methyl)-1H^yrazol-4-yl)phenyl)piperidin-4- yl)methylcarbamate (lnt-15e)
To a solution of lithium 4-bromo-1-((2-(trimethy!silyl)ethoxy)methyi)-1 H- imidazole-2-carboxylate InMc (29 mg, 0.088 mmol) and lnM5d (40 mg, 0.080 mmol) in DMF (3 mL) were added 0-(7-azabenzotriazoi-1-yl)-M/V,/V',/V- tetramethyluronium hexafluorophosphate (39 mg, 0.096 mmol, HATU), and 4- dimethylaminopyridine (5 mg, D AP). The reaction mixture was stirred at r.t. for 19 h. Then, the reaction mixture was diluted with EtOAc (50 mL), washed with sat. NaHC03(aq) (2 x 50 mL), H20 (4 x 50 mL), brine (1 x 50 mL), dried over Na2SO4, filtered, and concentrated. The crude product was purified by column chromatography using EtOAc and hexanes as eluents to yield amide lnt-15e (52 mg, 81 %) as a white solid. LCMS m/e (M + H+) = 804.2
Step F - Synthesis of tert-butyl (1-(4-(1^(2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazol-4-yl)~2-(1-((2-(trimethylsilyl)ethoxy)meth ^
(trimethylsilyi)ethoxy)methyl)-1H^yrazol-4-yl)~1H-imidaz
Amide lnt-15f was prepared from lnt-15e and lnt-15a by following a similar procedure to that described in Example 1 , Step F. LCMS m/e (M + H+) = 923.4.
Step G - Synthesis of N~[2-[4-(aminomethyl)~1-piperidinyl]-5-(1 H-pyrazol-4- yl)phenyl]-4-(1H~pyrazol-4-yl)-1H-imidazole-2-carboxamide (51)
To a solution of lnt-15f (43 mg, 0.047 mmol) in CH2CI2 (2 ml_) and MeOH (1 mL) was added a solution of HCi in dioxane (4 N, 500 μΙ_). The reaction mixture was treated with additional HCI in dioxane (4N, 250 pL) after 5 h of stirring at r.t. The reaction mixture was stirred at r.t. for 20 h. Then, the
reaction mixture was diluted with E†.20 (10 mL) and filtered to yield the hydrochioric acid salts of the amide 51 (19 mg, 77%) as a white solid. LCMS m/e ( + H+) = 432.2.
EXAMPLE 16
Preparation of N~[2~[4-(1-amino-1-methyfethyl)-1-piperidinyl]-3- fluorophenyl]-4~(2-methyl-4^yridinyl)-1H-imida (67)
Step A - Synthesis of Ethyl-4-(2-methylpyridin~4yl)~1-((2- (trime
A mixture of bromoimidazole lrtt-1 b (1.00 g, 2.85 mmol), 2- methylpyridine 4-boronic acid pinacol ester (0.75 g, 3.42 mmol) and potassium carbonate (1.18 g, 8.55 mmoi) in DMF (15 mL) at r.t was purged with nitrogen gas for 5 min. PdCI2(dppf) was added. The mixture was heated at 85 °C for 16 h. Water and ethyl acetate were added and the layers were separated. The separated aqueous layer was extracted with ethyl acetate. The separated organic layer was filtered through Celite®, washed with brine and dried over sodium sulfate. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave lnt-16a (0.61 g, 59%) as a yellow oil.
Step B - 4-(2-methylpyridin-4-yl)-1-((2-(trimethylsiW
lnt-16a lnt-16b
A mixture of lnt-16a (0.69 g, 1.91 mmol) and NaOH (9 mL, 18 mmol) in methanol (9 mL) was stirred at room temperature overnight. The solvent was removed in vacuo. The reaction was then neutralized with HCI (9 mL, 18 mmol), extracted with ethyl acetate. The separated organic layer washed with brine and dried over sodium sulfate. The solvents were removed in vacuo to give carboxylic acid lnt-16b (285 mg, 45%) as a light brown solid
lnt-16c !nt-16d
A mixture of amine lnt-16c (0.55 g, 2.27 mmol) (prepared according to Synthesis 2006, 24, 4143), potassium carbonate (0.99 g, 7.14 mmol) in diethyl ether (12 mL) and water (4 mL) was cooled to 0 °C. Benzy!chloroformate (1 .22 g, 7.14 mmol) was added and the reaction was warmed up to 25 °C stirred for 90 minutes. The mixture was diluted with ethyl acetate (30 mL), washed with water (10 mL) and brine (10 mL), dried over sodium sulfate, filtered, and purified on silica gel (ethyl acetate - hexane) to give amine lnt-16d (0.62 g, 73%) as a white solid.
lnt-16d lnt-16e
A mixture of piperidine lnt~16d (0.62 g, 1.66 mmoi) and TFA (4 mL) in dichioromethane (4 mL) was stirred at 25°C for 4 h. The solvent and excess TFA were removed in vacuo to give amine lnt-16e (0.47 g, > 99%) as a clear oil.
Step E - Synthesis ofBenzyl-2-(1-(2 luoro~6~nitrophenyl)piperidin-4-yl)propan- 2-ylca
Int-I6f
A mixture of amine lnt-16e (200 mg, 0.72 mmol), diflouro nitrobenzene (115 mg, 0.72 mmol), and DIPEA (374 mg, 2.90 mmol) in acetonitrile (5 mL) was stirred at 80 °C overnight. After cooling to room temperature, the mixture was diluted with ethyl acetate (30 mL), washed with water (10 mL) and brine (10 mL), dried over sodium sulfate, filtered, and the solvent removed in vacuo to give lnt-16f (300 mg, >99%) as an orange foam.
Step F - Synthesis of Benzyl 2-(1-(2-amino-6-fluorophenyl)piperidin~4~ yl)prop -2-ylcarbamate (lnt-16g)
Int-I6f lnt-16g
A mixture of lnt-16f (300 mg, 0.72 mmoi) and iron powder (400 mg, 7.4 mmol) in acetic acid (10 mL) was stirred at room temperature overnight. The solvent was removed in vacuo. The reaction was quenched with a mixture of ethyl acetate (20 mL) and saturated aqueous sodium bicarbonate (20 mL). The reaction mixture was stirred for 10 minutes. The separated organic layer was
washed with brine and dried over sodium sulfate, filtered, and purified on silica gel (ethyl acetate - hexane) to give amine lnt-16g (250 mg, 90%) as a white solid.
Step G - Sythesis of Benzyl2-(1-(2 luoro-6-(4-(2-methylpyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxam
lnt-16g lnt-16b lnt-16h
A mixture of aniline lnt-16g (80 mg, 0.24 mmol), acid lnt-16b (77 mg, 0.20 mmol), HATU (1 15 mg, 0.30 mmol) and DIPEA (77 mg, 0.6 mmol) in DMF (3 mL) was stirred at room temperature overnight. The mixture was diluted with ethyl acetate (25 mL), washed with saturated aqueous sodium bicarbonate (10 mL) and brine (10 mL), dried over sodium sulfate and filtered. The solvent was removed in vacuo, and the residue was purified on silica ge! (ethyl acetate - hexane) to give compound lnt-16h (38 mg, 27%) as a yellow oil.
Step H - Synthesis of N-(2-(4~(2~aminopropan-2-yl)piperdin-1-yl)-3- fluouophenyl)-4-(2-methylpyridin-4-yl) 1 -((2-(trimethylsilyl)ethoxy)methyl)-1H- imidazole-2-carboxamide (Int- 16i)
lnt-16h lnt-16i
A mixture of lnt-16h (38 mg, 0.054 mmol) and Pd/C (20 mg, 0.094 mmol) in ethyl acetate (4 mL) was stirred under a balloon of hydrogen gas at room temperature overnight. The reaction was filtered through a pad of
diatomaceous earth and the solvent was removed in vacuo to give Int»16i (30 mg, >99%) as a yellow foam.
Step I - Synthesis of N-[2-[4-(1-amino-1-methyiethyl)-1-piperidinyl]-3- fluorophenyl]-4~(2~methyl-4-pyridinyl)-1H-imidazole-2-carboxam^ (67)
A mixture of amide lnt-16i (30 mg, 0.054 mmol) and HCI (4 N in dioxane, 2 mL) in water (0.5 mL) was stirred at 25 °C for 3 h. The solvent was removed in vacuo and the residue purified on prep-HPLC to afford 67 (24 mg, 27%) as a yellow solid. ES! MS m/e (M + H+) = 437.4.
EXAMPLE 17
This example describes the preparation of Imidazole Carboxamide
Preparation of N-[3~fluoro-2-[4-[(methylamino)methyl]~1- piperidinyt]phenyl]-4-(2-methyl~4-pyridinyl)- 1 H-imidazole-2-carboxamide (57)
Step A - Synthesis of tert-Butyl (1~(2-fluoro-6-nitrophenyl)piperidin-4- yi)meth l(methyl)carbamate (lnt-17a)
lnt-17a
To a flask containing 2,3-difluoronitrobenzene (167 mg, 1.05 mmol) in CH3CN (11 mL) was added diisopropylethylamine (0.37 mL, 2.1 mmol) followed by the piperidine reagent (240 mg, 1.05 mmol). The reaction was heated at 80 °C for 18 h. The solvents were removed in vacuo and the residue was purified by chromatography (ethyl acetate - hexane) to give lnt-17a (0.385 g, 99 % yield) as a bright yellow oil. LCMS m/e (M + H+) - 368.3.
Step B - Synthesis of teii-Butyl (1-(2-fluoro-6-nitrophenyl)piperidin-4- yl)methyl(methyl)carbamate (lnt-17b)
lnt-17a lnt- 7b
To a flask containing lnt-17a (173 mg, 0.47 mmol) in 2-propanoS (5 mL) was added Pd/C (~100 mg). The reaction was stirred under ¾ (1 atm) overnight. The reaction was filtered through a pad of Celite®, and the solvents were removed in vacuo to give lnt-17b (122 mg, 76 % yield) as a colorless oil/film. LCMS m/e (M + H+) = 338.3.
Step C - Synthesis oftert-Butyt (1-(2-fluoro-6-(4-(2-methyipyridin-4-y()-1-((2- (trimethylsilyl)ethoxy)methyl)-1H~imidazole-2-carboxamido)phe
yl)me
To a flask containing the lithium salt lnt-16b (12 mg, 0.04 mmoi) and Int- 17b (12 mg, 0.04 mmol) in DMF (1 mL) was added NMM (0.02 mL, 0.18 mmol) and HATU (40 mg, 0.1 1 mmol). The reaction was stirred at r.t. overnight.
Water (5 mL) was added to the reaction flask and the resulting solid was
collected via filtration to give lnt-17c (21 mg, 91 % yield) as a yellow solid. LCMS m/e (M + H+) = 653.5.
Step D - Synthesis of N-[3~fluoro-2-[4-[(methylamino)methyl]-1- pipe
To a flask containing lnt-17c (21 mg, 0.03 mmoi) in THF (0.3 mL) and MeOH (0.3 mL) was added a solution of 4 N HC! in 1 ,4-dioxane (1 ml). The reaction was heated at 60 - 80 °C for 30 min. Ether was carefully added and the solid was collected by filtration to give 57 (9.6 mg, 60 % yield) as an off- white solid. LCMS m/e (M + H+) = 423.2.
Compounds 50, 52, 54, 55, and 58 were prepared by essentially the same procedures as described in Steps A-D. Thus the amines listed in Table 3 below were reacted with difluoro nitrobenzene followed by reduction of the nitro moiety to provide the intermediate anilines.
Table 3
EXAMPLE 18
Preparation of N-[3-fluoro-2~(octahydro-6H-pyrrolo[2, 3-c]pyridin- yl)phenyl]-4-(2-methyl-4φyridinyl)-1H-imidazole~2-carboxam (43)
Step A - Synthesis of tert-butyl 6-(2~fluoro-6-nitrophenyl)octahydro-1H- pyrrol -c]pyridine-1-carboxylate (lnt-18b)
int-18b
A mixture of amine lnt-18a (920 mg, 4.1 mmol) (prepared according to Le Huerou, Y. et al. WO 2009/140320), difluoro-nitr (678 mg, 4.1 mmol), and DIPEA (1.05 g, 8.2 mmol) in acetonitriie (12 mL) was stirred at 80 °C overnight. After cooling to room temperature, the mixture was diluted with ethyl acetate (60 mL), washed with water (20 mL) and brine (20 mL), dried over sodium sulfate, filtered, and the solvent removed in vacuo to give lnt-18b ( .5 g, >99%) as an orange foam.
Step B - Synthesis of tert-butyl 6-(2-amino-6-fiuorophenyt)octahydro-1H- pyrrolo -c]pyridine- 1 -carboxyla te (lnt-18c)
!nt-18b lnt-18c
A mixture of lnt-18b (1.5 g, 4.1 mmol) and Pd/C (500 mg, 0.236 mmol) in ethyl acetate (10 mL) was stirred under a balloon of hydrogen gas at room temperature overnight. The reaction was filtered through a pad of
diatomaceous earth and the solvent was removed in vacuo to give aniline Int- 18c (1.27 mg, 93%) as a white solid.
Step C - Synthesis of tert-butyl6-(2-fluoro-6-(4~(2-methylpyridin-4~yl)~1-((2~ (trimethylsilyl)ethoxy)methyl)-1H-imidazole~2~carboxamido)
-pyrro!o(2,3-cJpyridine-1-carboxyiate (lnt-18d)
lnt-18c lnt-16b lnt-18d
A mixture of aniline lnt-18c (100 mg, 0.3 mmol), acid lnt-16b (120 mg, 0.36 mmol), HATU (170 mg, 0.45 mmol) and DIPEA (116 mg, 0.9 mmoi) in DMF (2 mL) was stirred at room temperature overnight. The mixture was diluted with ethyl acetate (75 mL), washed with saturated aqueous sodium bicarbonate (20 mL) and brine (20 mL), dried over sodium sulfate, filtered, the solvent removed in vacuo, and purified on siiica gel (ethyl acetate - hexane) to give compound lnt-18d (130 mg, 51 %).
Step D - Synthesis ofN-[3-fluoro-2-(octahydro-6H-pyrrolo[2,3-c]pyridin-6- yl)phθ -4-(2-methyl-4φyridinyl)-1H-imidazole~2-carboxamide (43)
!nt-18d 43 A mixture of amide lnt-18d (130 mg, 0.2 mmoi) and HCI (4 N in dioxane, 4 mL) in methanol (2 mL) and water (1 mL) was stirred at 60 °C overnight. After cooling to room temperature, the solvent was removed in vacuo and the residue purified on prep-HPLC to afford 43 (35 mg, 48%) as a white solid. ESI MS m/e (M + H+) = 421.
EXAMPLE 19
Preparation of N-[2-(2, 9-diazaspiro[5.5]undec-9-yl)-3-fluorophenyl]~4-(2- methyl-4-pyridinyl)- 1 H-imidazole-2-carboxamide (46)
Step A - Synthesis of tert-butyl 9-(2-fluoro-6-nitrophenyl)~2,9- diazaspiro[5.5]undecane-2-carboxyIate (lnt-19b)
A mixture of difluoro nitrobenzene (188 mg, 1.18 mmol), amine int-19a, (300 mg, 1.18 mmol), and DIPEA (305 mg, 2.36 mmol) in acetonitrile (4 mL) was stirred at 80 °C overnight. After cooling to room temperature, the mixture was diluted with ethyl acetate (30 mL), washed with water (10 mL) and brine (10 mL), dried over sodium sulfate, filtered, and the solvent removed in vacuo to give lnt-19b (470 mg, >99%) as an orange foam.
Step B - Synthesis of tert-butyl 9-(2-amino-6-fluorophenyl)-2,9- diazaspiro[5.5]undecane~2-carboxylate (lnt-19c)
A mixture of lnt-19b (464 mg, 1.18 mmol) and Pd/C (500 mg, 0.236 mmol) in ethyl acetate ( 1 mL) was stirred under a balloon of hydrogen gas at room temperature overnight. The reaction was filtered through a pad of diatomaceous earth and the solvent was removed in vacuo to give aniline Int- 19c (389 mg, 91 %) as a tan foam.
Step C - Synthesis of tert-butyl 9~(2-fIuoro~6~(4-(2~methylpyridin~4-yl)-1-((2- (t methylsilyl)ethoxy)methyl)- 1 H-imidazole-2~carboxamido)phenyI)-2, 9- diazaspiro[5.5]undecane~2-carbox late (lnt-19d)
lnt-16b lnt-19d
A mixture of aniline lnt-19c (279 mg, 0.768 mmol), acid lnt-16b (130 mg, 0.64 mmol), HATU (365 mg, 0.96 mmol) and DIPEA (248 mg, 1.92 mmol) in DMF (9 mL) was stirred at room temperature overnight. The mixture was diluted with ethyl acetate (75 mL), washed with saturated aqueous sodium bicarbonate (20 mL) and brine (20 mL), dried over sodium sulfate, filtered, the solvent removed in vacuo, and purified on silica gel (methanol - dichloromethane) to give compound lnt-19d (130 mg, 49%) as a brown oil.
Step D - Synthesis ofN-[2-(2,9-diazaspiro[5.5]undec-9-yl)-3-fluorophenyl]-4-(2- methyl- -pyridinyl)- 1 H-imidazole-2-carboxami
A mixture of amide lnt-19d (130 mg, 0.192 mmol) and HCI (4 N in dioxane, 5 mL) in methanol (3 mL) and water (1 mL) was stirred at 60 °C overnight. After cooling to room temperature, the solvent was removed in vacuo and the residue purified by preparative HPLC to afford 46 (25 mg, 27%) as a yellow solid. ESI MS m/e (M + H+) = 449.1.
EXAMPLE 20
This example describes the preparation of Imidazole Carboxamide
Compounds wherein R is H, T is
, and D is The preparation is illustrated by the preparation of N-ethyl-1 -[2-fluoro-6-[[[4-(2- methyl-4-pyridinyl)-1H-imidazol-2-yl]carbonyl]amino]phenyl]-4- piperidinecarboxamide (60) .
Step A - Synthesis of Methyl 1-(2-fluoro-6-nitrophenyl)piperidine-4-carboxylate (lnt-20
A mixture of difluoronitrobenzene (0.34 mL, 3.10 mmol), methyl isonipecotate (0.51 mL, 3.78 mmol), and diisopropyiethylamine (1 .08 mL, 6.20 mmol) in acetonitrile (15 mL) was heated at 80°C overnight. The solvents were removed in vacuo. Chromatographic purification (20% ethyl acetate :hexane) of the residue gave lnt-20a (0.85 g, 97%) as a yellow oil.
Step B - Synthesis of Methyl 1~(2-amino~6~fluorophenyl)pipericline-4- carb
A mixture of lnt-20a (471 mg, 1.67 mmol) and palladium on carbon (0.1 eq in Pd) was stirred in methanol (18 mL) under hydrogen (1 atm) at r.t.
overnight. The solid was filtered through a pad of Celite® and solvents were removed in vacuo to give lnt-20b (4 2 mg, 98%) as a solid/oil. This product was used without further purification.
Step C - Synthesis of Methyl 1-(2-fluoro-6-(4~(2~methylpyridin-4-yl)-1-((2- (tnmethyisilyi)ethoxy)methyl)-1H-imidazole-2-carboxamido)p^
A mixture of the lithium salt of lnt-16b (72 mg, 0.21 mmol), lnt-20b (57 mg, 0.24 mmo!), 1-hydroxybenzotriazoSe hydrate (HOBt) (59 mg, 0.44 mmol), N-(3-dimethylaminopropyl)-/\/ -ethyl carbodiimide hydrochloride (EDCI) (99 mg, 0.52 mmol), and 4-methylmorpholine (NMM) (0.01 mL, 0.09 mmol) was stirred in /V,W-dimethylformamide (3 mL) at 55°C overnight. Water and ethyl acetate were added, and the layers were separated. The organic layer was washed with water, dried over Na2S04, filtered, and concentrated in vacuo.
Chromatographic purification (70% ethyi acetate:hexane) of the residue gave lnt-20c (71 mg, 61 %).
Step D - Synthesis of 1~(2-fluoro~6-(4-(2-methylpyridin-4-yl)-1~((2~
(trimethylsilyt)ethoxy)methyl)~1H-imidazole-2-carboxamido)phenyl)piperi^ carboxylic acid (lnt-20d)
Methyl ester lnt-20c (71 mg, 0.13 mmo!) was dissolved in MeOH/THF (2 mL each), and water (0.5 mL) was added to the round-bottomed fiask. Sodium hydroxide (4 pellets) was added to the round-bottomed flask, and the mixture was stirred vigorously at r.t. overnight. The solvents were concentrated in vacuo and 4 N HCI was slowly added to the solid until a neutral pH was reached. The solid product that crashed out was filtered and dried under vacuum to give lnt-20d (50 mg, 72%) as a white solid.
Step E - Synthesis of /V-ethy!-1-(2-fluoro-6-(4-(2-methylpyridin-4-yl)-1 -((2- (trimethyls'!lyl)ethoxy)methyl)- H-imidazole-2-carboxamido)phenyl)piperidine-4- carboxamide (lnt-20e)
Ethyl amine (0.2 mL, 0.41 mmol) was dissolved in N,N- dimethylformamide (3 mL), int~20d (28 mg, 0.05 mmol), 0-(7-Azabenzotriazol- 1-yl)-W,W,/V'(N -tetramethyluronium PF6 (HATU) (65 mg, 0.17 mmol), and 4- methylmorpholine (N M) (0.03 mL, 0.27 mmol) were added to the round- bottomed flask, and the reaction mixture was stirred at 55°C overnight. The reaction was cooled to r.t. and water was added to the round-bottomed flask. The solid that crashed out was filtered, washed with water, and dried under vacuum to give lnt-20e (17.9 mg, 60%) as a brown solid.
Step F - Synthesis of N-ethyl-1 -[2-fluoro-6-[[[4~(2-methyl-4-pyridinyl)-1 H- imidazol-2~yl]carbonyl]amino]phenyl]-4~piperidinecarboxamide (60)
To a soiution of lnt-20e (17.9 mg, 0.03 mmol) in THF (0.5 mL) and MeOH (0.5 mL) was added 4 N HCI (1.0 mL, excess). The reaction was stirred at 75°C for 30 min. The solvents were concentrated in vacuo and ether was added to the round-bottomed flask. The solid was collected by filtration to give compound 60 (13.1 mg, 94%) as a tan solid.
Using similar procedures to those described in Steps E and F, compounds 59, 60, 61, 62, 64-66, and 78-96 were prepared from lnt-20d and the appropriate amines. The LC S values are set forth for each of these compounds in Table 4 below.
0 462.5 463.2 2.01 N-|2-[4-(1- azetid ylcarbonyl)-1 - piperidiny!]-3-fluorophenyi]-4- (2-methyl-4-pyridinyi)-1 H- imidazote-2-carboxamide
518.6 519.2 2.00 N~[3-f!uQro-2-[4-(8-oxa-3- azabicyclo[3.2.1]oct-3~ ylcarbony!)-1- piperidinyl3phenyi]-4-(2- methyl-4-pyridin l)-1 H- imidazole-2-carboxamide
504.6 505.2 1.95 N-[3-fluoro-2-[4-(2-oxa-5- azabicyclo[2.2.1 ]hept-5- y!carbonyl)-1- piperidinyl]phenyl]-4-{2- methyi-4-pyridiny!)-1 H- imidazole-2-carboxamide
522.6 523.2 1 .81 N-[3-fluoro-2-[4-tI3- (hydroxymet y!)-4- morpholinyl3carbonyl]-1 - pi perid i ny l]phenyl]-4-(2- methyl-4-pyridtnyl)-1 H- imidazole-2-carboxamide
521.6 522.2 1.80 N-[2-[4-[[3-{aminomethyI)-4- morpholinyl]carbonyI]-1 - piperidinyi]~3-fluorophenyl]-4- {2-methyf-4-pyridinyl)-1 H- imidazole-2-carboxamide
422.5 423.2 1.87 1 -[2-f iuoro-6-[[[4-(2-methyi-4- pyridinyl)-1 H-imidazol-2-
y t]carbony !]am i nojpheny l]-4- piperid i necarboxa mide
0 465.5 466.2 1.75 N-(2-amirtoet yl)-1-[2-fluoro-
6-[[[4-(2-methyl-4-pyridinyl)-
91 517.6 518.2 1 .78 N-{2-[4-(3,6- diazabicyclo[3.2.1]oct~3- yScarbonyl)-1 -piperidinyl]-3- f I uorophe ny !]-4-(2-methy I-4- pyrtdinyl)-1 H-imidazole-2- carboxamide
92 494.5 495.2 2.04 N-[3-fluoro-2-[4-t(3(R)-ftuoro- 1 -pyrroIidinyl)carbonyl]-1 - piperidinylJp enyl]-4-(2- methyl-4-pyridtnyl)-1 H- imidazoie-2-carboxamide
93 559.6 560.2 1.92 N-[3-f!uoro-2-[4-[(3-oxo-2,8- diazaspiro[4.5ldec-8- yl)carbonyl]-1-
NH piperidinyl]pheny!]-4-(2- methyf-4-pyridinyl)-1 H- imidazo!e-2-carboxamide
94 0 531 .6 532.2 1.80 N~[2-[4-(2,7- diazaspiro[3.5]noN-7- ylcarbonyl)-1-piperidinyl]-3- fIuorophenyl]-4-(2-methy!-4- pyridinyl)-1 H-imidazole-2- carboxamide
95 O NH2 535.6 536.2 1 .85 N-[2-[4-[[2-(1 -aminoethyl)-4- morpho!inyi]carbony!]-1- piperidinyl]~3-fluoropheny!]-4- {2-methy!-4-pyridinyi)-1 H- imidazole-2-carboxamide
96 583.7 584.2 1 .80 N-[3-fluoro-2-[4-[[4-hydroxy- 4-(2-pyridinyl)-1- piperidiny l]carbonyl -1 -
OH piperidinyl]phenyi3-4-(2- methyi-4-pyridiny!)-1 H- imidazo le-2-carboxa mid e
EXAMPLE 21
Preparation of N-[2-[2-(dimethylamino)ethoxy]phenyl]~4-[1 -(phenylmethyl)-l H- pyrazol-4-yl]~ 1 H-imidazole~2-carboxamide ( 6)
Step A - Synthesis of 4-(1-benzyl-1H-pyrazol-4-yl)-N-(2-(2- (dimethylamino)ethy!amino)phenyl)-1~((2~(trimethylsilyl)^^
im/dazole-2-carboxamide (lnt-21b)
A mixture of carboxylate lnt-5b (106 mg, 0.27mmoi), aniline lnt-21a (48 mg, 0.27 mmol), HOBt (72 mg, 0.53 rnmoi), EDCI (102 mg, 0.53 mrnoi) and N M (14 mg, 0.13 rnmoi) was stirred in N,N-dimethylformamide (3 mL) at 50 °C overnight. Water and ethyl acetate were added and layers were separated. The separated organic layer was washed with water. The separated organic layer was dried (MgS04) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave amide lnt-21 b (107 mg, 72%) as a white solid.
Step B - Synthesis of N-[2-[2-(dimethylamino)ethoxy]phenyl]-4-[1- (phe
Amide lnt-21b (107 mg, 0.19 mmol) was stirred in 4 N hydrochloric acid in 1 ,4-dioxane (5 mL) at 50 °C for 4 h. The solvents were removed in vacuo. Chromatographic purification [dichloromethane -methanol (7 N ammonia)] of
the residue gave imidazole 6 (70 mg, 85%) as a colorless oil. LCMS m/e (M + H÷) = 431.2.
EXAMPLE 22
Preparation of N-[2-[2-(dimethylamino)ethoxy]phenyl]-4-(1 H-indol~3-yl)-1 H- imidazole-2-carboxamide (17)
Step A - Synthesis of 4~bromo-N-(2-(2~(dimethylamino)ethylamino)phenyl)-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H~imidazole~2-carboxam (lnt-22a)
A mixture of carboxylate lnt-1c (148 mg, 0.46 mmol), aniline lnt-21a (83 mg, 10.46 mmol), HOBt (125 mg, 0.92 mmol), EDCI (176 mg, 0.92 mmol) and NMM (23 mg, 0.23 mmol) was stirred in N,N-dimethylformamide (5 mL) at 50 °C overnight. Water and ethyl acetate were added, and the layers were separated. The separated organic layer was washed with water. The separated organic layer was dried (MgSO4) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave amide lnt-22a (156 mg, 70%) as a white solid.
Step B - Synthesis of N-(2~(2-(dimethylamino)ethoxy)phenyl)-4-(1- (phenylsuifonyl)- 1 H-in doi~3-yl)- 1-((2~( trimethylsilyl) e thoxy)methyl)~ 1 H- imidazole-2-carboxamide (lnt-22b)
A mixture of bromoimidazo!e lnt-22a (98 mg, 0.20 mmol), 1- (phenylsulfonyi)-3-indazoie boronic acid (73 mg, 0.24 mmol) and sodium hydrogen phosphate (86 mg, 0.61 mmol) in 1 ,4-dioxane (4 mL) and water (2 mL) at r.t. was purged with nitrogen gas for 5 min in a microwave vial.
Tetrakistriphenylphosphorous palladium was added. The mixture was heated in a microwave reactor at 110 °C for 1 h. Water and ethyl acetate were added, and the layers were separated. The separated aqueous layer was extracted with ethyl acetate. The separated organic layer was dried (MgS0 ) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave indole lnt-22b (112 mg, 84%) as a colorless oil.
Step C - Synthesis of N-(2~(2~(dimethylamino)ethoxy)phenyl)-4-(1 ~
(phe
Amide lnt-22b (112 mg, 0.068 mmol) was stirred in 4 N hydrochloric acid in 1 ,4-dioxane (5 ml) at 50 °C for 4 h. The solvents were removed in vacuo to give indole lnt-22c as a yellow solid. The product was used in the next step without further purification. LCMS m/e (M + H+) = 530.1.
Step D - Synthesis of N-[2~[2-(dimethylamino)ethoxy]phenyl]-4-(1 H-indol-3-yl)~ 1 H-imidazole-2-carboxamide (17)
Indole lnt-22c (87 mg) was stirred in a mixture of methanol (5 m!_) and 50% aqueous sodium hydroxide solution at 60 °C for 3 h. The solvents were removed in vacuo. Water and ethyl acetate were added, and the layers were separated. The separated aqueous layer was extracted with ethyl acetate (X4). The combined organic layers were dried (MgS04) and filtered. The solvents were removed in vacuo, and chromatographic purification (ethyl acetate - methanol) of the residue gave imidazole 17 (43 mg) as a yellow oil. LCMS m/e (M + H+) = 390.1.
EXAMPLE 23
Preparation of 4-(2-amino-6-methyl-4^yrimidmyl)-N-[2-(3(R)-am pip
Na2C03, Pd(PPh3)4
Toluene-EtOH-water, 110 °C
microwave, 1 hr
2. 4N HCI in 1 ,4-dioxane
MeOH, 50 °C
A mixture of bromide InMe (78 mg, 0.13 mmoi), bis(pinacolato)diboron (48 mg, 0.19 mmol), potassium acetate (37 mg, 0.38 mmol) and
Pd(dppf)CI2.CH2CI2 (10 mg, 0.013 mmol) in 1 ,4-dioxane (5 mL) at r.t. was purged with nitrogen gas for 5 min in a sealed-tube. The mixture was heated at 85 °C overnight. The mixture was cooled to r.t. and transferred to a microwave vial. Chloropyrimidine lnt-23a (87 mg, 0.25 mmol), sodium carbonate (67 mg, 0.64 mmol) in ethanol (2 mL), toluene (2 mL) and water (1 mL) and Pd(PPh3) (15 mg, 0.013 mmol) were added. The mixture was purged with nitrogen gas for 5 min and then heated in a microwave reactor at 1 10 °C for 1 h. Water and ethyl acetate were added, and the layers were separated. The separated
organic layer was dried (MgS0 ) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave impure pyrimidine as a colorless oil.
The colorless oil was stirred in 4 N hydrochloric acid in 1 ,4-dioxane (2 mL) and methanol (2 mL) at 50 °C for 2 h. The solvents were removed in vacuo. Chromatographic purification [dichloromethane -methanol (7 N
ammonia)] of the residue gave pyrimidine 29 (15 mg, 28%, 2 steps) as a white solid. LCMS m/e (M + H÷) = 41 1.2.
EXAMPLE 24
Preparation of N-[2-[4-(aminomethyl)~1 -piperidinyl]-3-fluorophenyl]-4~(2- - -methyl-4^yrimidinyl)~1H-imidazole-2-carboxamide (47)
Cs2C03, Pd(dppf)2Cl2.CH2C!2
1,4-Dioxane - water, 110 °C
microwave, 1 hr
Step A - Synthesis of lnt-24a
A mixture of bromide lnt-2c (74 mg, 0.12 mmoi), bis(pinacolato)diboron (66 mg, 0.26 mmol), potassium acetate (39 mg, 0.39 mmol) and
Pd(dppf)CI2 CH2CI2 (1 1 mg, 0.013 mmol) in 1 ,4-dioxane (5 mL) at r.t. was purged with nitrogen gas for 5 min in a sealed-tube. The mixture was heated at 85 °C overnight. The mixture was cooled to r.t. and was transferred to a microwave vial. Chloropyrimidine lnt-23a (90 mg, 0.26 mmol) in 1 ,4-Dioxane (1 mL) and cesium carbonate (213 mg, 0.66 mmol) in water (2 mL) and
Pd(dppf)CI2 CH2CI2 (1 1 mg, 0.013 mmo!) were added. The mixture was purged with nitrogen gas for 5 min and was heated in a microwave reactor at 1 10 °C for 1 h. Water and ethyl acetate were added, and the layers were separated.
The separated organic layer was dried ( gS04) and filtered. The solvents were removed in vacuo and chromatographic purification (ethyl acetate - hexane) of the residue gave pyrimidine lnt-24a (54 mg, 48%) as a colorless oil LCMS m/e (M + H+) = 855.4.
Step B - Synthesis ofN-[2~[4~(aminomethyt)-1~piperidinyl]-3-fluorophenyl]-4-(2- amino~ 'methyl-4φyrimidinyl)'1H-imΐdazole-2-caώoxamidθ (47)
lnt-24a
Pyrimidine lnt-24a (54 mg, 0.063 mmol) was stirred in 4 N hydrochloric acid in 1 ,4-dioxane (2 mL) and methanol (2 mL) at 50 °C for 2 h. The solvents were removed in vacuo. Chromatographic purification [dichloromethane - methanol (7 N ammonia)] of the residue gave imidazole 47 (20 mg, 77%) as a white solid. LCMS m/e (M + H+) = 425.2.
Using similar procedures to those described in Steps A and B, N-[2-[4- (aminomethyl)-1-piperidinyl]-3-fluorophenyl3-4-(6-amino-2-methyl-4- pyrimidinyl)-1 H~imidazoie-2
This example describes the preparation of Imidazole Carboxamide
rein R6 is H, T is a substituted pyrimidine moiety, and D is
The preparation is illustrated by the preparation of compound
69.
Step - Synthesis of lnt-25a
Cs2C03, Pd(dppf)2CI2.CH2Cl2
1 ,4-Dioxane - water, 110 °C
microwave, 1 hr
Starting from lnt-2c and the protected dichioropyrimidine, lnt-25a was prepared using similar procedures as described in Step A of Example 24.
Cs2C03, Pd{dppf)2Ci2-CH2Cl2
1,4-Dioxane - water, 1 0 °C
microwave, 1 hr
Starting from lnt-2c and 4,6-dichloropyrimidine, lnt-25b was prepared using similar procedures as described in Step A of Example 24.
Step C - Synthesis ofN-[2-[4~(ammQmethyl)-1^iperidinylJ-3-fluoroph
9)
A solution of lnt-25a (40 mg, 0.046 mmol) and benzylamine (25 mg, 0.23 mmol) in isopropyl alcohol (3 ml) was heated at 110 °C in a microwave reactor for 2 h. The solvents were removed in vacuo. The residue was diluted with ethyl acetate and water. The layers were separated and the separated organic layer was dried (MgS04) and filtered. The solvents were removed in vacuo. Chromatographic purification (ethyl acetate - hexanes) gave a benzylaminopyrimidine intermediate as a colorless oil. The
benzylaminopyrimidine intermediate was stirred in trifluoroacetic acid (3 mL) for 2 h at 60 °C. The solvents were removed in vacuo and chromatographic purification [dichloromethane - methanol (7 N ammonia)] of the residue gave compound 69 (11 mg, 45%, 2 steps) as a colorless oil. LCMS m/e (M + H+) = 516.3.
Compounds 70-77 were prepared by essentially the same procedures as described in Steps A and B for the preparation of compound 69. Thus the amines listed in the Table 5 below were reacted with lnt-25a or lnt-25b
followed by acid deprotection to provide compounds 70-77.
Table 5
LCMS
Amine Compound m/e
EXAMPLE 26
Preparation of 2-amino-6~(2-(2-(4-(aminomethyl)piperidin fluorophenylcarbamoyl)-1 H-imidazol~4-yl)pyrimidine-4- carboxamide (68)
Step A - Synthesis of lnt-26a
Cs2C03, Pd(dpp¾CI2.CH2C!2
1 ,4-Dioxane - water, 110 °C
microwave, 1 r
Starting from lnt-2c and methyl 2,6-dichloropyrimidine-4-carboxylate, lnt-26a was prepared using similar procedures as described in Step A of Example 24.
- Synthesis of Compound 68
lnt-26a 68
A solution of lnt-26a (30 mg, 0.042 mmoi) in methanol (5 mIL 7 N in ammonia) were heated in a sealed-tube at 70 °C overnight. Th solvents were removed in vacuo. The residue was stirred in trifiuoroacetic acid (2 mL) and methanol (2 mL) at 50 °C for 2 h. The solvents were removed in vacuo and chromatographic purification [dichloromethane - methanol (7N in ammonia)] of the residue gave 68 (13 mg, 68%). LCMS m/e ( + H+) = 454.1.
EXAMPLE 27
Imidazole Carboxamide Compounds can be prepared which bear 2H substituents. This example describes a method useful for preparing Imidazole Carboxamide Compounds wherein R6 is 2H.
lnt-27c
The methyl ester lnt-27a is heated with palladium on carbon in the presence of 2H20 to provide the deuterium-containing intermediate lnt-27b. Alternatively, lnt-27b is prepared by treating lnt-27a with N-bromosuccinimide followed by hydrogenation with deuterium gas. int-27b is converted to Int-27c using procedures similar to those described in Steps A and B of Example 1.
Int-27c is saponified as described in Step C of Example 1 to provide Int
lnt-27d is condensed with substituted anilines and, if necessary, is deprotected to provide Imidazole Carboxamide Compounds such as lnt-27e and lnt-27f wherein R6=2H.
EXAMPLE 28
This example describes a method useful for preparing Imidazole Carboxamide Compounds wherein R is 2H.
The nitrobenzene lnt-28a is displaced with the substituted piperidine using conditions such as those described above in Step A of Example 2 to provide lnt-28b. Hydrogenation of lnt-28b with Pd/C in deuterium gas provides aniline lnt-28c. Int-28c can be condensed with various imidazole carboxylic acid intermediates and deprotected as described above to provide Imidazole Carboxamide Compounds wherein R1 is 2H.
EXAMPLE 29
The assay used to test the compounds' abilities to inhibit
phosphorylation of a substrate by PDK1 uses the IMAP® technology system available from Molecular Devices (Silicon Valley, CA, United States). The technology enables the detection of the phosphorylation of protein substrates by PDK1 and does not require the addition of antibodies to detect substrate phosphorylation. The technology is based on the high-affinity interaction of triva!ent metal containing nanoparticles (beads) with phospho-groups on the substrate of interest. The readout for the assay was fluorescence polarization (FP) which increased once the fluorescently labeled substrate was
phosphorylated and was bound to the beads as opposed to the
unphosphorylated substrate which did not bind the beads and had relatively lower polarization.
In a microwell assay format, the fluorescently-labeled peptide substrate from glycogen synthase-1 , 5FAM-PLSRTLSVSSLPGL-NH2 (SEQ ID NO:1), Molecular Devices part no RP7045), was phosphorylated in a kinase reaction. Addition of the IMAP® Binding System (available from Molecular Devices) stopped the kinase reaction and specifically bound the phosphorylated substrates. Phosphorylation and subsequent binding of the substrate to the beads was detected by FP.
The PDK1 IMAP assay utilized recombinant human PDK1 produced in Sf9 insect cells and containing amino acids 51-556 of the human PDK1 enzyme. The assay measured the change in fluorescence polarization caused by phosphorylation of a peptide substrate by PDK1. Addition of smali molecule PDK1 inhibitors results in the reduction of peptide phosphorylation changing the fluorescence polarization which is measured using a fluorescence plate reader. The assay was performed in a 384-well plate with 10 nM PDK1 enzyme, 100 nM peptide substrate 1 (SEQ ID NO:1 ), 100 nM activated peptide PIFtide and 2.5 uM ATP for 1.5 hours. PIFtide is added separately to the IMAP reaction at 100 nM. The peptide sequence of PIFtide is
RREPRILSEEEQEMFRDFDYIADWC (SEQ ID NO:2). PIFtide is a peptide sequence that interacts with PDK-1 and is derived from PRK2 kinase, a PDK-1 substrate. This sequence is present in the hydrophobic motif present in PDK-1 substrates and binds to the kinase domain of PDK-1. It is thought to act as a docking site for PDK-1 on the substrate and in vitro has been shown enhance PDK-1 phosphorylation of substrates by approximately 4-fold. See Biondi et al., EMBO 19, 979-988 (2000).
The detection beads were then added and allowed to incubate for 1 hour at room temperature and the fluorescence was then read. Staurosporine, a broad spectrum kinase inhibitor, was used as a positive control for the assay resulting in typical tCsos of 3 nM. Test compounds in 100% DMSO at a range of concentrations were added at 0.5 μί 15 minutes prior to ATP addition. The fluorescence polarization units (mP) generated with 1 uM stauroporine is considered to be background mP and the mP units generated with DMSO is considered to be total mP for each assay. The IC5o value is calculated based on fitting the mP units to the total and background mP and the concentration required to inhibit the mP units by 50% is reported to be the IC50.
Table 6 below lists representative compounds of the invention with activity data whereby the IC50 values are rated "A", "B," "C," or "D." The IC50 values are rated "A" for IC50 values in the range of 1 nM to 50 nM, "B" for 1C50 values in the range from 51 nM to 250 nM, "C" for IC50 values in the range from 251 nM to 1 μΜ, and "D" for IC50 values in the range from 1-5 μΜ.
Table 6
Compound ICso Compound ICso
1 B 49 B
2 D 50 C
3 C 51 C
4 B 52 B
5 B 53 A
6 D 54 D
7 D 55 B
8 A 56 B
9 D 57 C
10 C 58 D
11 B 59 D
12 B 60 D
13 B 61 D
14 C 62 D
15 D 63 D
16 B 64 D
17 C 65 D
18 A 66 D
19 B 67 B
20 A 68 A
21 B 69 /
22 C 70 B
23 B 71 A
24 72 A
25 D 73 B
26 A 74 B
27 A 75 A.
28 B 76 c
29 77 A
30 A 78 C
31 B 79 D
32 A 80 C
33 B 81 B
34 B 82 D
35 A 83 B
36 c 84 B
37 D 85 C
38 C 86 C
39 C 87 B
40 C 88 B
41 B 89 B
42 B 90 C
43 B 91 E¾
44 C 92 D
45 D 93 C
46 B 94 B
47 A 95 C
48 C 96 D
Preparation of Intermediates 60a-g (Table 7)
(T OLi lnt-60a-g
Starting from amines (see Table 7) and 1 , 2-difluoro-3-nitrobenzene, intermediates 60a-g were prepared using procedures as described for the preparation of lnt-2.
Table 7
4,6-dichloro- V- methylpyrimidirt-2- intermediates 61a-t amine General Procedures for the Preparation of Intermediates 61a-t (Tabte 8)
A mixture of amines (see Table 8) and 4,6-dichloro-N-methyIpyrimidin-2-amine in isopropanol were heated in a microwave reactor at 140 °C for 2 hr. After being cooled to r. , solvents were removed in vacuum and chromatographic purification (hexanes - ethyl acetate) gave lnt-61a-t.
Tabte 8
Preparation of Compound 97 to Compound 132 fTabie 10)
Starting from intermediate 1e, 2c, or 60a-g and intermediates 61a-t, compounds 97-132 were prepared using procedures as described in Steps A and B in Example 24.
Table 10
The Imidazole Carboxamide Compounds are useful in human and veterinary medicine in the therapy of proliferative diseases such as cancer other non-cancer proliferative disorders. The Imidazole Carboxamide
Compounds are useful where inhibiting PDK1 or inhibiting PDK1 variants is indicated, such as in treating various diseases associated with abnormal PDK1 signaling and/or abnormal signaling upstream or downstream of PDK1 (or variants thereof), which is often associated with up- regulated activity of one or more receptor tyrosine kinases, Ras, PDK1 , PKB/Akt, RSK, PKC, 70S6K, or SGK. In some embodiments, the compounds of the invention are useful in inhibiting PDK1 variants wherein the wild type PDK1 contains one or more point mutations, insertions, or deletions. Examples of PDK1 variants include PDK1T354M and PDK1 D527E.
While not being bound by any specific theory, it believed that the
Imidazole Carboxamide Compounds are useful in treating proliferative diseases such as cancer and other proliferative diseases because of their PDK1 inhibitory activity.
The general value of the compounds of the invention in inhibiting PDK1 can be determined, for example, using the fluorescence polarization-based assay described above in Example 29. In addition, the general value of the compounds of the invention in inhibiting PDK1 function can be evaluated using other known assays such as those described in Xu et al. in J. Biomol. Screen. 14, 1257-1262 (2009).
The Imidazole Carboxamide Compounds can be used to treat diseases and disorders characterized by excessive or pathologically elevated cell growth such as is characteristic of various cancers and non-cancer proliferative disorders. Examples of cancers for which the Imidazole Carboxamide
Compounds are useful, include lung cancer, bronchial cancer, prostate cancer, breast cancer, pancreatic cancer, colon cancer, rectal cancer, colorectal cancer, thyroid cancer, liver cancer, intrahepatic bile duct cancer,
hepatocellular cancer, gastric cancer, glioma/glioblastoma, endometrial cancer,
melanoma, kidney cancer, renal pelvic cancer, urinary bladder cancer, uterine corpus cancer, uterine cervical cancer, ovarian cancer, multiple myeloma, esophageal cancer, acute myelogenous leukemia, chronic myelogenous leukemia, lymphocytic leukemia, myeloid leukemia, bram cancer, oral cavity cancer, and pharyngeal cancer, laryngeal cancer, small intestinal cancer, non- Hodgkin's lymphoma, and villous colon adenoma.
In some embodiments, the compounds of the invention are used to treat cancers of the prostate, lung, colon, or breast.
Examples of non-cancer proliferative disorders for which the Imidazole Carboxamide Compounds are useful include neuro-fibromatosis,
atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis, proliferative diabetic retinopathy (PDR), hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, angiogenesis, and endotoxic shock.
Thus, in one embodiment the invention provides a method of treating a patient {e.g., human) having a disease or disorder characterized by excessive or pathologically elevated cell growth by administering a therapeutically effective amount of an Imidazole Carboxamide Compound, or a
pharmaceutically acceptable salt of said compound to the patient. In some embodiments, the disease or disorder being treated is a cancer. In other embodiments, the disease or disorder being treated are non-cancer
proliferative disorders.
In the therapies described above, a preferred dosage for administration to a patient is about 0.001 to 1000 mg/kg of body weight/day of the Imidazole Carboxamide Compound. An especially preferred dosage is about 0.01 to 25 mg/kg of body weight/day of the Imidazole Carboxamide Compound, or a pharmaceutically acceptable salt of said compound.
Combination Therapies
The Imidazole Carboxamide Compounds may also be useful in combination (administered together or sequentially) with one or more of other therapies such as radiation therapy and/or chemotherapeutic regimens with
therapeutic agents other than the Imidazole Carboxamide Compounds for treating a disease or disorder characterized by excessive or pathologically elevated cell growth, such as cancer.
In one embodiment, the invention provides a method of treating a disease or disorder characterized by excessive or pathologically elevated cell growth, the method comprising administering an Imidazole Carboxamide Compound or a pharmaceutically acceptable salt thereof, and one or more of a MAP Kinase pathway inhibitor such as bRaf, MEK, or ERK inhibitors to a patient in need thereof. In one embodiment, the disease or disorder is cancer.
In one specific embodiment of the method, the Imidazole Carboxamide
Compound or a pharmaceutically acceptable salt thereof is administered with a bRaf inhibitor.
In another embodiment, the Imidazole Carboxamide Compound or a pharmaceutically acceptable salt thereof is administered with a MEK inhibitor.
In yet another embodiment, the Imidazole Carboxamide Compound or a pharmaceutically acceptable salt thereof is administered with an ERK inhibitor such as those described in U.S. Patent Application Publication Nos.
2007/0191604, 2009/0118284, and 2007/0232610; U.S. Application No.
12/601 ,476, filed June 17, 2008; and in U.S. Provisional Application No.
61/247,238, filed September 30, 2009. The disclosures of the aforementioned patent publications and applications are incorporated herein by reference in their entireties.
In another embodiment, the invention provides a method of treating a disease or disorder characterized by excessive or pathologically elevated ceil growth, the method comprising administering an imidazole Carboxamide
Compound or a pharmaceutically acceptable salt thereof, and one or more of a PI3 Kinase pathway inhibitor, such as an mTOR or AKT inhibitor, to a patient in need of such treatment. In one embodiment, the disease or disorder is cancer.
In a specific embodiment of the method, the Imidazole Carboxamide Compound or a pharmaceutically acceptable salt thereof is administered with an mTOR inhibitor such as those described in U.S. Provisional Application No. 61/168,093, filed April 9, 2009; U.S. Provisional Application No. 61/222,529,
filed July 2, 2009; and 61/296,252, filed January 19, 2010. The disclosures of the aforementioned provisional applications are hereby incorporated by reference in their entireties.
In another specific embodiment of the method, the Imidazole
Carboxamide Compound or a pharmaceutically acceptable salt thereof is administered with an mTOR inhibitor such as Ridaforolimus, also known as AP 23573, K-8669 and deforolimus. Ridaforolimus is a unique, non-prodrug analog of rapamycin that has antiproliferative activity in a broad range of human tumor cell lines in vitro and in murine tumor xenograft models utilizing human tumor cell lines. Ridaforolimus has been administered to patients with advanced cancer and is currently in clinical development for various advanced malignancies, including studies in patients with advanced soft tissue or bone sarcomas. Thus far, these trials have demonstrated that ridaforolimus is generally well-tolerated with a predictable and manageable adverse event profile, and it possesses anti-tumor activity in a broad range of cancers. A description and preparation of ridaforolimus is described in U.S. Patent No. 7,091 ,213 to Ariad Gene Therapeutics, Inc., which is hereby incorporated by reference in its entirety.
In another specific embodiment of the method, the Imidazole
Carboxamide Compound or a pharmaceutically acceptable salt thereof is administered with an AKT inhibitor such as MK-2206, which is described in U.S. Patent No. 7,576,209 to Kelly ef a/. MK-2206 is a highly selective non- ATP competitive aliosteric AKT inhibitor that is currently in clinical development in patients with advanced solid tumor.
The Imidazole Carboxamide Compounds may also be useful in combination (administered together or sequentially) with one or more of anticancer treatments such as radiation therapy, and/or one or more anticancer agents different from the Imidazole Carboxamide Compounds.
Combinations of an Imidazole Carboxamide Compound with one or more anticancer agents different from the Imidazole Carboxamide Compounds are referred to herein as the the "the combination anticancer agents of the invention."
In one embodiment, the invention provides a method of treating cancer, comprising administering an amount (such as 0.1 mg to 5000 mg) of an
Imidazole Carboxamide Compound or a pharmaceutically acceptable salt thereof, and an amount (such as 0.1 mg to 5000 mg) of one or more additional anticancer drugs to a patient in need thereof.
In one embodiment, the Imidazole Carboxamide Compound and the additional anti-cancer agent(s) are administered in doses commonly employed when such agents are used as monotherapy for treating cancer.
The Imidazole Carboxamide Compound and the additional therapeutic agent(s) can act additively or synergisticaily. For instance, in one embodiment, the Imidazole Carboxamide Compound and the additional anticancer agent(s) are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating cancer.
In another embodiment, the Imidazole Carboxamide Compound and the additional anticancer agent(s) act synergisticaily and are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating cancer.
In one embodiment, the Imidazole Carboxamide Compound and the additional anti-cancer agent(s) are present in the same composition. In one embodiment, this composition is suitable for oral administration. In another embodiment, this composition is suitable for intravenous administration. In another embodiment, this composition is suitable for subcutaneous
administration. In still another embodiment, this composition is suitable for parenteral administration.
in other embodiments, the Imidazole Carboxamide Compounds may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate. The invention is not limited by the sequence of administration; the Imidazole Carboxamide Compounds may be administered either prior to or after administration of the known anticancer or cytotoxic agent. The order of administration for the sequence depends on the particular combinations chosen. For example, the cytotoxic activity of the cyclin-dependent kinase inhibitor flavopiridol is affected by the
sequence of administration with anticancer agents. Cancer Research, (1997) 57, 3375. Selecting the appropriate administration sequence is well within the skill of medical practitioners, such as attending physicians.
Another aspect of the invention is a method of treating one or more a disease or disorder characterized by excessive or pathologically elevated cell growth e.g., cancer, comprising administering to a patient, e.g., a human patient, in need of such treatment: an amount of a first compound, which is an Imidazole Carboxamide Compound, or a pharmaceutically acceptable salt thereof; and an amount of at least one second compound, the second compound being an anticancer agent different from the Imidazole Carboxamide Compound, wherein the amounts of the first compound and the second compound result in a therapeutic effect.
Non-limiting examples of suitable additional anti-cancer agents are selected from the group consisting of MAP Kinase pathway inhibitors {e.g., bRaf, MEK, or ERK inhibitors) hormones, PI3 Kinase pathway inhibitors (e.g., mTOR inhibitors, AKT inhibitors), hormone analogues and antihormones (e.g., tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, flutamide, nilutamide, bica!utamide, aminoglutethimide, cyproterone acetate, finasteride, buserelin acetate, fludrocortisone, fluoxymesterone, medroxyprogesterone, octreotide), aromatase inhibitors (e.g., anastrozoie, letrozole, liarozole, vorozole, exemestane, atamestane), LHRH agonists and antagonists (e.g., goserelin acetate, luprolide), inhibitors of growth factors (growth factors such as for example "platelet derived growth factor" and "hepatocyte growth factor", inhibitors are for example "growth factor" antibodies, "growth factor receptor" antibodies and tyrosine kinase inhibitors, such as for example cetuximab, gefitinib, imatinib, lapatinib and trastuzumab); antimetabolites {e.g., antifolates such as methotrexate, raltitrexed, pyrimidine analogues such as 5- fluorouracil, capecitabine and gemcitabine, purine and adenosine analogues such as mercaptopurine, thioguanine, cladribine and pentostatin, cytarabine,
f!udarabine); antitumour antibiotics (e.g., anthracyclins such as doxorubicin, daunorubicin, epirubicin and idarubicin, mitomycin-C, bleomycin, dactinomycin, pSicamycin, streptozocin); platinum derivatives (e.g., cisplatin, oxalip!atin,
carbop!atin); alkylation agents (e.g., estramustin, meclorethamine, melpha!an, chlorambucil, busulphan, dacarbazin, cyclophosphamide, ifosfamide, temozolomide, nitrosoureas such as for example carmustin and iomustin, thiotepa); antimitotic agents {e.g., Vinca alkaloids such as for example vinblastine, vindesin, vinorelbin and vincristine; and taxanes such as paclitaxel, docetaxel); topoisomerase inhibitors {e.g.. epipodophyl!otoxins such as for example etoposide and etopophos, teniposide, amsacrin, topotecan, irinotecan, mitoxantron) and various chemotherapeutic agents such as amifostin, anagrelid, clodronat, filgrastin, interferon alpha, !eucovorin, rituximab, procarbazine, ievamisole, mesna, mitotane, pamidronate and porfimer.
The combination anticancer agents of the invention can be administered separately, simultaneously, or sequentially to a patient. The combination anticancer agents of the invention can also be cyclically administered. Cycling therapy involves the administration of one anticancer agent of the invention for a period of time, followed by the administration of a second anticancer agent of the invention for a period of time and repeating this sequential administration, i.e., the cycle, in order to reduce the development of resistance to one or both of the combination anticancer agents of the invention, to avoid or reduce the side effects of one or both of the combination anticancer agents of the invention, and/or to improve the efficacy of the treatment.
In one embodiment, the combination anticancer agents of the invention are administered simultaneously to a patient in separate compositions. The combination anticancer agents of the invention may be administered to a patient by the same or different routes of administration.
When the combination anticancer agents of the invention are
administered to a patient concurrently, the term "simultaneously" is not limited to the administration of the combination anticancer agents of the invention at exactly the same time, but rather it is meant that they are administered to a patient in a sequence and within a time interval such that they can act synergtstically to provide an increased benefit than if they were administered otherwise. For example, the combination anticancer agents of the invention may be administered at the same time or sequentially in any order at different
points in time; however, if not administered at the same time, they should be administered sufficiently close in time so as to provide the desired therapeutic effect, preferably in a synergistic fashion.
Compositions and Administration
This invention is also directed to pharmaceutical compositions which comprise at least one Imidazole Carboxamide Compound, or a
pharmaceutically acceptable salt of said compound and at least one
pharmaceutically acceptable carrier.
When administered to a patient, the Imidazole Carboxamide
Compounds can be administered as a component of a composition that comprises a pharmaceutically acceptable carrier or vehicle. The present invention provides pharmaceutical compositions comprising an effective amount of at least one Imidazole Carboxamide Compound and a
pharmaceutically acceptable carrier. In the pharmaceutical compositions and methods of the present invention, the active ingredients will typically be administered in admixture with suitable carrier materials suitably selected with respect to the intended form of administration, i.e., oral tablets, capsules (either soiid-fiiled, semi-solid filled or liquid filled), powders for constitution, oral gels, elixirs, dispersible granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania. For example, for oral administration in the form of tablets or capsules, the active drug
component may be combined with any oral non-toxic pharmaceutically acceptabie inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms) and the like. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. Powders and tablets may be comprised of from about 0.5 to about 95 percent inventive
composition. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
Moreover, when desired or needed, suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated in the mixture. Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellu!ose, polyethylene glycol and waxes. Among the lubricants there may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include starch, methylcelluiose, guar gum, and the like. Sweetening and flavoring agents and preservatives may also be included where appropriate.
Liquid form preparations include solutions, suspensions and emulsions and may include water or water-propylene glycol solutions for parenteral injection.
Liquid form preparations may also include solutions for intranasal administration.
Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
For preparing suppositories, a low melting wax such as a mixture of fatty acid giycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
The Imidazole Carboxamide Compounds of the present invention may also be delivered transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a
transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
Additionally, the compositions of the present invention may be
formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize
therapeutic effects, i.e., anti-cancer activity and the like. Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
In one embodiment, the Imidazole Carboxamide Compound is administered orally.
In another embodiment, the Imidazole Carboxamide Compound is administered intravenously.
In another embodiment, the Imidazole Carboxamide Compound is administered topically.
In still another embodiment, the Imidazole Carboxamide Compounds is administered sublingually.
In one embodiment, a pharmaceutical preparation comprising at least one Imidazole Carboxamide Compound is in unit dosage form, in such form, the preparation is subdivided into unit doses containing effective amounts of the active components.
Compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present compositions can contain, in one embodiment, from about 0.1 % to about 99% of the Imidazole
Carboxamide Compound(s) by weight or volume. In various embodiments, the present compositions can contain, in one embodiment, from about 1% to about
70% or from about 5% to about 60% of the Imidazole Carboxamide
Compound(s) by weight or volume.
The quantity of Imidazole Carboxamide Compound in a unit dose of preparation may be varied or adjusted from about 0.1 mg to about 5000 mg. in various embodiments, the quantity is from about 10 mg to about 5000 mg,
about 10 mg to about 1000 mg, 1 mg to about 500 mg, 1 mg to about 00 mg, and 1 mg to about 50 mg.
For convenience, the total daily dosage may be divided and
administered in portions during the day if desired. In one embodiment, the daily dosage is administered in one portion. In another embodiment, the total daily dosage is administered in two divided doses over a 24 hour period. In another embodiment, the total daily dosage is administered in three divided doses over a 24 hour period. In still another embodiment, the total daily dosage is administered in four divided doses over a 24 hour period.
For administration to human patients, the amount and frequency of administration of the Imidazole Carboxamide Compounds will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. Generally, a total daily dosage of the Imidazole Carboxamide
Compounds range from about 0.1 to about 5000 mg per day, although variations will necessarily occur depending on the target of therapy, the patient and the route of administration. In one embodiment, the dosage is from about 1 to about 200 mg/day, administered in a single dose or in 2-4 divided doses. In another embodiment, the dosage is from about 0 to about 5000 mg/day, administered in a single dose or in 2-4 divided doses. In another embodiment, the dosage is from about 100 to about 5000 mg/day, administered in a single dose or in 2-4 divided doses. In still another embodiment, the dosage is from about 500 to about 5000 mg/day, administered in a single dose or in 2-4 divided doses.
The compositions of the invention can further comprise one or more additional therapeutic agents, selected from those specified above.
Accordingly, in one embodiment, the present invention provides compositions comprising: (i) at least one Imidazole Carboxamide Compound or a
pharmaceutically acceptable salt thereof; (ii) one or more additional therapeutic agents, e.g., anticancer agents, that are not an Imidazole Carboxamide Compound; and (tii) a pharmaceutically acceptable carrier, wherein the amounts in the composition are together effective to treat disease or disorder
characterized by excessive or pathologically elevated cell growth, such as cancer.
Kits
Another aspect of this invention is a kit comprising a therapeutically effective amount of at least one Imidazole Carboxamide Compound, or a pharmaceutically acceptable salt of said compound, and a pharmaceutically acceptable carrier, vehicle or diluent.
Yet another aspect of this invention is a kit comprising an amount of at least one Imidazole Carboxamide Compound, or a pharmaceutically acceptable salt of said compound and an amount of at least one additional anti-cancer agent listed above, wherein the amounts of the two or more active ingredients result in a desired therapeutic effect. In one embodiment, the at least one Imidazole Carboxamide Compound and the at least one additional anti-cancer agent are provided in the same container. In one embodiment, the at least one Imidazole Carboxamide Compound and the at least one additional anti-cancer agent are provided in separate containers.
While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fail within the spirit and scope of the present invention.
Claims
What is claimed is:
1. A compound of the Formula I)
wherein:
T is RA, H, halo, Ci-C6 alkyl, (C2-C3 alkyny1ene)~(CrC6 alkyi), or
(C2-C3 alkynylene)-cyclopropyl;
wherein RA is selected from the group consisting of:
(i) 5- to 10-membered mono- or bicyclic heteroaryl wherein said heteroaryl of RA contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
(ii) 4- to 7-membered monocyclic heterocyclyl wherein said
heterocyclyl of RA contains at least one ring nitrogen atom ring member, and optionally one additional heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur;
(iii) 4- to 7-membered monocyclic heterocyclenyl wherein said
heterocyclenyl of RA contains one heteroatom selected from the group consisting of nitrogen, oxygen, and suifur;
(iv) phenyl;
(v) C3-C7 cycloalkyl; and
(vi) C3-C7 cyc!oalkenyl;
wherein said RA is unsubstituted or substituted by one to three moieties selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halo, C1-C3 fluoroalkyl, hydroxy, amino, C Ce aikylamino,
C1-C6 dialkyiamino, Ci-C6 hydroxyalkyl, Ci-Ce aikylamino, cyano,
-C(0)-(d-C6 alkyl), -C{0)-0-(C C6 alkyl), suifonamido,
-N(H)-C(0)-(CrC6 alkyl), benzylamino, -Y-R9, and -C(0)-N(R11)2;
Y is a bond, C C3 alkylene, -0-, -N(H)-, or -N(H)-(Ci-C3
alkyiene), wherein said C1-C3 alky!ene or -N(H)-(CrC3 alkylene) of Y is unsubstituted or substituted by C1-C3 hydroxyalkyl;
R9 is
(i) phenyl;
(ii) 5- to 6-membered heteroaryl, wherein said
heteroaryl of R9 contains one to two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; or
(Hi) C3-C7 cycloalkyl;
wherein said R9 is unsubstituted or substituted by one to two
C1-C3 alkyl, C1-C3 alkoxy, halo, or C1-C3 fluoroalkyl;
each R11 is independently H, Ci-C6 alkyl,
-(C1-C3 aiky!ene)-N(Ci-C3 alkyl)2, -(C1-C3 alkylene)-RB, or optionally, the R11 groups together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclyl containing one to two nitrogen atoms, which is heterocyclyl is optionally substituted by C1-C3 alkyl;
wherein RB is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, wherein said R8 is unsubstituted or substituted by one to two C1-C3 alkyl, Ci-C3 alkoxy, ha!o, or C1-C3 fluoroalkyl;
R6 is H, 2H, C1-C3 alkyl, Ci-C3 aikoxy, or halogen;
D is
(i) -(Ci-C3 dialkylamino)-(CrC3 alkoxy);
(ii) -C(0)-N(H)-heterocyclyl wherein said heterocyclyl moiety is a 5- to 6-membered ring containing one to two nitrogen atoms, and is unsubstituted or substituted by one to two Ci-C3 alkyl, C-1-C3 alkoxy, halo, or phenyl;
(iii) a grou of the formula
n is 0, 1 , or 2;
R4, R5 and R 0 are independently H, C1-C3 alkyl, fluoro, hydroxy, amino, C1-C3 alkylamino, C1-C3 dialkylamino, ureido, azetidinyl, pyrrolidinyl, piperidino, pyrazolyl, -(Ci-C3)alkylene- OH,
-M-N(R7)(R8), or -N(R7)-C(0)(R8);
M is
(i) a direct bond;
(ii) -C(O)-;
(iii) -(C1-C3 alkylene)-C(O)-;
(iv) C1-C3 alkylene; or
wherein ring E or said aikyiene of is unsubstituted or substituted by one to two C1-C3 alkyl;
R7 and R8 are independently selected from the group consisting of H, C1-C3 alkyl, (C C6 alkylene)-NH2i (CrC6 alkylene)-N(H){Ci-C3 alkyl), (C C6 alkylene)-N(Ci-C3 alkyl)2, (C3-Ce cycIoalkyl)-NH2, (C1-C3 alkylene)-(C3-C6 cycloalkyl)-NH2, {S^^-trif!uoro^-hydroxyJpropyi, and C C3 alkanoyl;
or optionally, wherein R4, R5, or R10 is -M-N(R7)(R8), R7 and R8 together with the nitrogen atom to which it is attached form (t) Rc, wherein Rc is a 4- to 10-membered mono- or bicyclic heterocyclyi containing one nitrogen atom
and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein Rc is unsubstituted or substituted by 1 to 4 R15 moieties; or
(ii) RD, wherein RD is a 4- to 10-membered mono- or bicyclic heterocyciyi containing one nitrogen atom and wherein RD is substituted by R16, and wherein RD is optionally and additionally substituted by 1 to 3 R15;
wherein each R15 is independently selected from the group consisting of Ci-C3 alkyl, fluoro, Ci- C3 trifluoroalkyl, (Ci-C3 alkylene)-OH, (d-C3 alkylene)-NH2, and (Ci-C3 alkylene)- C(0)NH2, or optionally two R15 moieties together with the carbon atom to which they are attached form a carbonyl;
wherein R1S is selected from the group
consisting of (Ci-C3 alkylene)-OH, (C1-C3 aikylene)-NH2, and (Ci-C3 alkylene)- C(0)NH2;
or two of R4, R5 and R10 together with the carbon atom(s) to which they are attached form a 5- or 6-membered cycioalkyl or heterocyciyi ring containing one to two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; R14 is H or C1-C3 alkyi;
, R2 and R3 are independently selected from the group consisting of H, 2H, halo, Cr } alkyl, amino, CrC3 a!kylamino, Ci-C3 dialkylamino, carbamyl, hydroxy, cyano, trifluoromethy!, C3~C7 cycioalkyl, and 5- to 6- membered heteroaryl containing one two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R6 is H.
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein D is
M is a direct bond, -C(O)-, or methylene;
R4 and R5 are independently selected from the group consisting of H, C1-C3 alkyl, and fluoro, and
R7 and R8 are independently selected from the group consisting of H, C1-C3 alkyl, -CH2CH2NH2, -CH2CH2NHCH2CH3, -CH2CH2CH2CH2NHCH3( cyclohexylamino,
or optionally R7 and R8 together with the nitrogen atom to which it is attached form:
(i) Rc, wherein Rc is a 4- to 10-membered mono- or bicyclic heterocyclyl containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein Rc is unsubstituted or substituted by 1 to 4 R 5 moieties; or
(ii) RD, wherein RD is a 4- to 10-membered mono- or bicyclic
heterocyclyl containing one nitrogen atom and wherein RD is substituted by R16, and wherein RD is optionally and additionally substituted by 1 to 3 R15;
wherein each R15 is independently selected from the group consisting of C C3 alkyl, fluoro, C1-C3 trifluoroalkyi, (C C3 alkylene)-OH, (C C3 alkylene)-NH2, and (C^-C3 alkylene)-C(0)NH2, or optionally two R15 moieties together with the carbon atom to which they are attached form a carbonyl;
wherein R16 is selected from the group consisting of (C1-C3 alkylene)- OH, (C1-C3 alkyiene)-NH2, and (C^Cs a!kylene)-C(0)NH2;
4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein D is selected from the roup consisting of:
5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein T is selected from the group consisting of
H, and Br; and
RA, wherein RA is selected from the group consisting of cyclopropy!, phenyl, pyrazolyl, thienyl, pyridinyl, pyrimidinyl, pyridaziny!, indolyl, piperidinyl, piperaziny!, and dihydropyranyl, wherein RA is unsubstituted or substituted by one to three moieties selected from the group consisting of C1-C3 alkyi, C1-C3 a!koxy, halo, trifluoromethyi, hydroxy, amino, C Ce alkylamino, Ci-C6 dialkylamino, C C6 hydroxyalkyl, cyano, -C(0)-(Ci-C6 alkyi),
-C(0)-0-(C C6 alkyi), sulfonamido, -N(H)-C(0)-(Ci-C6 alkyi), benzylamino, -Y-R9, and ~C(0)N(R1 )2.
6. The compound of claim 5 or a pharmaceutically acceptable salt thereof, wherein T is selected from the group consisting of:
7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:
T is A, wherein RA is selected from the group consisting of substituted or unsubstituted cyclopropyl, phenyl, pyrazolyl, pyridinyl, pyrimidinyl, indo!yl, piperidinyl, piperazinyl, and dihydropyranyi, wherein RA is unsubstituted or substituted by one to three moieties selected from the group consisting of C1-C3 alkyt, C1-C3 alkoxy, halo, trifluoromethyl, hydroxy, amino, C C6 alkylamino, Ci-C6 dia!kylamino, Ci-Ce
hydroxyalkyi, sulfonamido,
-N(H)-C(0)-(C C3 alkyl), benzylamino, -Y-R9, and -C(0)N(R1 )2;
D is
M is a direct bond, -C(O)-, or methylene;
R4 and R5 are independently selected from the group consisting of H, C1-C3 alkyl, and fluoro;
R7 and R8 are independently selected from the group consisting of H, C1-C3 alkyl, -CH2CH2NH2, -CH2CH2NHCH2CH3, - CH2CH2CH2CH2NHCH3, cyclohexylamino,
or optionally R7 and R8 together with the nitrogen atom to which it is
attached form:
(i) Rc, wherein Rc is a 4- to 10-membered mono- or bicyclic
heterocyclyi containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein Rc is unsubstituted or substituted by 1 to 4 R15 moieties; or
(ii) RD, wherein RD is a 4- to 10-membered mono- or bicyclic
heterocyclyi containing one nitrogen atom and wherein RD is substituted by R 6, and wherein RD is optionally and additionally substituted by 1 to 3 R15;
wherein each R15 is independently selected from the group consisting of C1-C3 alkyl, fluoro, C C3 trifluoroalkyl, (C1-C3 alkyiene)-OH, (C1-C3 alky!ene)-NH2, and (C C3 alkylene)-C(0)NH2, or optionally two R15 moieties together with the carbon atom to which they are attached form a carbonyl;
wherein R16 is selected from the group consisting of (C1-C3 alkylene)-
OH, (C1-C3 alkylene)-NH2, and (C1-C3 alkylene)-C(0)NH2;
R6 is H; and
R1, R2, and R3 are independently selected from the group consisting of H, fluoro, and pyrazotyL
8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R1, R2, and R3 are independently selected from the group consisting of H, haio, and pyrazolyl.
9. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula (la):
X is CH or N;
R12 and R13 are independently selected from the group consisting of H, Ci~ C3 alkyl, amino, C1-C3 alkylamino, carbamyl, hydroxymethyl, benzylamino, 4- fluorobenzylamino, 3,4-difluorobenzylamino, 4-trifluorobenzylamino, 3,4- dimethoxybenzylamino, and 2-hydroxy-1-phenylethylamino;
R1 is H or halo;
M is a direct bond or methylene; and
R7 and Rs are independently H or C1-C3 alkyl.
10, The compound of claim 9 or a pharmaceutically acceptable salt thereof,
1. The compound of claim 9 or a pharmaceutically acceptable salt thereof
12. A compound selected from one of the following compounds:
N-[5-amino-2-(3(R)-amino-1-piperidinyl)phenyl]-1H-imidazole-2- carboxamide (1);
1-[4-amino-2-[(1 H-imidazol-2-ylcarbonyl)amino]phenyl]-4-(methylamino)-^ piperidinecarboxamide (2);
N-[5-amino-2- 4-(aminomethyl)-1-piperidinyl]phenyl]-1H-imidazoie-2- carbaxamtde (3);
N-[2-(3(R)-amino~1 -pipertdinyl)-3-f iuorophenyl]-4-[1 -(phenylmethyl)-l H~ pyrazol-4-yl]-1 H-imidazole-2-carboxamide (4);
N-i2~(3(R)-amino-1 -piperidinyl)-3-fluorophenylH»[1 -(2-thienyimethyl)-1 H- pyrazol~4-yl]-1 H-imidazole-2-carboxamide (5);
N-[2-[2-(dimethylamino)ethoxy^^
1 H-imidazoIe-2-carboxamtde (6);
N-[2-(3(R)-amino-1 -piperidinyl)-3-fluorophenyi]-4-[1 -(2-pyridinylmethyl)-1 H- pyrazol-4-yf]-1 H-imidazote-2-carboxamide (7);
N-[2-(3(R)-amino-1-piperidinyl)-3-fiuorophenyiH-(2-methyl-4-pyridinyl)-1 H- imidazoie-2-carboxamide (8);
N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenylH-[5-(trifluoromethyl)-3- pyridinyl]-1 H-irnidazoIe-2-carboxamide (9);
N~[2-(3(R)-amino-1-piperidinyl)-3-ftuoropheny!]-4-(4-pyridinyl)-1 H-imidazole- 2-carboxamide (10);
N-[2-(3(R)-amino-1 -piperidinyl)-3-fluorophenyl]-4-(1 H-pyrazoi-4-yI)-1 H- imidazole-2-carboxamide (11);
N"[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-bromo-1 H-imidazQle-2- carboxamide (12);
N-[2-(3(R)-amino-1 -piperidinyl)-3-fluorophenyl]-4-|1 -(3-pyridinylmethyi)-1 H- pyrazol-4-yl]-1 H-imidazole-2-carboxamide (13);
N-[2~(3(R)-amino-1 -piperidinyl)-3-fluorophenyt]-4-(1 -methyl-1 H-pyrazol-4- yl)-1 H-imidazole-2-carboxarnide (14);
N-[2 3(R)-[(aminocarbonyl)amino]-1-piperidinyl]-3-fluorophenyl]-4-bromo- 1 H-imidazole-2-carboxamide {15);
N-t5-amino-2-(3(R)-amino-1-piperidinyi)phenylH-bromo-1H-imidazole-2- carboxamide (16);
N-[2-[2~(dimethylamino)ethoxy]phenyl]-4-(1H-indol-3-yl)-1 H-imidazoie-2- carboxamide (17);
N-[2-E4-(aminomethyl)-1-piperid ^
1H-imidazole-2-carboxamide (18);
N-i2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-[2-(trifluoromethyl)-4- pyridinyl]-1 H-irnidazole-2-carbQxamide (19);
N-[2-("3(R)-amino-1-piperidinyl)-3 luorophenyl]-4-(2-amino-4-pyridinyl)-1H- imidazole-2-carboxam'tde (20);
N-[2-(3(R)-amino-1-piperidinyi)-34luorophenyl]-4-(2--methQxy-4-pyridinyi)- 1H-imidazole-2-carboxamide (21);
N-[2-(3(R)-amino-1-piperidinyl)-3-fluQrophenyI]-4-(3,6-dihydro-2 -pyran-4- yl)-1 H-imidazole-2-carboxamide (22);
N-[2-(3(R)-aminQ-1-piperidmyi)-3 luorQ
1H-irnidazole-2-carboxamide (23);
4-(2-amino-6-methyl-4-pyridinyl)-N-[2-(3(R)-amino-1-piperidinyi)-3- fluorophenyl]-1 H-imidazole-2-carboxamide (24);
N 2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-(2-hydroxy- -pyridinyI)-1 H- imidazoie-2-carbQxamide (25);
N-[2-(3(R)-amino-1-piperidinyl)-3 luorophenyl]^-[2-(hydroxymethyl)-4- pyridinyl]-1 H-imidazole-2-carboxamide (26);
N-[2-[4-(aminomethyi)-1-piperidinyl]-3 luorophenyl]-4-(2-amino-4-pyridi 1 H-imidazole-2-carboxamide (27);
N-f2-[4-(aminomethyi)-1-piperidinyl]-3^-difluorophenyi]-4-(2-amino^ pyridirtyi)-1 H-imidazole-2-carboxamide (28);
4-(2-amino-6-methyM-pyrimidinyl)-^
fluorophenyl]-1 H-imidazole-2-carboxamide (29);
N-t2-|4-(aminomethyl)-1-piperidinyl]-3 luorophenyl]-4-(2-ethyl-4-pyridinyi)-- 1 H-imidazole-2-carboxamide (30);
N-[2-[4-(ammomethyl)-1-piperidinyl]-3-fluorophenyi]-4-[3- (aminosulfonyl)phenyl]-1 H-imidazole-2-carboxamide (31);
N-[2-t4~(aminomethyl)-1-piperidinyl]-3-fiuorophenyll-4-[2-(methylamino)-4- pyridinyl]-1 H-imidazoie-2-carboxamide (32);
4-[2-(acetylamino)-4-pyridinylJ-N-[2-[4-(aminomethyl)--1-piperidinyl]-3- fluorophenyl]-1 H-imidazoie-2-carboxamide (33);
N-[2-[4-(aminomethyl)~1-piperidinyl]-3-fluorophenyl]-4-{3-chlorQpheny!)-1H- imidazoie~2-carboxamide (34);
N-t2-[4-(am!nomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[2- [(phenylmethyl)amino]-4-pyridinyl]-1 H-imidazole-2-carboxamide (35);
N-[2-[4-(aminomethyl)-1-piperidinyl]-3 iuorophenyl]^-[2-{dimethylamino)-4- pyridinyl]-1 H-irnidazole-2-carboxarnide (36);
N-[2-[4 amtnQmethyl)-1 -piper^
1 H-imidazole-2-carboxamide (37);
N 2-(3(R)-amino-1-piperidmyi)-3-fluorophenyl]-4-(2l4-difiuorophenyl)-1 H- imtdazole-2-carboxamide (38);
N-[2-(3(R amino-1 -piperidiny!)-3-f luorophenyI]-4-[2-(1 H-pyrazol-1 -yl)-4- pyridinyi]-1 H-imidazole-2-carboxamtde (39);
4-(2-amino-4-pyridinyl)-N-[2-[4-[(dimethylamino)methyl]-1- piperidinyl]phenyl]-1 H-imtdazole-2-carboxamide (40);
N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[3-(2- hydroxyethyl)phenyl]-1 H-imidazoie-2-carbQxamide (41);
N-[2-[4-(aminomethyl)-1-piper!dinyl]-3-fluoropheny(H-[2- (cyciopropylaminQ)-4-pyridinyl]-1H-imidazole-2-carboxamide (42);
N-i3-fluoro-2-(octahydro-6h-pyrrolo[2s3-c]pyridin-6-yi)phenyl]-4-(2-methyl-4- pyridmyi)"1 H-imidazo!e-2-carboxamide (43);
N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-(6-cyanQ-2-pyridinyl)- 1 H-tmidazQle-2-carboxamide (44);
4^5-acetyl-2-thienyl)-N»[2 4-(aminomethyl)-1-piperidtnyl|-3-fluorophenyi]-- 1 H-imidazo!e-2-carboxamide (45);
N-[2-(2,9-diazaspiro[5.5]undec>-9-yl)-3-fiuorophenyl3-4-(2-methyl-4-pyndin 1 H~imidazole-2-carboxamide (46);
N-[2-t4-(aminomethyi)-1-piperidinyl]-3 luorophenylH-(2-arnino-6-methyl-4- pyrimidinyl)-1 H-imidazoie-2-carboxamide (47);
N-[244-(aminomethyl)-1-piperidinyI]-3-fluorophenylH-[3-(trifiuorQm
1H-pyrazoi-5-yl]-1 H-imidazoie-2-carboxamide (48);
N 2-[4-(aminQmethyi)-1-piperidinyl3-3 ^^
pyrimidinyl)-1 H-imidazole-2-carboxamide (49);
N-[2-[4-[(dimethylamino)methyl]-1-piperidinyl]-3-ftuorophenyl]-4-(2-methy pyridirtyl)-1 H-imidazole-2-car oxamide (50);
N-[2-[4-(arninQmethyl)-1 -piperidinyl]-5-(1 H-pyrazoi~4-yl)phenyl]-4-(1 H- pyrazol-4-yl)-1 H-imidazole-2-carboxamide (51);
N-[2-[4"(aminomethyl)-4-ethyl-1-piperidinyl]-3-fluorophenyl3-4-(2-rnethyl-4- pyridinyl)-1 H-imidazole-2-carboxamide (52);
N-[2-[4-(aminomethyl)-1 -piperidinyl3-3-fluorophenyi]-4-(1 H-pyrazoi-4-yl)-1 H- imidazote-2-carboxamide (53);
N-[2-(3,8-diazabicyclo[3.2.1]oct-3»yl)-3-f!uorophenyl]-4-(2-methyi-4- pyridinyl)-1 H-imidazole-2-carboxamide (54);
N-[2-i4-(aminomethyl)-4-methyl-1-piperidinyl]-3-fluorophenyIH-(2-met^ pyridinyl)-1 H-imidazole-2-carboxamide (55);
methyl 3-[2-[[[2-[4-(aminomethyl)-1 -piperidiriyl]-3~
fluorophenyilamino]carbonyl]-1 H-imidazol-4-yl]benzoate (56);
N 3 luoro-2^4-[(methylamino)met^
pyridinyl)-1 H-imidazole-2-carboxamide (57);
N»[3-fluoro-2-(hexahydropyrrolo[3,4~c]pyrrol-2(1H)-yl)phenyl]-4--(2-rnethyl-4- pyridiny!)-1 H-imidazole-2-carboxamide (58);
1 -[2-f luoro-6-[[[4-(2-methyl-4-pyridinyi)->1 H-imidazol-2- yl]carbonyl]amino]phenyl]-N-methyl-4-piperidinecarboxamide (59);
N-ethyi-l-l2-fluoro-6-[[[4-(2-methyl-4-pyridinyl)~1 H-imidazol-2- yl]carbonyi3amino]phenyl3-4-piperidinecarboxamide (60);
1 -[2-f luoro-6-[[[4-(2-methy!-4-pyridinyl)-1 H-imidazoi-2- yi3carbonyl3amino]phenyll-N,N-dtmethyi-4-piperidinecarboxamide (61);
1 -[2-fluorQ-6-[[[4-(2-methyi-4-pyridinyl)-1 H»imidazol-2- ylJcarbonyt]aminoJphenylj-N-(3t3,3-tnfluoro-2-hydroxypropyf)-4- piperidinecarboxamide (62);
N-[2-[4-(aminomethy!)-1-piperidinyl3-3 luoropheny!3^-(5-pyrimidinyi)-1H- imidazole-2-carboxamide (63);
N-[3 luoro-2»[4-[(3(S)-fluoro-1-pyrrolidinyl)carbonylJ-1-piperidinyl]phenyl]-4- (2-methyl-4-pyridinyi)-1 H-imidazole-2-carboxamide (64);
1 -[2-f iuoro-6-[f[4-(2-methyl-4-pyridiny!)-1 H-imidazol-2- yl]carbQnyi3amino]pheny!]-N-(1 (R)-phenytethyl)-4-piperidinecarboxamide (65);
N-[2-[4-(1 -azetidinylcarbanyi)-1 -piperi^
1 H-imidazole-2-carboxamide (66);
N-[2-f4-(1-amino-1-methylethyl)"1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4- pyridinyl)-1 H-imidazQle-2-carboxamide (67);
6-[2-[[[2 4-(aminomethyl)-1-piperidinyl]-3-fluorophenyi]amino3carbonyIJ~1H- imidazoi-4-yil-2-hydroxy-4-pyrimidinecarboxamide (68);
N-[2"[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[2-aiTiino-6- f(phenylmethyl)amino]-4-pyrimidinyl]-lH-imidazole-2-carboxamide (69);
N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[2-amino-6-[[t4- (trifluoromethyl)pheny!]methyl]aminQ]-4-pyrimjdinyl]-1 H-imidazQle-2- carboxamide (70);
4-[2-amino-6 [(4-fiuorophenyl)methyl]amino]-4-pyrimidinyl]-N-[2-[4- (aminomethyl)-l -piperidinyl]-3-f luorophenyl]-1 H-imidazole-2-carboxamide (71 );
4-[2-amino-6- ¾droxy-1(R)-phenylethyi]amino]-4-pyrimidinyl}-N-[2-f4- (aminomethyl)-l -piperidinylJ-3-fluorophenyl]-1 H-imidazole-2-carboxamide (72);
N_[2-[4-(aminomethyl)-1-piperidinyl]-3-fiuorophenyl]-4-[6-[t(4»
fluorophenyi)methyl]amino]-4-pyrimidinyI]-1 H-imidazoIe-2-carboxamide (73);
N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[6-[[(3,4- diftuorophenyi)methyl]amino]-4-pyrimidinyl]-1H-imidazole-2-carboxam (74);
4-[2-amino-6-it(3,4-dif1uorophenyl)methyl]amjnQ]-4-pyNmidinyl]-N-[2-[4- (aminomethyl)-l -piperidiny!]-3-fluorophenyl]-1 H-tmidazole-2-carboxamide (75);
4-[2-amino-6 K 4-dimethoxyphenyl)methyl]aminQH»pyrimidinyl]-N-|2-t4- {arninomethyt)-1 -piperidinyl]-3-fluorophenyl]-1 H-imidazole-2-carboxamide (76);
4-[2-amino-6-[(2-hydroxy-1(S)-phenylethyl)amino]-4-pyrimidinyl]-N-[2- 4- (aminomethyl)-l -piperidinyl]-3-f luorophenyl]-1 H-imidazole-2-carboxamide (77);
N-[3-f iuoro-2-|4-(8-oxa-3-azabicyclo[3.2.1 ]oct-3-yicarbonyl)-1 - piperidiny!]phenyl]-4-(2-methyl-4-pyridiny!)-1 H-imidazole-2-carboxamide (78);
N-[3-fluoro-2-[4-(2-oxa-5-azabicyclo[2.2.1 ]hept-5-ylcarbonyl)-1 - piperidtnyllphenylH-(2-me^yl-4-pyridinyl)-1H-imtdazole-2-carboxamW (79);
N-[3-fluQro~2»[4-[[3-{hydroxymethyi)-4-morpholinyl]carbonytl-1- p!peridinyi]phenyl]-4-(2-methy!-4-pyridinyl)-1H-imidazole-2-carboxamide (80);
N-[2-[4-[[3-(aminQmethyiH-morpholinyl]carbonyl3-1-piperidinyIl-3- f!uorophenyl]-4-(2-methyl-4-pyrtdiny!)-1 H-imidazole-2-carboxamide (81 );
1 -[2-f iuoro-6-[[[4-(2-methyl-4-pyridinyl)-1 H-imidazol-2- yl]carbonyl]aminolphenyl]-4-piperidinecarboxamide (82);
N-(2-aminQethyl)-1-[2-fluoro-6-[[[4-(2~methyl-4-pyridinyl)-1 H-imidazoi-2- yt]carbonyl]aminQ]phenyl]-4-piperidinecarbQxarnide (83);
N-(2-aminocyclohe>cy!)-H2 luoro-^
2-y(]carbonyl]amtno]phenyi]-4-piperidinecarboxamide (84);
1 -[2-f luoro-6-[[[4-(2-methyl-4-pyrtdinyl)-1 H-imidazol»2- yl|carbonyl]aminolphenyl]-N-[4-(methylaminQ)butylH-piperidinecarboxamide (85);
N 2-(ethyIamino)ethyl]-1-i2-fluorQ-6-[[[4-(2-methyl-4-pyridinyl)-1H-imid
2-yl]carbonyllamino]phenyS]-4-piperidinecarboxamide (86);
N-[2-[4-(3l8-diazabicyclo[3.2.1]oct-8-ytcarbonyl)-1-piperidinyl]-3- f!uorophenyl]-4-(2-methyi-4-pyridinyi)-1 H-imidazole-2-carteoxamide (87);
N-[(1 -aminQcyclopentyl)methyi)-1 -[2-fluoro-6-t[[4-(2-methyI-4-pyridinyl)-1 H- imidazol-2-yi]carbonyl]amino]phenyl]-4-piperidinecarboxamide (88);
N-t2-[4-[[2-(arninQmethyl)-4-morpholinyl]carbonyl]-1-p!peridinyl]-3- fluorophenyl]-4-(2-methyl-4-pyridinyl)-1 H-imidazole-2-carboxarnide (89);
N-i3~fluoro-2-[4-[t2-(2-hydroxyethyl)-4-morpholinyl]carbonyi]-1- piperidinyl]phenyi]-4-(2-methyi-4-pyr!dinyt)-1 H-imidazole-2-carboxam (90);
N-[2-[4-(3»6-dtazabicycio|3.2.1 ]oct-3-ytcarbonyl)-1 -piperidinyl]-3- f luorophenyl]-4-(2-methyi-4-pyridinyl)-1 H-imidazole-2-carboxamide (91 );
N-[3-fluoro-2-[4-[(3(R)-fluoro-1-pyrrolidinyl)carbonyl]-1-piperidinyl3phenyl]-4- (2-rnethyl-4-pyridinyl)-1 H-imidazole-2-carboxamide (92);
N-[3-fluorQ-2~[4-[(3-oxo-2,8-diazaspfro[4.5]dec-8-yl)carbonyl]-1- piperidinyi]phenyl]^-(2-methy!-4-pyridiny!)-lH-imidazole-2-carboxamide (93);
N-f2-[4-(2,7-diazaspiro[3.5]noN-7-ylcarbonyl)-1-piperidinylJ-3-fluorophenyl]- 4-(2-methyl-4-pyridinyl)-l H-imidazole-2-carboxamide (94);
N-[2-[4-[_2-(1-aminQethyi)-4-mor^
fiuorophenyl]-4-(2-methyl-4-pyridinyl)-1 H-imidazole-2-carboxamide (95);
N-[3-fluoro-2-[4-[[4-hydroxy-4-(2-pyridinyl)-1-piperidinyl]carbonyt]-1- piperid!nyi]phenyl]-4-(2~methyl-4-pyridinyl)-1H-imidazole-2-carboxarnide (96);
N-(2-(4-(aminomethy!)piperidin-1-yl)-3-fluorophenyl)^-(1-(difluoromethyl)-6- oxo-1 l6-dihydropyridin-3-yl)-1H-imidazole-2-carboxamide (97);
(R)-N-(2-(3-aminopiperidin-1-yl)-3-fluorophenyl)-4-(2-chloro-6-methylpyridin- 4-yl)-1 H-imidazoie~2-carboxamide (98);
4-(2-amino-6-morpholinopyrimidin-4-y!)~N-(2-(4-(aminomethyl)piperidin yl)-3-fluorophenyl)-1 H-imidazQie-2-carboxamide (99);
methyl 4-(6-(2-(2-(4-(aminomethyt)piperidin-1-yl)-3-fluorophenylcarbamQyl)- 1 H-imidazol-4-y()-2-(methylamino)pyrimidin-4-yl)piperazine-1-carboxy^
(100) ;
4-(6-(4-acetylptperazin-1-yi)-2-(methyIamino)pyrirnidin-4-yl)»N-(2-(4- (aminomethyl)piperidin-1-yl)-3 !uorophenyl)-1H-imidazole-2-carboxamide
(101) ;
N-cyclohexyl-6-methy!-1-(2-(methylamino)-6-(2-(2-(piperazin-1- yl)pherty!carbamoyl)-1 H-imidazol- -yl)pyrimidin-4-yl)piperidine-3-carboxamide
(102) ;
4-(6-(4-acetylpiperazin-1-yl)-2-(m
1-yl)phenyt)-1 H-imidazole-2-carboxamide (103);
N-cyclohexyl-6-methyl-1-(2-(methylamino)-6-(2-(2-(piperazin-1- yl)phenylcarbamoyl)-1 H-imidazol-4-yl)pyrimidin-4-yl)piperidine-3-carbQxamide (104);
benzyl 4-(2-(methylamino)-6-(2-(2-(piperazin-1 ~yl)phenytcarbamoyl)-1 H- imidazol-4-yl)pyrimidin-4-yi)piperazine-1 -carboxylate (105);
N-cyclohexyl-4-(2~(methylamino)-6-(2-(2-(piperazin-1-yl)phenylcarbamoyl)- 1H-!midazoM-yl)pyrimidin-4-yl)morphQline-2-carboxamide (106);
1-(6-(2-(2-(4~(aminomethyi)piperidin-1-y
imidazQl-4-yl)-2-(methylamino)pyrimidin-4-yl)-N-cyciohexyt-6- 3-carboxamide (107);
N»cyclohexyl-6-methyl-1-(2-(methylamino)-6-(2~(2-(piperidin-4- yloxy)phenylcarbamoyl)-1 H-imidazol-4-yl)pyrimidin-4-yl)piperidine-3- carboxamide (108);
N-cyclohexyl-1-(6-(2-(3-fluoro-2-morphoiinophenylcarbamoyl)-1H-irnidazol- 4-yl)-2-(methyiamino)pyrimidin-4-yl)-6-met ylpiperidine-3-carboxamide (109);
1-(6-(2-(2~((S)-2-(aminomethyi)morpholm^
imidazot-4-yl)-2-(methylamino)pyrimidin-4-yt)-N-cyclohexyl-6-methy
3-carboxamide (110);
1-(6-(2-(2-((R)-2-(aminomethyl)morpholino)-3-fluQrophenylcarbamoyl)-1 H- imidazoI-4-yi)-2-(methylamino)pyrimidin-4-yl)~N-cyclohexyi-6-methylp
3-carboxamide (111);
1 -(2-arnino-6-(2-(5-amlno-2-(2 , 9-d iazaspiro[5.5]u ndecan-9- yl)phenylcarbamoyl)-1 H-imidazol-4-yl)pyrimidin-4-yl)-N-cyclohexyl-6- methylpiperidine-3-carboxarnide (112);
1 -(6-{2-(2-(1 ,4-dioxa-8-azaspiro[4.5]decan-8-yl)phenylcarbamoyl)-1 H- imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-N-cyclohexyi-6-methy[piperW 3-carboxamide (113);
1 -(6-(2-(2-((R)-3-arninopiperidin-1 -yl)-3-fluorophenyicarbamoyi)-l H- imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)~N-cyclohexyl-6»methylpip 3-carboxamide (114);
(3S,6R)-1-(6-(2-(2-(4-(aminomethyl)piperidin-1-yl)-3- fluorophenylcarbamoyl)-1 H-imidazo!-4-yl)-2-(methylamino)pyrimidin-4-yl)-N- cyclohexyl-6-methylpiperidine-3-carboxamide (115);
(3R,6S)-1-(6-(2-(2-(4-(aminomethyi)piperidin-1-yl)-3- fluoropheny!carbamoyl)-1 H-imidazQi-4-yl)-2-(methylamino)pyrimidin-4-yl)-N- cyclohexyl-6-methylpiperidine-3-carboxamide (1 6);
(3S)6R)-1-(6-(2-(2-((S)-2-(aminomethyl)morpholino)-3- ftuoropheny!carbamoyl)-1 H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-N- cyc!ohexyl-6-methylpiperidine-3-carboxamide (117);
N-cyciohexyi-1-(6-(2-(3-fiuoro-2-(2,7-diazaspirot3,5]nonan-7- yl)phenylcarbamoyt)-1 H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-6- methyipiperidine-3-carboxamide (118);
N-cyc[ohexyl-1-{6-(2-(3-fIuoro-2-(2!8-diazaspiro[4.5]decan-8- yi)pheny!rarbamoyl)-1 H-imidazol-4^
methylpiperidtne-3-carboxamide (119);
(R)~N-(2-(4-(aminomethyl)piperidin-1-y!)-3-fIuorophenyi)-4-(2- (methylamino)-6-(2-methylpiperazin-1^
carboxamide (120);
(R)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(2- (methylamino)-6-(3-methylmorpholino)pyrimidin-4-yl)-1H-imidazQle-^
carboxamide (121);
N-cydohexyi-1-(6-(2-(3-fluoro-2-((R)^
1 H-imidazol-4-yi)-2-(methylamino)pyr!midin-4-yt)-6-methylpiperidm
carboxamide (122);
(R)-4-(6-(2-(aminomethyl)morpholino)-2~(methylamino)pyrimidin-4-yl)-N-(2- (4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-1 H-imidazole-2-carboxamide (123);
(S)-N-(2-(4-(aminomethyl)piperidin-1-yi)-3-f!uorophenyl)-4-(2-(methy!amino)- 6-(3-methylpiperazin-1 ~yl)pyrimidin-4-y!)-1 H-imidazote-2-carboxamide (124);
4-(6-(4-(aminomethyl)piperidin-1-yI)-2-(methylamino)pyrimidin-4-yl)-N-(2-(4- (aminomethyl)piperidin-1-yl)-3-fluorophenyl)-1H-imidazole-2-carboxamide
(R)"N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyi)-4-(6-(3- amtnopiperidin-1-yi)-2-(methylamino)pyrimidin-4-yl)-1H-imtdazole-2- carboxamide (126);
1 -(6-(2-(2-(4-(aminomethyi)piperidin-1 -yl)-3-fluorophenytcarbamoyl)-1 H- !m!dazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-4-(methyiaminQ)piperidine-4- carboxamide (127);
(S)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(6-(3-carbamoyl- 3-methoxypyrrolidin-1-yl)-2-(methylamino)pyrimidin-4-yl)~1H-imidazo!e-2- carboxamide (128);
(S)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(6-(3- (cyclohexyicarbamoyl)-3-methoxypyrrolidin-1-yl)-2-(methyiarnino)pyrimidin-4- yl)-1 H-imidazole-2-carboxamide (129);
{R)-N-{2-(4-(aminomethyl)pi
(benzylcarbamoyI)-3-(methoxymethyl)pyrroiidin-1-yl)-2-(methylamino)pyr! 4-yi)-1 H-imidazoie-2-carboxamide (130);
(R)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluQrQphenyl)-4-(6-(3- (cyclopropylcarbamoyl)-3-(rnethoxymethyl)pyrroiidin~1-yl)-2»
(methylaminQ)pyrimidin-4-y()~1 H-imidazole-2-carbQxamide (131); and
(R)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(6-(3- (cyclohexylcarbamoyl)-3-(methoxymethyl)pyrrolidin-1-yl)-2- (methylamino)pyrimidin-4-yl)-1 H-imidazole-2-carbQxamide (1 2); or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claim 1-12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
14. A compound of any one of claims 1 -12 or a pharmaceutically acceptable salt thereof for use in therapy. 15. The compound of any one of claims 1 -12 or a pharmaceuticaliy acceptable salt thereof, for use in treating a disease or disorder characterized by excessive or pathologically elevated cell growth.
16. The compound or pharmaceutically acceptable salt of claim 15 wherein the disease or disorder is cancer.
17. A combination comprising a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof and an additional anti-cancer agent for simultaneous, separate or sequential use in treating cancer.
18. A method of treating a disease or disorder characterized by excessive or pathologically elevated eel! growth comprising administering a therapeutically
effective amount of a compound of claim 1 or a pharmaceuticaily acceptable salt thereof to a patient in need of such treatment.
19. The method of claim 18, wherein the disease or disorder is cancer.
20. A method of treating cancer comprising administering a compound of claim 1 or pharmaceutically acceptable salt thereof and an additional anticancer to a patient in need of such treatment.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11787211.9A EP2627650A2 (en) | 2010-05-26 | 2011-05-24 | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 |
US13/699,547 US8623857B2 (en) | 2010-05-26 | 2011-05-24 | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34853810P | 2010-05-26 | 2010-05-26 | |
US61/348,538 | 2010-05-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011149874A2 true WO2011149874A2 (en) | 2011-12-01 |
WO2011149874A3 WO2011149874A3 (en) | 2014-03-20 |
Family
ID=45004697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/037651 WO2011149874A2 (en) | 2010-05-26 | 2011-05-24 | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 |
Country Status (3)
Country | Link |
---|---|
US (1) | US8623857B2 (en) |
EP (1) | EP2627650A2 (en) |
WO (1) | WO2011149874A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015503505A (en) * | 2011-12-23 | 2015-02-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Heteroaryl and uses thereof |
CN105503832A (en) * | 2015-12-18 | 2016-04-20 | 浙江大学 | Substituted pyrazol ring derivative and application thereof |
WO2017120194A1 (en) * | 2016-01-05 | 2017-07-13 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
WO2017157735A1 (en) | 2016-03-15 | 2017-09-21 | Bayer Cropscience Aktiengesellschaft | Substituted sulfonyl amides for controlling animal pests |
WO2018041964A1 (en) * | 2016-09-02 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers |
US10022387B2 (en) | 2015-02-09 | 2018-07-17 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
US10065963B2 (en) | 2015-11-06 | 2018-09-04 | Incyte Corporation | Heterocyclic compounds as PI3K-γ inhibitors |
WO2018177995A1 (en) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Tricyclic carboxamides for controlling arthropods |
US10138248B2 (en) | 2016-06-24 | 2018-11-27 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors |
CN109195965A (en) * | 2016-03-01 | 2019-01-11 | 普罗佩纶治疗公司 | The inhibitor that WDR5 protein-protein combines |
US10738057B2 (en) | 2017-10-18 | 2020-08-11 | Incyte Corporation | Tertiary alcohols as PI3K-γ inhibitors |
CN111646945A (en) * | 2020-05-29 | 2020-09-11 | 凯美克(上海)医药科技有限公司 | Synthetic method of 4-bromo-2-nitro-1H-imidazole |
US11174250B2 (en) | 2016-03-01 | 2021-11-16 | Propellon Therapeutics Inc. | Substituted carboxamides as inhibitors of WDR5 protein-protein binding |
US11186580B2 (en) | 2018-09-05 | 2021-11-30 | Incyte Corporation | Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6560243B2 (en) * | 2014-02-11 | 2019-08-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Pyrimidineimidazolamine as a modulator of kinase activity |
JP2023519892A (en) | 2020-03-27 | 2023-05-15 | ランドス バイオファーマ インコーポレイテッド | PLXDC2 ligand |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094808A1 (en) * | 2001-05-19 | 2002-11-28 | Smithkline Beecham P.L.C. | Imidazole-2-carboxamide derivatives as raf kinase inhibitors |
WO2003104481A2 (en) * | 2002-06-08 | 2003-12-18 | University Of Dundee | Methods |
WO2009014637A2 (en) * | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
US20090048313A1 (en) * | 2004-08-13 | 2009-02-19 | Genentech, Inc. | 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7705042B2 (en) * | 2004-10-22 | 2010-04-27 | Janssen Pharmaceutica Nv | Class of arylamide compounds useful as inhibitors of c-fms kinase |
MX2008013532A (en) * | 2006-04-20 | 2009-01-15 | Janssen Pharmaceutica Nv | Inhibitors of c-fms kinase. |
-
2011
- 2011-05-24 WO PCT/US2011/037651 patent/WO2011149874A2/en active Application Filing
- 2011-05-24 US US13/699,547 patent/US8623857B2/en not_active Expired - Fee Related
- 2011-05-24 EP EP11787211.9A patent/EP2627650A2/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094808A1 (en) * | 2001-05-19 | 2002-11-28 | Smithkline Beecham P.L.C. | Imidazole-2-carboxamide derivatives as raf kinase inhibitors |
WO2003104481A2 (en) * | 2002-06-08 | 2003-12-18 | University Of Dundee | Methods |
US20090048313A1 (en) * | 2004-08-13 | 2009-02-19 | Genentech, Inc. | 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
WO2009014637A2 (en) * | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
Non-Patent Citations (1)
Title |
---|
ZHU ET AL.: 'From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors.' CANCER RES. vol. 64, 2004, pages 4309 - 4318, XP008041499 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2793894A4 (en) * | 2011-12-23 | 2015-07-08 | Millennium Pharm Inc | Heteroaryls and uses thereof |
JP2015503505A (en) * | 2011-12-23 | 2015-02-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Heteroaryl and uses thereof |
US10022387B2 (en) | 2015-02-09 | 2018-07-17 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
US10596184B2 (en) | 2015-02-09 | 2020-03-24 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
US10065963B2 (en) | 2015-11-06 | 2018-09-04 | Incyte Corporation | Heterocyclic compounds as PI3K-γ inhibitors |
US11773102B2 (en) | 2015-11-06 | 2023-10-03 | Incyte Corporation | Heterocyclic compounds as PI3K-γ inhibitors |
US11091491B2 (en) | 2015-11-06 | 2021-08-17 | Incyte Corporation | Heterocyclic compounds as PI3K-y inhibitors |
US10472368B2 (en) | 2015-11-06 | 2019-11-12 | Incyte Corporation | Heterocyclic compounds as PI3K-γ inhibitors |
CN105503832A (en) * | 2015-12-18 | 2016-04-20 | 浙江大学 | Substituted pyrazol ring derivative and application thereof |
US11952367B2 (en) | 2016-01-05 | 2024-04-09 | Incyte Corporation | Pyridine and pyridimine compounds as PI3K-gamma inhibitors |
WO2017120194A1 (en) * | 2016-01-05 | 2017-07-13 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
US11352340B2 (en) | 2016-01-05 | 2022-06-07 | Incyte Corporation | Pyridine and pyridimine compounds as PI3K-gamma inhibitors |
EP3792256A1 (en) * | 2016-01-05 | 2021-03-17 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
JP2019512482A (en) * | 2016-03-01 | 2019-05-16 | プロペロン セラピューティクス インコーポレイテッド | Inhibitors of WDR5 protein-protein binding |
CN109195965A (en) * | 2016-03-01 | 2019-01-11 | 普罗佩纶治疗公司 | The inhibitor that WDR5 protein-protein combines |
US11174250B2 (en) | 2016-03-01 | 2021-11-16 | Propellon Therapeutics Inc. | Substituted carboxamides as inhibitors of WDR5 protein-protein binding |
CN109195965B (en) * | 2016-03-01 | 2022-07-26 | 普罗佩纶治疗公司 | Inhibitors of WDR5 protein-protein binding |
US11319299B2 (en) | 2016-03-01 | 2022-05-03 | Propellon Therapeutics Inc. | Substituted carboxamides as inhibitors of WDR5 protein-protein binding |
WO2017157735A1 (en) | 2016-03-15 | 2017-09-21 | Bayer Cropscience Aktiengesellschaft | Substituted sulfonyl amides for controlling animal pests |
US10138248B2 (en) | 2016-06-24 | 2018-11-27 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors |
US12030885B2 (en) | 2016-06-24 | 2024-07-09 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors |
US10975088B2 (en) | 2016-06-24 | 2021-04-13 | Incyte Corporation | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors |
US10479795B2 (en) | 2016-06-24 | 2019-11-19 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors |
WO2018041964A1 (en) * | 2016-09-02 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers |
WO2018177995A1 (en) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Tricyclic carboxamides for controlling arthropods |
US11825838B2 (en) | 2017-03-31 | 2023-11-28 | Bayer Cropscience Aktiengesellschaft | Tricyclic carboxamides for controlling arthropods |
US11225486B2 (en) | 2017-10-18 | 2022-01-18 | Incyte Corporation | Tertiary alcohols as PI3K-γ inhibitors |
US11926630B2 (en) | 2017-10-18 | 2024-03-12 | Incyte Corporation | Tertiary alcohols as PI3K-γ inhibitors |
US10738057B2 (en) | 2017-10-18 | 2020-08-11 | Incyte Corporation | Tertiary alcohols as PI3K-γ inhibitors |
US11186580B2 (en) | 2018-09-05 | 2021-11-30 | Incyte Corporation | Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor |
CN111646945A (en) * | 2020-05-29 | 2020-09-11 | 凯美克(上海)医药科技有限公司 | Synthetic method of 4-bromo-2-nitro-1H-imidazole |
Also Published As
Publication number | Publication date |
---|---|
US20130079326A1 (en) | 2013-03-28 |
WO2011149874A3 (en) | 2014-03-20 |
EP2627650A2 (en) | 2013-08-21 |
US8623857B2 (en) | 2014-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8623857B2 (en) | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 | |
JP6496376B2 (en) | Inhibitor compound | |
AU2012328167B2 (en) | New compounds | |
TWI534145B (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
AU2011253057B2 (en) | Nitrogen heterocyclic compounds useful as PDE10 inhibitors | |
EP3066104B1 (en) | Triazolopyrazine derivatives as brd4 inhibitors | |
EP2920175B1 (en) | Triazolopyridazine derivatives as bromodomain inhibitors | |
EP2925761B1 (en) | Triazolopyrazines as brd4 inhibitors for use in the treatment of cancer | |
EP2552905B1 (en) | B-Raf kinase inhibitors | |
JP2018150358A (en) | Tank-binding kinase inhibitor compounds | |
EP2571877B1 (en) | 1h-imidazo[4,5-c]quinolines | |
EP3036235B1 (en) | New bis-amido pyridines | |
EP3140304B1 (en) | Benzimidazole derivatives | |
AU2018237123B2 (en) | Bruton's tyrosine kinase inhibitors | |
MX2013005897A (en) | Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases. | |
TW200815417A (en) | New compounds II | |
MX2014014110A (en) | Pteridines as fgfr inhibitors. | |
EP3036228B1 (en) | New 6-alkynyl pyridine compounds | |
BR112014010177B1 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND | |
BR112014010183B1 (en) | Compound, pharmaceutical composition, product and use of a compound | |
JP2013501002A (en) | Compounds and compositions as SYK kinase inhibitors | |
EP3180339B1 (en) | 6-alkynyl-pyridine derivatives as smac mimetics | |
WO2013012500A1 (en) | Trpv4 antagonists | |
WO2019089835A1 (en) | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | |
CN116685585A (en) | High-activity HPK1 kinase inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11787211 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13699547 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011787211 Country of ref document: EP |